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I 
Resumo 
 
Palavras-chave: “Splicing” Alternativo, Inflamação, Interleucina-1!, Factores 
de “Splicing” 
 
A descrição dos quatro sinais de Inflamação (rubor, calor, tumor e dor) 
por Celsus retrata talvez pela primeira vez a existência desta resposta Imune 
(revisto por Rocha e Silva, 1978). Durante muito tempo, como descrito por 
Metchnikoff em 1892, julgava-se necessária a presença de um micróbio para a 
indução de Inflamação, no entanto, sabe-se actualmente que a sua presença não é 
necessária para que o processo de Inflamação ocorra, sendo cada vez mais 
observadas respostas inflamatórias na sua ausência (revisto por Metchnikoff, 1892; 
Dinarello, 2004; Medzhitov, 2008). Ao longo dos últimos anos, têm surgido novas 
áreas de investigação com a finalidade de estudar o complexo mecanismo de 
regulação da resposta inflamatória. Alguns dos grandes marcos que originaram 
mudanças significativas na compreensão do mecanismo de Inflamação foram (1) a 
descoberta da secreção  de mediadores pró-inflamatórios por parte das células do 
Sistema Imune (como por exemplo, as Interleucinas 1! (IL-1!)  e 8 (IL-8), Menkin, 
1944; Dinarello, 2009), (2) a definição de “Pattern Recognition Receptors” 
(Janeway, 1989), como receptores envolvidos no reconhecimento de diversas 
estruturas conservadas presentes em diversos micróbios ou mediadores de 
sinalização celular; e (3) a descoberta do Inflamassoma, um complexo 
multiproteico envolvido no processamento de diversas Interleucinas, incluindo a 
IL-1! (Martinon et al., 2002). Com a melhoria dos conhecimentos relativos ao 
mecanismo de regulação da resposta inflamatória, foi possível associar mutações 
em componentes-chave desta resposta a um elevado número de doenças, como é o 
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caso do Síndrome de Muckle-Wells ou a Febre Mediterrânica Familiar, mutações 
ao nível do NALP3 ou Pyrin, respectivamente (Ogura et al., 2001; Maeda et al., 
2005; McGonagle et al. 2007; Church et al. 2008; Martinon et al., 2009).  
No que respeita às citocinas pró-inflamatórias, a IL-1! foi uma das 
primeiras Interleucinas a ser identificada e representa um dos mais importantes 
mediadores da Inflamação e da resposta do hospedeiro à infecção (revisto por 
Dinarello, 2004). A elevada correlação entre defeitos na regulação da secreção 
desta citocina e o aparecimento de doenças inflamatórias, fez desta um dos focos 
de maior investigação na área da Inflamação nos últimos anos (revisto por O'Neill, 
2008). Actualmente, várias doenças são já tratadas com sucesso, quer com 
antagonistas do receptor de IL-1!, como por exemplo usando o antagonista 
Anankira, quer com outros métodos que visam diminuir a concentração de IL-1!, 
recorrendo, por exemplo, à neutralização de IL-1! com o recurso a anticorpos 
monoclonais anti-IL-1! (revisto em Fitzgerald et al ., 2005; Kalliolias et al., 2008; 
Lequerre et al. 2008; Martinon et al., 2009).  
O processo que leva à secreção da IL-1! ocorre essencialmente em dois 
passos fundamentais, a Produção e o Processamento. Esta citocina é produzida 
numa pró-forma inactiva (pro-IL-1!), sendo maioritariamente transcrita após a 
activação do factor de transcrição “Nuclear Factor-kB” (NF-kB) e seguidamente 
traduzida em proteína. Posteriormente, esta forma inactiva de IL-1! é processada 
na sua forma activa, por um mecanismo que envolve a presença da Caspase-1, num 
passo que precede a sua secreção (revisto por Martinon et al., 2009). Por sua vez, a 
Caspase-1 é também sintetizada de forma inactiva, que requer processamento pelo 
complexo multiproteico Inflamassoma para se tornar activa (revisto por Martinon 
et al., 2009). Em suma, os dois passos que levam à secrecão da IL-1! são a 
Produção e a Activação do Inflamassoma, que levará à activação da Caspase-1, 
processamento da IL-1!  e subsequente secreção desta. Porém, embora o complexo 
mecanismo envolvido na regulação da secreção desta citocina tenha vindo a ser 
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amplamente estudado, não é ainda inteiramente conhecido, pelo que é de extrema 
importância o seu estudo de uma forma mais aprofundada.  
Com o aumento do conhecimento dos mecanismos envolvidos na 
regulação da secreção de IL-1!, alguns investigadores têm direccionado agora a 
sua atenção na pesquisa de como serão reguladas as moléculas envolvidas nesse 
processo, no decurso de uma resposta inflamatória. Foram identificados diversos 
níveis de mecanismos de regulação como: diferenças ao nível de expressão, 
distintos estados de fosforilação, existência de várias isoformas da mesma 
molécula, entre outros (revisto por Hayden et al., 2004; Lynch, 2004; Anderson, 
2010). Foram, também, identificados genes envolvidos na regulação da secreção de 
IL-1! como sendo regulados por “Splicing” Alternativo (AS), como por exemplo o 
MyD88, o IRAK2 e o NOD2 (revisto em Leeman et al., 2008). Assim, o aumento 
do número de funções celulares regulados por AS bem como a forte correlação 
entre alterações ao nível do “Splicing” e a existência de doença (revisto por 
Leeman et al., 2008; Tazi et al. 2008), indica que o AS pode desempenhar um 
papel importante na iniciação e na regulação de uma resposta inflamatória, 
particularmente na secreção de citocinas pró-inflamatórias como a IL-1!. 
Na tentativa de identificar os Factores de “Splicing” (SF) que 
desempenhem um papel na secreção de IL-1! após um estímulo inflamatório, 
usamos como modelo o estímulo de uma linha celular monocítica (THP-1) com 
E.coli, na triagem da secreção daquela citocina recorrendo à tecnologia de RNA de 
interferência (RNAi). Resumidamente, foi utilizada uma sub-colecção da 
biblioteca de RNAi disponibilizada pelo “The RNAi Consortium” (TRC) que 
permitiu estudar os efeitos da perda de função de 425 genes envolvidos no 
mecanismo de “Splicing” durante a produção e secreção de IL-1!. Após o 
“knockdown” e posterior estimulação com E.coli, os níveis de IL-1! secretados 
foram medidos por ELISA. Após triagem e sucessivas experiências de validação, 
foram identificados 19 genes que afectam significativamente a secreção de IL-1! 
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no nosso modelo. Entre os candidatos validados, os factores de Splicing (SF), 
ASF/SF2 e SRp20 mostraram um fenótipo consistente com o de reguladores 
negativos, pois após a diminuição da sua  expressão usando a técnica de RNAi, 
detectaram-se níveis elevados de secreção de IL-1!. Seguidamente, reverteu-se o 
fenótipo observado, por clonagem dos dois SFs e sobre-expressão na mesma linha 
celular. A sobre-expressão destes SF fez diminuir os níveis de IL-1! secretados, 
validando os resultados anteriores, e implicando o ASF/SF2 e o SRp20 como 
reguladores negativos da secreção de IL-1!.   
Com o aumento de doenças associadas a alterações ao nível de “Splicing”, 
nalguns estudos são usadas actualmente drogas que controlam a expressão ou 
actividade de diversos SF, de forma a modular as respostas em questão. Dois 
desses estudos, efectuados por Stoilov e Keriel (Stoilov et al. 2008; Keriel et al., 
2009), identificaram vários compostos capazes de modular eventos de “Splicing” 
dependentes destes dois SF em estudo. Usando estas mesmas drogas, observou-se 
um aumento na secreção de IL-1! após o estímulo com E.coli, uma vez mais 
confirmando os nossos resultados de RNAi. 
A fim de avaliar o papel dos dois candidatos, ASF/SF2 e SRp20, nos dois 
passos necessários para a secreção de IL-1!, Produção e Processamento, foram 
efectuadas várias experiências. Analizaram-se os níveis de expressão de IL-1! por 
PCR quantitativo após o silenciamento destes dois candidatos e posterior estímulo 
com E.coli. Foram observados valores de expressão de IL-1! superiores nas 
células onde a expressão dos dois SF tinha sido anteriormente reduzida por RNAi. 
Os resultados permitem concluir que ambos os candidatos são reguladores 
negativos da produção de IL-1!. Como forma de verificar o impacto do 
“knockdown” dos dois candidatos no segundo passo necessário para a secreção de 
IL-1!, medimos a actividade da Caspase-1 recorrendo a uma técnica de citometria 
de fluxo (FACS). O “knockdown” do ASF/SF2 não apresentou qualquer impacto 
na activação de Caspase-1. Em oposição, observou-se um notável aumento de 
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activação de Caspase-1 após o “knockdown” do SRp20. Com estes resultados 
pudemos concluir que o SRp20 é um regulador negativo de ambas as etapas 
necessárias para a secreção de IL-1!, Produção e Processamento, enquanto que o 
ASF/SF2 é um regulador negativo da produção de IL-1!. Observaram-se também, 
níveis elevados de expressão de Caspase-1 após o “knockdown” do SRp20, 
podendo talvez desta forma explicar os níveis superiores de activação de Caspase-1 
observados nestas condições. 
Entre as diversas funções já descritas como sendo mediadas por estes dois 
SF, um estudo recente implicou o ASF/SF2 no processo inflamatório (Xiong, 
2006). Nesse estudo foi demonstrado que a expressão do ASF/SF2 é reduzida em 
músculo inflamado ou após um estímulo inflamatório (por exemplo usando TNF",  
Xiong, 2006). Decidimos então analisar a expressão dos dois candidatos mediante 
estimulação com E.coli, no sistema em estudo. Notou-se uma redução da expressão 
do ASF/SF2 ao nível do mRNA, ao passo que a expressão diminuída do SRp20 foi 
observada somente ao nível de proteína. Os mecanismos envolvidos neste processo 
de regulação dos dois SF mediante estimulação com E.coli estão agora a ser 
investigados. 
Como supracitado, o aumento do número de genes que são regulados por 
AS que desempenham um papel na Inflamação precisam ser estudados mais 
profundamente. Foram inicialmente analisados os perfis de “Splicing” de alguns 
dos genes anteriormente identificados como sendo regulados por AS e que podem 
ter um papel activo na regulação da secreção de IL-1!. Foram estudados os 
padrões de “Splicing” de alguns genes após o “knockdown” do ASF/SF2 ou 
SRp20 e/ou estimulação com E.coli, porém sem resultados conclusivos. Assim, 
decidimos realizar uma análise das alterações nos padrões de “Splicing” 
recorrendo à tecnologia de “microarrays” usando a plataforma Affymetrix®  
GeneChip ® Human Exon 1.0 ST. Foram analisadas as alterações dos padrões de 
“Splicing” de todos os genes Humanos após “knockdown” do ASF/SF2 e/ou 
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estimulação com E.coli, ficando o estudo das alterações relativas ao outro 
candidato, SRp20, para futuras experiências. Após a análise dos dados e respectiva 
validação, vários dos genes, já anteriormente relatados em diversas publicações 
como sendo regulados por AS nas mesmas condições, foram encontrados 
utilizando a nossa abordagem, validando assim o nosso método. No futuro serão 
efectuados estudos mais detalhados para os genes mais promissores com o intuito 
de desvendar o seu papel na regulação da secreção de IL-1!. 
Podemos concluir que a tecnologia de RNAi é uma ferramenta poderosa 
para desvendar os genes envolvidos em diferentes vias celulares. No nosso estudo, 
foram identificados vários SF que podem desempenhar um papel na regulação da 
secreção de IL-1! após um estímulo com E.coli. Entre os candidatos identificados, 
o ASF/SF2 foi demonstrado como desempenhando papel na primeira etapa da 
secreção de IL-1!, a Produção; ao passo que o outro candidato estudado, o SRp20, 
desempenha um papel importante, quer na Produção de IL-1!, quer na etapa de 
Processamento por parte do Inflamassoma. São necessários vários estudos para 
determinar os mecanismos pelos quais estes SF desempenham  um papel regulador 
da secreção de IL-1!. 
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Abstract 
 
Keywords: Alternative Splicing, Inflammation, Interleukin-1!, Splicing 
Regulation 
 
Inflammation was one of the first immune responses to be reported to exist 
and has been a focus of intensive research ever since (reviewed in Rocha e Silva, 
1978; Medzhitov, 2010). During the course of an inflammatory response several 
components are involved, such as inflammatory inducers and mediators or 
different sensors that mediate the detection of a pro-inflammatory stimulus. 
Amongst the most studied pro-inflammatory mediators is the Interleukin-1! (IL-
1!). Interleukin-1! was one of the first Interleukins to be identified and represents 
one of the most important mediators of Inflammation and host responses to 
infection (reviewed in Dinarello, 2004). The large connection between 
misregulation of IL-1! release and the appearance of inflammatory diseases made 
this cytokine one of the “hotspots” of intensive research in the past years (reviewed 
in O'Neill, 2008). Nowadays, several diseases are being treated successfully using 
different methods that decrease IL-1! circulant levels or block its effects, such as 
using IL-1! receptor antagonists or by neutralizing IL-1! with monoclonal anti-IL-
1! antibodies (reviewed in Fitzgerald et al., 2005; Kalliolias et al., 2008; Lequerre 
et al., 2008; Martinon et al., 2009).  
The IL-1! secretion pathway is a “two-step” fashion mechanism, 
Production and Processing steps. The cytokine is produced in an inactive pro-form 
(pro-IL-1!) mainly upon activation of the nuclear factor-kB (NF-kB) transcription 
factor and posterior translation into protein. The second and processing step is 
mediated by active Caspase-1, that will give rise to its mature and secreted form 
(reviewed in Martinon et al., 2009). Caspase-1 is also synthesized as an inactive 
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form that requires processing by the Inflammasome complex to become active 
(reviewed in Martinon et al., 2009). Upon Inflammasome formation, Caspase-1 
becomes active, leading to subsequent IL-1! processing and posterior release. 
However, despite the increase knowledge that has been obtained during the past 
years, a lot still remains to be unveiled concerning the mechanisms involved in the 
regulation of IL-1! secretion and the effects elicited by this cytokine.  
Several genes involved in the regulation of IL-1! secretion were shown to 
be regulated by Alternative Splicing (AS), such as MyD88, IRAK2 and NOD2, 
among others (reviewed in Leeman et al., 2008). Moreover, the increasing number 
of cellular processes regulated by AS and the strong correlation between defects in 
Splicing and disease (reviewed in Leeman et al., 2008; Tazi et al., 2008), strongly 
suggest that AS may play a role in the initiation and regulation of an inflammatory 
response, particularly in the secretion of the pro-inflammatory cytokine IL-1!. 
In an attempt to identify the Splicing Factors and Regulators (SF) with a 
potential role in the secretion of IL-1! upon an inflammatory stimulus, we 
performed an RNAi-based screen. Briefly, we used a subset of the TRC Lentiviral 
Human Library to generate loss-of-function phenotypes for most of SFs. We 
silenced the expression of 425 genes involved in Splicing with an average 5-fold 
coverage.  After the primary screen and several rounds of phenotypic validation, 
19 genes were identified to significantly affect the secretion of IL-1! by THP-1 
cells after a 24 hours challenge with E. coli, as measured by ELISA. Among the 
candidates, ASF/SF2 and SRp20, showed a clear negative regulator phenotype, 
where upon decreased expression of these two candidates, elevated levels of 
secreted IL-1! secretion were detected, in comparison to control. Thus, we decided 
to focus our attention in these two SFs. In order to confirm the phenotype observed 
using the RNAi technology, we overexpressed these two candidates in THP-1 
cells. As expected, overexpression decreased the levels of secreted IL-1!, therefore 
validating the previous results as implicating ASF/SF2 and SRp20 as negative 
  
 
 
                                                                                                                                     Abstract          
 
IX 
regulators of IL-1! secretion. In addition, using drugs already described to block 
the Splicing dependant on ASF/SF2 or SRp20, we observed increased levels of IL-
1! upon treatment, therefore, once more confirming the results obtained in the 
RNAi based screen. 
Next, we studied the role of ASF/SF2 and SRp20 in the regulation of  the 
two-steps necessary for IL-1! secretion. The levels of IL-1! mRNA expression 
were increased upon ASF/SF2 or SRp20 knockdown, when compared to control 
cells. We could then conclude that both SFs are negative regulators of IL-1! 
production. As mentioned before, the second step necessary for IL-1! secretion is 
its processing in a Caspase-1 dependant manner. We measured Caspase-1 
activation by FACS in cells upon ASF/SF2 or SRp20 knockdown and posterior 
challenge with E.coli. Knocking-down ASF/SF2 did not show any impact in 
Caspase-1 activation. In opposition, a remarkable increase in Caspase-1 activation 
was observed upon SRp20 knockdown, as compared to control cells. Thus, we 
could conclude that SRp20 acts as a negative regulator of both IL-1! Production 
and Processing, whereas ASF/SF2 is a negative regulator of IL-1! Production. In 
addition, increased Caspase-1 mRNA expression was observed in SRp20 
knockdown cells as compared to control, consequently suggesting that increased 
Caspase-1 activation in SRp20 knockdown cells might be due to increased 
Caspase-1 expression. However further experiments are still required to prove this 
assumption. 
 In the past years, several reports clearly show the involvement of these two 
SFs in the regulation of different cellular processes such as transcription, 
translation and apoptosis (reviewed in Huang et al., 2004; Li et al., 2005a; Long et 
al., 2009). A recent report implicates ASF/SF2 in Inflammation (Xiong, 2006), as it 
was shown that ASF/SF2 is downregulated in inflamed muscle or after an 
inflammatory stimulus, such as TNF". Thus, we decided to check the expression 
of ASF/SF2 and SRp20 upon E.coli challenge. Decreased expression of ASF/SF2 
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was observed at the mRNA level, whereas decreased expression of SRp20 was 
only observed at the protein level after an E.coli challenge. The mechanisms 
involved in the downregulation of these two SFs upon E.coli challenge are now 
being investigated. 
The increased number of genes that are regulated by AS already reported 
to play a role in Inflammation strongly suggested us to look for their Splicing 
profiles in ASF/SF2 or SRp20 knockdown cells upon an E.coli challenge. Several 
PCR experiments were performed to identify differences in the Splicing patterns of 
the described genes, however with no conclusive results. Consequently, we 
decided to perform an unbiased and high-throughput analysis of Alternative 
Splicing Events (ASE) that take place either after an E.coli challenge or after 
knockdown of ASF/SF2, using the Affymetrix® GeneChip® Human Exon 1.0 ST 
Arrays platform. Upon data analysis and validation, several genes already reported 
to undergo AS in different publications were found using our approach, therefore 
validating our method. We are now focusing on the most relevant candidates to 
perform follow-up studies. 
In sum, this work allowed us to identify two novel regulators of IL-1! 
secretion after an E.coli challenge. Our results clearly show that both ASF/SF2 and 
SRp20 are negative regulators of IL-1! secretion. While SRp20 is involved in the 
regulation of the two-steps required of IL-1! secretion, Production and Processing, 
ASF/SF2 is only involved in the regulation of the first step, Production. In addition 
to IL-1!,  increased Caspase-1 expression was also observed upon SRp20 
knockdown, suggesting the involvement of this SF in the regulation of the 
expression of  this inflammatory Caspase. Moreover, the expression of the two SFs 
was also shown to be altered in the course of an inflammatory response to E.coli 
challenge, however the mechanism involved has yet to be determined. Several 
studies are now required to determine the mechanisms by which these two SFs 
play a role in IL-1! secretion.  
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Chapter 1 - Introduction 
 
 
 
 
 
 
 
 
 The four signs of Inflammation by Celsus: calor, rubor, tumour and dolor. 
(Adapted from Rocha e Silva, 1994). 
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Inflammation is normally defined as a complex response to infection, 
trauma and other conditions of homeostatic imbalance (reviewed in Nathan, 2002). 
If one wants to trace the first descriptions of the Inflammatory response, we would 
probably have to go back to beginning of the first century A.D., where Celsus 
described the four signs of Inflammation: rubor (redness), tumour (swelling), calor 
(heat) and dolor (pain) (reviewed in Rocha e Silva, 1978). Several other 
descriptions of this process can be found along the years, such as Galen’s 
definition in the third century A.D, as the “reaction of the body against injury” 
(reviewed in Rocha e Silva, 1978). However, some authors claim that the real 
history of Inflammation started in the middle of the nineteenth century, when 
scientific methods began to be applied in higher extent to unveil the causes of 
many infections by germs and viruses. More than 100 years ago, Metchinikov 
described that an Inflammatory response is normally mounted as a response to a 
pathogenic microbe (Metchnikoff, 1892), however, the presence of an infectious 
agent is not always mandatory to induce Inflammation, as we know nowadays 
(reviewed in Medzhitov, 2008).  
The Inflammatory response to infection consists of multiple components 
with distinct functions. Along the past years, several new “highways” of research 
have been “opened”, namely after the discovery of the release of pro-inflammatory 
mediators by Immune cells (such as the cytokines, Menkin, 1944; Dinarello, 2009), 
the notion of Immune Pattern Recognition Receptors (PRR) by Janeway’s 
(Janeway, 1989) and more recently with the discovery of the Inflammasome, as an 
important multicomponent complex that regulates the secretion of several 
cytokines, such as the Interleukin-1! (IL-1!, Martinon et al., 2002). Upon 
recognition of a specific molecular signature, normally defined as a Pathogen 
Associated Molecular Pattern (PAMP) by the PRR, the Inflammation signaling 
cascade is activated and needs to be tightly regulated, otherwise the excessive 
Inflammatory process can lead to a variety of pathological conditions, including 
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septic shock, autoimmunity, as other chronic Inflammatory disorders (Karin et al., 
2006; Church et al., 2008; Medzhitov, 2008; Martinon et al., 2009). Thus, a defect 
in the PRR signaling pathway makes the host susceptible to various pathogens, and 
the overactivation or misregulation can lead to a chronic Inflammatory disease 
(reviewed in Medzhitov, 2008).  
A growing number of systemic Inflammatory diseases, characterized by 
fever, anemia, and elevated levels of acute-phase proteins, have been linked to 
excessive production and elevated circulating levels of IL-1! (reviewed in 
Dinarello, 2009). Thus, seminal work has been performed in the past years 
attempting to better understand the underlying mechanisms involved in the 
regulation of this important pro-inflammatory cytokine. The mechanism of IL-1! 
secretion has been extensively studied, and made this field as one of the “hotspots” 
in the last years. Important regulators have been found to be able to modulate this 
response in order not to be detrimental to the body, however the entire picture is 
not fully drawn so far. Different regulator molecules were found to be expressed 
upon the initiation of the Inflammatory process, such as Decoy Receptors, that 
show the capability to modulate the extent of an Inflammatory response (reviewed 
in Liew et al., 2005; Lee et al., 2007; Martinon et al., 2009).  
Nowadays, due to the actual knowledge related to the regulation of the 
secretion of this cytokine, several patients are being treated successfully using IL-
1! receptor antagonists, such as Anankira, or other methods to decrease IL-1! 
concentrations, for example neutralizing IL-1! by monoclonal anti-IL-1! 
antibodies (reviewed in Fitzgerald et al., 2005; Kalliolias et al., 2008; Lequerre et 
al., 2008; Martinon et al., 2009).  
However, despite the intensive work that have been developed in the past 
years, the entire mechanism involved in the regulation of IL-1! secretion is not yet 
fully unveiled. Thus, we have decided to study the regulation of IL-1! secretion in 
the context of a bacterial challenge, such as Escherichia coli (E.coli).  
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Among the mechanisms already found to regulate IL-1! secretion, it was 
found that several genes involved in this pathway are regulated post-
transcriptionally by an Alternative RNA Splicing (AS) dependant mechanism 
(reviewed in Wells et al., 2006; Leeman et al., 2008). Thus, the increasing number 
of genes and cellular processes found to be regulated by AS (Pan et al., 2008; 
Wang et al., 2008), and the strong connection between AS misregulation and 
disease (reviewed in Leeman et al., 2008; Tazi et al., 2008), lead us to study the 
role that it may play in the initiation and regulation of an Inflammatory response, 
particularly in the secretion of the pro-inflammatory cytokine IL-1!. We decided to 
study the impact of different AS regulators in the context of IL-1! secretion 
regulation. 
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Chapter 1.1 - Interleukin-1!  and Inflammation 
 
 
 
“The experiment I have just outlined shows the first stage of Inflammation 
in the animal world. Now Inflammation as understood in man and the higher 
animals is a phenomenon that almost always results from the intervention of some 
pathogenic microbe. So it is held that the afflux of mobile cells towards points of 
lesion shows the organism's reaction against foreign bodies in general and against 
infectious microbes in particular. On this hypothesis, disease would be a fight 
between the morbid agent, the microbe from outside, and the mobile cells of the 
organism itself. Cure would come from the victory of the cells and immunity would 
be the sign of their acting sufficiently to prevent the microbial onslaught.” 
 
    Metchnikoff, Nobel Lecture in 1908 
 
  
 
 Inflammation is one of the oldest Immune responses reported to occur, 
where the description of the four signs of Inflammation by Celsus (rubor, tumour, 
calor and dolor) in the I century A.D., represents probably the first “building-
stone” (reviewed in Rocha e Silva, 1978).  Along the years, the notion of 
Inflammation as an Immune response triggered by tissue injury, with the goal to 
restore organism’s homeostasis became clear, as can be observed in the definitions 
by Galen (III century A.D) and Neumann (1889), “a reaction of the body against 
injury” or as “a series of local phenomena developing as a result of primary lesions 
to the tissues and that tend to restore their health”, respectively (reviewed in Rocha 
e Silva, 1978). In the XIX century, the work of Elie Metchnikoff, clearly marks the 
importance of Inflammation as an Immune system reaction to the presence of 
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infectious microbes, preventing the organism against disease (Metchnikoff, 1892). 
However, as we know nowadays, despite the great importance of this Immune 
response against infection, the presence of a microbe is not mandatory to an 
Inflammatory response to occur (reviewed in Medzhitov, 2008).   
 The Inflammatory response is characterized by an increased blood flow 
and vascular permeability along with the accumulation of fluid, leukocytes, and the 
release of Inflammatory mediators. Among the released mediators of Inflammation 
is a group of cell-derived polypeptides, known as cytokines, which play an 
important role in the outcome of this response (reviewed in Oppenheim, 2001). 
The different roles played by these molecules in the generation and regulation of 
this Immune response definitely shows their importance as large “orchestrators” of 
Inflammation (reviewed in Feghali et al., 1997; Oppenheim, 2001). The first 
description of cytokine dates from Menkin’s work that “purified” factors 
(“pyrexins”) with fever-inducing capacities from Inflammatory exudates (Menkin, 
1943; Menkin, 1944).   
 The Inflammatory cytokines can be divided into different families 
according to their pro or anti-inflammatory properties, structural similarities or 
their involvement in acute or chronic Inflammation (reviewed in Feghali et al., 
1997; Dinarello, 2009; Sims et al., 2010). One such family is the Interleukin-1 
family (IL-1) of cytokines, where 11 members were already identified: IL-1", IL-
1!, IL-1 receptor antagonist (IL-1Ra), IL-18, IL-33 and IL-1(F5-F10, reviewed in 
Dinarello, 2009; Sims et al., 2010).  The different members of this family have 
been identified to possess either pro- and anti-inflammatory properties, as shown in 
Table 1. As an example,  IL-1Ra can bind to the IL-1 receptor (IL-1R) at higher 
affinity than the IL-1 itself, therefore reducing IL-1" and IL-1! responses (Arend 
et al., 1985; reviewed in Dinarello, 2009). In opposition, IL-1! has been 
extensively studied as an important pro-inflammatory mediator released by 
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monocytes and tissue macrophages following an Inflammatory stimulus, such as a 
bacterial challenge (reviewed in Dinarello, 2009; Sims et al., 2010).  
 
Table 1 – IL-1 family members and their roles in Inflammation. (Adapted from 
Dinarello, 2009). 
 
Name 
New Name 
(Sims et al., 2001) 
Property 
IL-1"  IL-1F1 Agonist 
IL-1!  IL-1F2 Agonist 
IL-1Ra IL-1F3 Receptor antagonist 
IL-18 IL-1F4 Agonist 
FIL1#  IL-1F5 Anti-Inflammatory 
FIL-1$  IL-1F6 Agonist 
IL-1H4, IL-1%  IL-1F7 Anti-Inflammatory 
IL-1H2 IL-1F8 Agonist 
IL-1$  IL-1F9 Agonist 
IL-1Hy2 IL-1F10 Receptor antagonist (?) 
IL-33 IL-1F11 Agonist 
 
 Interleukin-1, as the name suggests, was the first interleukin identified, the 
so-called fever-producing endogenous pyrogen, and represents one of the most 
important mediators of Inflammation and host responses to infections (reviewed in 
Dinarello, 2004; Sims et al., 2010). The biological activity of IL-1 is mediated by 
two cytokines, IL-1" and IL-1!, produced from two different genes both located at 
chromosome 2. The aminoacid homology between IL-1" and IL-1! is 22% 
(reviewed in Burger et al., 2006). These two cytokines bind to the same receptor 
complex, the IL-1 receptor type-I (IL-1RI), thus having identical biological 
activities (Sims et al., 1988; reviewed in Dinarello, 2009; Sims et al., 2010). 
Although, besides their similarities, they differ in several ways such as their 
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expression profile. Whereas IL-1" expression is widespread (e.g. keratinocytes and 
endothelial cells), IL-1! expression is more confined to Immune system cells, such 
as monocytes and macrophages (Dinarello, 1996; Dinarello, 2009). Interleukin-1" 
is generally associated with the plasma membrane of the producing cells, therefore 
acting mainly at a local level (Kurt-Jones et al., 1985; reviewed Dinarello, 2009). 
In opposition, IL-1! is secreted and circulates systemically, therefore stimulates 
both local and systemic responses, and represents one of the most important 
mediators of Inflammation and host responses to infections (Kurt-Jones et al., 
1985; reviewed in Dinarello, 2004; Dinarello, 2009).  IL-1! promotes the 
recruitment of Inflammatory cells at the site of Inflammation due to its ability to 
increase the expression of adhesion molecules on endothelial cells and through the 
release of chemokines by stromal cells, which will promote the infiltration of 
Inflammatory and immunocompetent cells from the circulation into the site of 
infection (reviewed in Gabay et al., 2010; Sims et al., 2010). Interleukin-1! was 
also shown to be involved in the activation of the expression of other pro-
inflammatory mediators, such as the Tumour Necrosis Factor (TNF) and IL-6 
(reviewed in Gabay et al., 2010). Several other biological effects have also been 
attributed to IL-1!, however, besides its beneficial role in mediating host responses 
to microbial invasion, IL-1! can also have detrimental effects, such as in chronic 
Inflammatory diseases and septic shock, discussed further (reviewed in Church et 
al., 2008; Martinon et al., 2009). 
Interleukin-1! is expressed at low levels under normal conditions and 
requires induction at both the transcription and translational levels (reviewed in 
Dinarello, 2009). Augmented IL-1! production has been found in patients with 
viral, bacterial, fungal and parasitic infections, as a result of Innate Immune 
response activation via recognition of different PAMPs by several PRRs (reviewed 
in Dinarello, 2009; Martinon et al., 2009). Following a bacterial challenge, several 
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PRRs and signaling pathways become activated, that will increase the production 
and release of this cytokine. Interleukin-1! is synthesized as a 31 kDa precursor 
(pro-IL-1!) that needs to be further cleaved in order to generate its mature and 
secreted 17 kDa form (Figure 1, Mosley et al., 1987; Black et al., 1988; Jobling et 
al., 1988; reviewed in Martinon et al., 2009). Thus, IL-1! secretion is normally 
described as a “two-step” mechanism, requiring production and a final processing 
step, prior to its release (reviewed in Eder, 2009).  
 
 
Figure 1 – IL-1!  processing. The inactive pro-IL-1! (31 kDa) is cleaved at the residue 
116 by Caspase-1, originating the mature and secreted form (17kDa). Adapted from 
(Dinarello, 2009). 
 
The processing step required for the activation and release of IL-1! is 
mostly mediated by the IL-1-converting enzyme, Caspase-1 (Figure 1, Cerretti et 
al., 1992; Thornberry et al., 1992; Wilson et al., 1994; reviewed in Dinarello, 
2009). Though, in resting cells, Caspase-1 is produced as a catalytically inactive 
pro-form that also requires an activation step in order to be able to process pro-IL-
I! into the active IL-1!. Activation of Caspase-1 is regulated by a multimeric 
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cytosolic protein complex, called the Inflammasome (Martinon et al., 2002; 
reviewed in Martinon et al., 2009). The formation of the Inflammasome triggers an 
autocatalytical activation of Caspase-1, mediated by the oligomerization of two or 
more Caspase-1 monomers, resulting in the cleavage of the pro-enzyme into a 
20kDa (p20) and a 10-kDa (p10) subunits. Caspase-1 becomes active upon the 
assembling of two heterodimers of p20 and p10 subunits, containing two active 
sites (Thornberry et al., 1992; Wilson et al., 1994; reviewed in Stutz et al., 2009). 
Caspase-1 can also cleave other members of the IL-1 family of cytokines, such as 
IL-18 and IL-33 (reviewed in Martinon et al., 2009; Netea et al., 2010). The 
mechanisms that lead to Inflammasome and Caspase-1 activation will be discussed 
further in detail. 
The mechanism leading to the secretion of mature IL-1!, and other pro-
Inflammatory cytokines, is also not yet well understood. Despite the identification 
of several possible mechanisms, such as by the usage of unidentified transporters at 
the plasma membrane, secretion of multivesicular bodies containing exosomes or 
as a passive mechanism as a result of cell lysis (MacKenzie et al., 2001; Andrei et 
al., 2004; Brough et al., 2007; Qu et al., 2007; reviewed in Eder, 2009), no 
unifying picture is yet drawn. 
The IL-1! activation process has been extensively studied, and alternative 
mechanisms which do not involve Inflammasome activation or Caspase-1 were 
also described (reviewed in Netea et al., 2010). Several studies have identified 
Proteinase-3, a neutrophil and macrophage derived serine protease, Elastase and 
Cathepsin-G as IL-1! processing enzymes (Coeshott et al., 1999; Greten et al., 
2007; reviewed in Dinarello, 1996; Netea et al., 2010). Nonetheless, these 
alternative mechanisms are important players in the regulation of IL-1! secretion, 
they are not under the scope of my thesis, which will focus only on Inflammasome 
dependent IL-1! processing.  
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1.1.1 - The “Inflammable” players  
  
 
 
 
 1.1.1.1 - The cells 
 
 
 During the course of the Inflammation process, several cell types are 
important at the different stages of this Immune response. Among the different cell 
types involved in an Inflammatory response are the phagocytic leukocytes (e.g. 
monocytes, macrophages and neutrophils), professional antigen presenting cells 
(e.g. Dendritic Cells, DCs) and cells from the skin and the epithelia that line our 
internal organs such as gut and lungs.  The epithelia surfaces of the body are the 
first lines of defense against infection providing a physical barrier between the 
internal milieu and the external environment. Besides providing this physical 
barrier, epithelial cells also produce chemical substances that are microbicidal or 
inhibit microbial growth, as the case of the antibacterial enzymes (lysozyme and 
phospholipase A that are secreted in tears and saliva), and the antimicrobial 
peptides (reviewed in Schroder et al., 2006; Nevalainen et al., 2008). However, 
during Inflammation, several other cell types play important roles, as the case of 
the myeloid cells. These myeloid cells include mononuclear phagocytes and 
polymorphonuclear phagocytes. The polymorphonuclear phagocytes include the 
neutrophils, basophils and eosinophils (reviewed in Dale et al., 2008; Blanchard et 
al., 2009; Sullivan et al., 2009). The mononuclear phagocytes are the macrophages, 
which are derived from the monocytes, and the closely related dendritic cells, also 
from myeloid lineage. During acute Inflammation, is often observed a rapid influx 
of blood granulocytes, typically neutrophils, followed by monocytes that mature 
into Inflammatory macrophages that subsequently proliferate and thereby affect the 
functions of resident tissue macrophages (reviewed in Serhan et al., 2005). The 
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resolution of Inflammation can occur if granulocytes are eliminated and the tissue 
mononuclear cell population (macrophages and lymphocytes) returns to a normal 
pre-inflammation state number and phenotype (reviewed in Serhan et al., 2005; 
Medzhitov, 2008). 
 Despite the fact that several Immune cell types play an important role in 
this process, in this thesis, I will focus mainly the monocytes and macrophages, 
which are the main producers of the pro-inflammatory cytokine IL-1! (reviewed in 
Dinarello, 2009; Eder, 2009).  
 Monocytes are usually defined as a pleomorphic and pleiotropic 
population of circulating mononuclear cells, which contribute to antimicrobial 
defense by supplying tissues with macrophage and DC precursors (van Furth et al., 
1968; van Furth et al., 1972; Gordon et al., 2005).  
 
“The function and fate of the monocytes in the circulation is not clearly 
understood. In vitro these cells can mature into a cell with characteristics of tissue 
macrophages and similar transformations were shown to occur in vivo at 
extravascular sites. Recently it has been reported that macrophages in 
Inflammatory exudates originate from monocytes.” 
     Ralph van Furth, 1968 
 
The monocytes originate in the bone marrow from a common myeloid 
progenitor that is shared with neutrophils (Volkman et al., 1965), and are released 
into the peripheral blood, where they circulate for several days before entering 
tissues and replenish the tissue macrophage populations (reviewed in Taylor et al., 
2003; Serbina et al., 2008). The morphology of mature monocytes in the peripheral 
circulation is heterogeneous, and these cells constitute approximately 5-10% of 
peripheral-blood leukocytes in humans (Gordon et al., 2005). Monocytes do not 
proliferate in steady state (reviewed in Auffray et al., 2009). These cells are 
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equipped with chemokine receptors and adhesion receptors that allow the 
migration from blood into tissues during infection (reviewed in Serbina et al., 
2008; Geissmann et al., 2010). As an example, after bacterial infection, such as  
Listeria monocytogenes, there is an influx of monocytes to the site of infection, 
occurring normally 72 to 96 h following infection (reviewed in Serbina et al., 
2008) where, according to the Inflammatory milieu, they differentiate into 
Inflammatory DCs and macrophages (reviewed in Serbina et al., 2008; Geissmann 
et al., 2010). Besides differentiation into macrophages, monocytes can also exert 
bactericidal functions by producing several cytokines (e.g. IL-1!, IL-8) or toxic 
molecules, such as reactive nitrogen intermediates (RNIs) or reactive oxygen 
intermediates (ROIs, Serbina et al., 2008). 
 
Macrophages are commonly defined as the “phagocytic cells per 
excellence”. These phagocytic cells play a key role in Innate immunity due to their 
capability to recognize, ingest and destroy many pathogens without the aid of an 
adaptative Immune response. The important role of macrophages in phagocytosis 
is in the origin of its name, the term macrophages (from the Greek for “large 
eaters”, reviewed in Pollard, 2009). Phagocytosis has been largely studied, 
however Metchnikov, for the majority considered the “father” of Innate immunity, 
has already described its importance in the beginning of the XX century. 
 
“Whenever the organism enjoys immunity, the introduction of infectious 
microbes is followed by the accumulation of mobile cells, of white corpuscles of 
the blood in particular which absorb the microbes and destroy them. The white 
corpuscles and the other cells capable of doing this have been designated 
“phagocytes”, i.e. devouring cells, and the whole function that ensures immunity 
has been given the name of “phagocytosis”.” 
Metchnikoff, Nobel Lecture in 1908 
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Macrophages mature continuously from monocytes that leave the 
circulation to migrate into tissues throughout the body (reviewed in Pollard, 2009). 
In mammals, macrophages are found in all tissues. In some tissues they constitute 
10-20% of all cells, as for example microglial cells in the brain and Kupffer cells 
in the liver, whereas in other tissues, such as musculo-skeletal junctions, they are 
rare (Perry et al., 1985; Sasmono et al., 2003; Pollard, 2009). Macrophages, as 
monocytes, upon bacterial recognition are able to produce several adhesion 
molecules, cytokines, chemokines and other signaling molecules (reviewed in 
Gordon et al., 2005). 
 
 
   
 
 1.1.1.2 - The Sensors – PRRs 
 
 
 
Over the last years, a large number of studies in Immunology and 
Microbiology have unveiled pivotal roles of the host Innate Immune system in 
sensing microbial infections via specific Innate Immune receptors, the Pattern 
Recognition Receptors (PRRs, Janeway, 1989). The PRRs act as a molecular 
switch to trigger Innate Immune activation and tightly regulate the subsequent 
adaptative Immune responses to microbial infections. These receptors can be 
expressed at the cell surface, in intracellular compartments, or secreted into the 
bloodstream and tissue fluids (Medzhitov et al., 1997a; Janeway et al., 2002). The 
PRRs are germline encoded, and each receptor has broad specificities for 
conserved and invariant features of microorganisms, sometimes referred as 
pathogen-associated molecular patterns (PAMPs), although being present in 
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pathogenic and non-pathogenic microorganisms (Janeway et al., 2002). These 
molecules are vital for the survival of the microorganism, and as such are unlikely 
to vary in their structures because that could be disadvantageous for the 
microorganisms. Another interesting aspect of the PAMPs is the fact of being 
invariant among microorganisms of a given class and products of pathways unique 
to microorganisms, allowing in this way the discrimination between the self and 
non-self molecules (Medzhitov et al., 1997a; Medzhitov, 2007). Examples of 
PAMPs include Lipopolysaccharide (LPS), bacterial lipoprotein, peptidoglycan 
(PGN), among others. However, PAMPs are not the only triggers of the Innate 
immunity, as suggested by the Danger Model of Immune System activation 
(Matzinger, 2001; Matzinger, 2002b). This model suggests that the Immune system 
is more concerned with damage than with the recognition of “foreignness”, and is 
called into action by alarm signals from the injured tissues, rather than the 
recognition of non-self molecules. Several “self” molecules have now been shown 
to be released by injured tissues and to activate an Innate Immune response. These 
are called Damage Associated Molecular Patterns (DAMPs), such as DNA, RNA 
or uric acid, which should not normally be present outside the cells or at certain 
locations within the cell under physiological conditions (Matzinger, 2002a; Shi et 
al., 2003; Bianchi, 2007).  
 Several families of PRR have so far been identified differing in their 
cellular and subcellular location, and the signaling pathways elicited, which is 
reflected in the different biological roles (reviewed in Janeway et al., 2002; 
O'Neill, 2008; Werts et al., 2006). In fact, the subcellular location of the receptors 
has been used to distinguish between the several families of PRRs, the membrane 
bound and the cytosolic families of receptors. The transmembrane Toll-like 
Receptors (TLRs) and the C-type Lectin Receptors are located at the plasma 
membrane and on internal membranes, such as the endosome. Whereas, the 
members of cytosolic receptors comprise the Retinoic Acid-inducible Gene-I like 
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Helicases (RLRs) and the Nucleotide-Binding Domain Leucine-rich Repeat-
containing Receptors (NLRs). Despite the importance of all the PRRs in the 
generation of an Immune response, this thesis will focus mainly on the TLR family 
of membranar receptors and the cytosolic family or PRR, the NLRs. 
 
 
 
 
  1.1.1.2.1 -  Toll-like Receptors (TLRs) 
 
 
 
The Toll discovery was achieved in Drosophila (Hashimoto et al., 1988), 
as one of the 12 maternal effect genes that function in a pathway required for 
dorso-ventral axis formation in fly embryos (reviewed in Belvin et al., 1996).  
Homologues of Drosophila Toll have been identified in mammals and are referred 
to as Toll-like Receptors (TLRs) (reviewed in Janeway et al., 2002; O'Neill, 2008). 
TLRs are transmembrane proteins characterized by an ectodomain that contains 
varying numbers of leucine-rich-repeat (LRR) motifs and a cytoplasmic signaling 
domain named Toll/IL-1R homology (TIR) domain (Akira et al., 2004; Creagh et 
al., 2006). The first human Toll to be characterized was the TLR4, which was 
shown to induce, like its Drosophila homologue, the activation of the nuclear 
factor-kB (NF-kB) signaling pathway (Medzhitov et al., 1997b). Since then, 
several members of this family have been described (reviewed in Ishii et al., 2008; 
O'Neill, 2008). To date 10 members of TLR family have been found in human, and 
a series of genetic studies have identified their ligands (Figure 2, reviewed in 
(Akira et al., 2004)). For example, LPS of gram-positive bacteria is recognized by 
the TLR4 (Poltorak et al., 1998; Hoshino et al., 1999). TLR2, in concert with 
TLR1 or TLR6, recognizes various bacterial components, including peptidoglycan, 
lipopeptide and lipoprotein of Gram-positive bacteria and Mycoplasma lipopeptide 
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(Aliprantis et al., 1999; Ozinsky et al., 2000; Takeuchi et al., 2000; Morr et al., 
2002). Moreover, TLR1/TLR2 and TLR2/TLR6 dimers can discriminate between 
triacyl lipopeptide (Takeuchi et al., 2002) and diacyl lipopeptide (Takeuchi et al., 
2001), respectively. TLR3 is involved in the recognition of viral double stranded 
RNA (Alexopoulou et al., 2001). TLR5 recognizes bacterial flagellin (Hayashi et 
al., 2001).  Different ligands have been found to be recognized by TLR7 and 
TLR8, among them are viral single-stranded RNA (Diebold et al., 2004; Heil et 
al., 2004) and several synthetic compounds such as Imidazoquinoline, Loxoribine 
and bropirimine (Hemmi et al., 2002; Jurk et al., 2002; Heil et al., 2003). TLR9 
recognizes bacterial and viral CpG DNA motifs (Hemmi et al., 2000; Lund et al., 
2003) and also malaria pigment hemozoin (Coban et al., 2005). TLR11 was shown 
to recognize Uropathogenic bacteria (Zhang et al., 2004). Upon recognition of the 
microbial pathogens, TLRs trigger intracellular signaling pathways that result in 
the induction of Inflammatory cytokines, type I interferon (IFN), chemokines and 
co-stimulatory molecules (reviewed in Akira et al., 2004). The signaling pathways 
elicited by the recognition of different PAMPs by the different TLRs will be 
discussed further. 
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Figure 2 – TLR mediated Immune responses. The different TLRs recognize different 
molecules (PAMPS and DAMPS), such as bacterial LPS and flagellin. The dimerization 
and the recruitment of different adaptor molecules allow the induction of different 
signaling pathways. Some receptors use the MyD88 and TIRAP/MAL adapters, whereas 
some use Trif. Upon activation of a MyD88-dependent pathway, an Inflammatory response 
is elicited, while Trif mainly mediates type I IFN responses. Exceptions can occur, for 
example, TLR7/8 and TLR9 induce type I IFN in a MyD88-dependent manner in 
plasmacytoid Dendritic cells. Adapted from (Kawai et al., 2006). 
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  1.1.1.2.1.1 - TLR signaling pathways 
 
 
TLRs initiate shared and distinct signaling pathways by recruiting different 
combinations of four signaling adaptor molecules (Figure 2), the TIR domain-
containing adaptor molecules: MyD88, TIRAP, TRIF and TRAM (Akira et al., 
2004). MyD88 is the most common adapter, which is used by all TLRs, with the 
exception of TLR3. The signaling pathway activated by TLR2 and TLR4 also use 
TIRAP, while TRAM is only used by TLR4. TRIF is used by TLR3 and TLR4 
(Kawai et al., 2006). These signaling pathways activate the NF-"B and activator 
protein-1 (AP-1) transcription factors, that are common to all TLRs, leading to the 
production of Inflammatory cytokines (such as Interleukin 1!, IL-1!) and several 
chemokines (reviewed in Akira et al., 2004). TLRs 3, 4, 7, 8, and 9 also activate 
interferon regulatory factor 3 (IRF3) and/or IRF7, leading to the production of type 
I IFNs such as IFN! and IFN# (Kawai et al., 2008). Subsequently, the cytokines 
and chemokines initiate and amplify Inflammatory responses by recruiting and 
activating various Innate Immune cells such as monocytes, neutrophils, and natural 
killer cells (Iwasaki et al., 2004). Type I IFNs can induce an antiviral state in most 
cells and, in addition, have diverse functions in the development of adaptive 
immunity (Stark et al., 1998; Iwasaki et al., 2004; Theofilopoulos et al., 2005; 
Pulendran et al., 2006). 
As mentioned above, TLRs can trigger both MyD88 dependent and 
MyD88 independent signaling cascades (reviewed in Kawai et al., 2006). Upon 
TLR stimulation, in a MyD88 dependent pathway, TIRAP and MyD88 are 
recruited via homophilic Toll/interleukin-1 receptor (TIR) domain interactions, 
allowing the association of IRAK4 (IL-1R-associated-kinase 4) with the receptor 
complex (Muzio et al., 1997; Wesche et al., 1997; Burns et al., 1998). IRAK4 then 
phosphorylates IRAK1 (Li et al., 2002). Tumour-necrosis-factor-receptor-
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associated-factor 6 (TRAF6) is also recruited to the receptor complex, by 
associating with phosphorylated IRAK1 (Ye et al., 2002). Phosphorylated IRAK1 
and TRAF6 then dissociate from the receptor and form a complex with TAK1 
(transforming-growth-factor-!-activated-kinase), TAB1 (TAK1-binding protein 1) 
and TAB2 at the plasma membrane, which induces the phosphorylation of TAB2 
and TAK1 (Shibuya et al., 1996; Takaesu et al., 2000). IRAK1 is degraded at the 
plasma membrane, and the remaining complex (consisting of TRAF6, TAK1, 
TAB1 and TAB2) translocates to the cytosol where it associates with the ubiquitin 
ligases UBC13 (ubiquitin-conjugating enzyme 13) and UEV1A (ubiquitin-
conjugating-enzyme E2 variant 1). This leads to the ubiquitylation of TRAF6, 
which induces the activation of TAK1 (Chen, 2005). TAK1, in turn, 
phosphorylates both mitogen-activated protein (MAP) kinases and the IKK 
complex (inhibitor of nuclear factor-kB (IkB)-kinase complex), which consists of 
IKK-", IKK-! and IKK-& (also known as IKK1, IKK2 and nuclear factor-kB (NF-
kB) essential modulator, NEMO, respectively (Chen, 2005; Kawai et al., 2006)). 
The IKK complex then phosphorylates IkB, which leads to its ubiquitination and 
subsequent degradation (reviewed in Mankan et al., 2009; Skaug et al., 2009). This 
allows NF-kB to translocate to the nucleus and induce the expression of its target 
genes, among them is the pro-inflammatory cytokine IL-1! (Dinarello, 2009; 
Mankan et al., 2009). TAK1 also activates MAP kinases such as c-Jun N-terminal 
kinases (JNKs), p38 and probably extracellular signal-related kinases (ERKs), 
leading to the activation of AP-1 and thus the regulation of Inflammatory cytokine 
expression (Wang et al., 2001; Sato et al., 2005). The transcription factor IRF5 is 
also critical for the expression of Inflammatory cytokines downstream of the TLR-
MyD88 signaling pathway, initiated by TLRs 4,5,7 and 9 (Sato et al., 2005). Thus, 
this classical MyD88 dependent pathway induces the expression of various 
Inflammatory cytokines (e.g.IL-1!) by a combination of NF-kB, AP-1 and IRF-5 
(Figure 3). 
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Figure 3 - TLR MyD88 dependent signaling pathways.  Upon TLR stimulation MyD88 
and TIRAP are recruited via homophilic TIR-TIR interactions. MyD88 then associates with 
IRAK4 and IRAK1, leading to sequential activation of IRAK4, IRAK1 and TRAF6. 
Ubiquitinated TRAF6 can be recruited to the TAK1-TAB1/2/3 complex by binding to 
TAB2, promoting TAK1 activation and therefore MAP kinases and NF-kB pathways, 
leading to the expression of Inflammatory cytokines. TAK1 also activates MAP kinases 
such as JNK, p38 and ERK, leading to the activation of AP-1, regulating Inflammatory 
cytokine expression. The transcription factor IRF5 can also be activated in a MyD88 
dependent signaling pathway, although the detailed mechanism is not yet known. Adapted 
from (Lee et al., 2007). 
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   1.1.1.2.1.2 - Regulation 
 
 
 Several regulators have been identified to function dampening responses of 
TLRs (reviewed in Liew et al., 2005). Several Decoy receptors have been found 
(e.g.TLR2 and TLR4) to be produced naturally during severe infection, and to 
block the interactions between the bacterial ligands and their respective TLRs 
(Iwami et al., 2000; LeBouder et al., 2003). Certain negative regulators of TLR 
signaling are upregulated following TLR stimulation, for example, ST2 (which 
sequester MyD88 or TIRAP, Kumar et al., 1997; Saccani et al., 1998; Brint et al., 
2004), MyD88s (the short isoform of MyD88 that abrogates NF-kB activation that 
is activated by the TLRs that signal via MyD88, Janssens et al., 2002; Burns et al., 
2003; Janssens, 2003), IRAK-M (which inhibits IRAK1 phosphorylation, 
Kobayashi et al., 2002), suppressor of cytokine signaling-1 (SOCS1, which 
mediates TIRAP degradation, Mansell et al., 2006) and A20 (which de-
ubiquitinates TRAF6, Boone et al., 2004). These negative regulators attenuate the 
TLR response via a negative feedback loop; although, others exist that target TLR 
signaling by downregulating the transcription or translation of TLR genes or by the 
degradation of TLR proteins. Among these are TRIAD3A (which ubiquitinates 
TLRs, targeting them for proteasomal degradation, Chuang et al., 2004), Toll-
interacting protein (TOLLIP, which controls the magnitude of responses to IL-1 
and LPS, Burns et al., 2000; Bulut et al., 2001; Zhang et al., 2002) and IRF4 
(which competes with IRF5 for MyD88 binding, Negishi et al., 2005), among 
others. A more detailed and complete list of negative regulators of TLR signaling 
can be seen in Figure 4 (reviewed in Lee et al., 2007). 
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Figure 4 - Negative regulation of TLR MyD88 dependent pathway. The negative 
regulator proteins that act at early time points and/or interfere with primary TLR signaling 
are represented in violet, and those acting in a negative feedback mechanism and/or at late 
time points are depicted in yellow. Soluble TLR (sTLR) may act as a decoy receptor, 
interfering with signal generation via the specific TLR. The mechanisms of TLR signaling 
dampening differ among the different negative regulator proteins: Toll/IL-1R homology 
(TIR) domain-containing transmembrane proteins STL2L (sequesters MyD88 and TIRAP) 
and SIGIRR (TLR signalosome assembly interference, by interacting with TLR4, IRAK 
and TRAF6); TRAILR, a tumor necrosis factor (TNF) superfamily member (stabilizes 
IkB" at later times after TLR stimulation, interfering with NF-kB activation); RP105, a 
TLR homolog lacking a signaling domain (interferes with the formation of the LPS-
signaling receptor complex TLR4-MD2); MyD88s, a splice variant of MyD88 (prevents 
the recruitment of IRAK4); IRAKM, an IRAK1 homolog (inhibits the dissociation of 
IRAK1 and IRAK4 from the TLR signaling complex); the ubiquitin-modulating enzymes 
A20 (cleave the ubiquitin chain of TRAF6, dampening further signaling activation); 
TRIAD3A (bind to the cytoplasmic domain of TLR and stimulate its ubiquitin-dependent 
degradation); SOCS1, suppressor of cytokine signaling-1 (mediates TIRAP degradation); 
IRF4, interferon regulatory factor-4 (competes with IRF5 for MyD88 binding); the 
activating transcription factor-3, ATF3 (suppresses the expression of certain TLR induced 
genes, probably due to alteration of the chromatin structure, preventing the access of NF-
kB to the promoters); IkBNS (inhibits NF-kB activity in the nucleus, possibly due to 
interaction with p50 protein) and !-arrestins (interact with TRAF6, inhibiting its 
ubiquitination and this NF-kB and AP-1 activation). Adapted from (Lee et al., 2007). 
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  1.1.1.2.2 - NOD-like Receptors (NLRs) 
 
 
Several studies have demonstrated the importance of the homologous and 
heterologous cooperation of TLRs and other PRRs in the detection and triggering 
of Innate Immune responses to microbial infections (reviewed in Creagh et al., 
2006; Trinchieri et al., 2007). Among those PRRs are the members of the NOD-
like receptor family (NLRs, reviewed in Inohara et al., 2005; Martinon et al., 
2005). NOD-like receptors are normally described as a specialized group of 
intracellular proteins that play a critical role in the regulation of the host Innate 
Immune response. They act as scaffolding proteins that assemble different 
signaling platforms triggering NF-kB and mitogen-activated protein kinase 
(MAPK) signaling pathways and control the activation of Inflammatory Caspases 
(Inohara et al., 2005). 
 The NLR family is characterized by a tripartite domain structure (Figure 
5), which shares structural similarity with a subclass of plant disease resistance (R) 
genes (Hammond-Kosack et al., 1997; Janeway et al., 2002).  The N-terminus is 
composed of an effector domain, normally a Pyrin domain (PYD) or Caspase-
recruitment domain (CARD), which is involved in homotypic and heterotypic 
binding. In this N-terminal domain other domains have been reported, such as the 
Baculovirus IAP Repeat (BIR). A nucleotide-oligomerization domain 
(NOD/NACHT) follows the effector domain, which might function in the 
regulation of self-oligomerization. The C-terminus is mainly composed of a series 
of LRR, similar to the TLR LRR motifs (Bella et al., 2008), although some 
exceptions were reported to occur, such as the HIN200 domain present in the 
AIM2 (Ludlow et al., 2005). The LRR domain has been implicated in ligand 
sensing and autoregulation of NLRs, although the precise mechanism of how NLR 
LRRs sense their ligands is largely unknown.   
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Figure 5 – Domain structures of the different NLRs. NLRs are characterized by a 
tripartite structure: the ligand-sensing leucine rich repeats (LRRs); the NOD domain, which 
is responsible for the oligomerization capacity of the NLRs; and the N-terminal effector 
domain, that can be a pyrin domain (PYD), CARD or BIR domain. NLRs are divided into 4 
subfamilies, NALPs, IPAF/NAIP,NODs and PIHYN, which differ mainly in their N-
terminal domains. (Abbreviations: CARD, Caspase recruitment domain; PYD, pyrin 
domain; FIIND, function to find; NOD, nucleotide-oligomerization domain; NAD, 
NACHT-associated domain; BIR, baculovirus IAP repeat; AD, activation domain; CIITA, 
MHC class II transcription activator). Adapted from (Martinon et al., 2009; Stutz et al., 
2009). 
 
There are more than 24 NLR proteins already described in the human 
genome, although little is known about their functions. The NLRs are subdivided 
in 4 major subfamilies (NALPs, NODs, IPAF/NAIP and PIHYN, Tschopp et al., 
2003; Stutz et al., 2009), mainly due to their different N-terminal effector domains 
(Figure 5), which mediate signal transduction to downstream targets, leading to 
activation of Inflammatory Caspases (Poyet et al., 2001; Martinon et al., 2002; 
Martinon et al., 2009) or NF-kB (NODs, Bertin et al., 1999; Inohara et al., 1999). 
NALPs represent the largest NLR subfamily and have 14 genes identified in 
humans (Tschopp et al., 2003; Ting et al., 2008). NALP proteins harbor a NOD 
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and LRR and are characterized by an N-terminal PYD domain. Notably, the LRR 
region within NALPs is organized in the genome in a very conserved and precise 
manner. NALP LRR regions are formed by tandem repeats of exons of exactly 171 
nucleotides and are defined completely by a preserved intron/exon structure. Each 
exon encodes one central LRR and two halves of the neighboring LRRs (Martinon 
et al., 2007b). This modular organization possibly allows extensive Alternative 
Splicing (AS) of the LRR region without destabilization of the structure and 
therefore maximizing variability in the ligand-sensing unit of the NALPs. A N-
terminal CARD domain and three BIR domains characterize IPAF and NAIP, 
respectively (Roy et al., 1995; Inohara et al., 2005). The third NLR subfamily, 
NODs, includes the CARD containing NLRs such as the NOD1, NOD2, NOD3, 
NOD4 and CIITA. This third subclass of NLRs also contains the NLRX1 and 
NOD5 without a defined N-terminal domain (Martinon et al., 2005; Proell et al., 
2008). Recently, another member of this family of PRR was discovered, called the 
Protein Absent in melanoma 2 (AIM2, Burckstummer et al., 2009; Fernandes-
Alnemri et al., 2009; Hornung et al., 2009; Roberts et al., 2009) which is the only 
member of the PIHYN subclass so far described. The PIHYN subclass is 
characterized by the  presence of an HIN200 domain (Roberts et al., 2009) at the 
C-terminus, whereas all the other NLRs described so far present a LRR domain. 
Several are the proteins described to possess an HIN200 (PIHYN family, reviewed 
in Ludlow et al., 2005), however, AIM2 is the only member described to be 
involved in Immune responses. In contrast to the majority of the identified PIHYN 
family members, AIM2 is the only showing cytoplasmic location. Moreover, the 
pyrin domain of AIM2 is more closely related to those of the NLRs than those of 
the other PYHIN family members (Hornung et al., 2009; Hornung et al., 2010). 
The different NLRs differ not only in their structure but also in the 
PAMPS they recognize, as well as in the signaling cascades elicited upon 
activation. NOD1 and NOD2 have been shown to recognize peptidoglycan (PGN)-
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derived products (reviewed in Inohara et al., 2005). NOD2 is a general sensor for 
both Gram-positive and Gram-negative bacteria since biochemical and functional 
analyses have identified muramyl dipeptide (MDP), the minimal motif common to 
all peptidoglycans, as the essential structure recognized by NOD2 (Inohara et al., 
2003; Franchi et al., 2009). In contrast to NOD2, NOD1 presents a strict sensing 
specificity towards DAP-type peptidoglycan (Chamaillard et al., 2003a; 
Chamaillard et al., 2003b). Moreover, it has been shown that the human NOD1 
detects a single muropeptide GM-TriDAP, which is produced as a peptidoglycan 
degradation product in Gram-negative bacterial metabolism (Benko et al., 2008). 
Stimulation of NOD1 or NOD2 results in the activation of NF-kB and MAPKs, 
which drive the transcription of numerous genes involved in both Innate and 
adaptative Immune responses (Hayden et al., 2004). Among the most studied 
NLRs are the members that have been shown to be important in the regulation and 
activation of pro-inflammatory Caspases, such as NALP3, NALP1 and IPAF 
(reviewed in Tschopp et al., 2003).  IPAF has been shown to recognize bacterial 
flagellin (Franchi et al., 2006; Miao et al., 2006). Flagellin is a bacterial protein 
that can self-assemble to form flagella, a macromolecular complex that plays a role 
in the motility of either Gram-negative or Gram-Positive bacteria. Moreover, 
flagellin monomers from a number of flagellated bacteria are extremely conserved, 
which has allowed the evolution of Innate Immune mechanism of bacterial 
flagellin detection (Miao et al., 2007).  NALP1 recognizes the Anthrax lethal 
toxin, from Bacillus anthracis (Boyden et al., 2006). Anthrax lethal toxin is the 
major cause of anthrax-related death and so far the only toxin identified to activate 
NALP1.  NALP3 mediates the activation of Caspase-1 in response to a variety of 
structurally unrelated stimuli. The repertoire of agonists capable of inducing 
NALP3 activation include nucleic acids such as bacterial and viral RNA 
(Kanneganti et al., 2006a; Kanneganti et al., 2006b; Allen et al., 2009), 
monosodium urate crystals (Martinon et al., 2006), changes in ion concentrations, 
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such as potassium (Pétrilli et al., 2007), pore forming toxins such as nigericin and 
maitotoxin (Mariathasan et al., 2006), reactive oxygen species produced following 
asbestos and silica exposure (Dostert et al., 2008) and fungal ligands, such as 
zymosan and mannan (Hise et al., 2009; Lamkanfi et al., 2009b). The only member 
of the PYHIN subclass of NLRs, the AIM2, recognizes dsDNA in cytosol 
(Burckstummer et al., 2009; Fernandes-Alnemri et al., 2009b; Hornung et al., 
2009; Roberts et al., 2009). This receptor binds directly to dsDNA, but not ssDNA 
through it C-terminal HIN200 domain, which results in AIM2 oligomerization and 
recruitment of other cytosolic proteins via homotypic PYD domain interaction, and 
subsequent activation of a signaling pathway (Roberts et al., 2009; Vilaysane et al., 
2009). 
The ligands that are already described to activate each NLR are showed in 
Table 2, however, the ligands for some NLR proteins still remain to be identified.  
 
Table 2 - NLR family members and the PAMPS recognized. Adapted from (Benko et 
al., 2008; Franchi et al., 2009; Mishra et al., 2010; Hornung et al., 2010).  
NLR PAMPs recognized 
NALP1 MDP, Anthrax Lethal Toxin 
NALP2 ? 
NALP3 Bacterial RNA 
Viral RNA 
Bacterial antigens (e.g. Esat6) 
Uric Acid Crystals (e.g. MSU, CPPD) 
Bacterial cell wall components (e.g. LPS, MDP) 
Pore forming toxins (e.g. nigericin, maitotoxin), 
Fungal ligands (e.g. Zymosan and mannan) 
Xenogeneous particles (e.g. Asbestos, Silica) 
NALP4-14 ? 
IPAF Flagellin 
NAIP Flagellin 
NOD1 GM-tripeptide, iE-DAP, FK156, FK565 
NOD2 MDP, M-TRILys 
NOD3-4 ? 
NLRX1 ? 
CIITA ? 
AIM2 dsDNA 
?- not yet identified  
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Expression patterns of most NLRs in various cell populations and tissues 
have not yet been studied in detail. However, the importance of NLRs in defense 
strategies of the body is supported by the fact that several NLRs are expressed in 
cell and tissues that have an important role in immunity, such as phagocytes. Some 
NLRs, such as NOD1, NOD2, NALP3 and NAIP are expressed in epithelial cells 
(Kufer et al., 2005; Kummer et al., 2007; Vinzing et al., 2008). NALP1 is widely 
expressed, whereas NALP3 is expressed mainly in Immune cells, epithelial cells 
and osteoblasts (Kummer et al., 2007; McCall et al., 2008). NAIP and IPAF are 
expressed in the brain and in macrophages and macrophage-rich tissues such as 
spleen, lung, and liver (Diez et al., 2000; Poyet, 2001). NALP5, NALP8, NALP4, 
NALP7, NALP10, and NALP11 are mainly expressed in germ cells and 
preimplantation embryos (McDaniel et al., 2009). The expression profile of 
different NLRs has also been shown to be influenced by other PRRs, as part of a 
regulatory network. TLR stimulation, for example, increases the expression of 
NLRs, such as NOD1, NOD2, and NALP3, possibly reflecting enhancement of 
NLR responses after TLR stimulation (Becker et al., 2007).  
 
 
  1.1.1.2.2.1 - NLR signaling pathways 
 
 The signaling pathways elicited upon recognition of PAMPs by the 
different NLR families differ, as well the outcome of that activation. As can be 
seen in Figure 6, ligand recognition by the NODs (NOD1 and NOD2) induces the 
recruitment of the CARD-containing serine/threonine kinase RICK (also called 
RIP2) to the receptors via prototypical CARD-CARD interaction (Inohara et al., 
2005; Martinon et al., 2005; Ting et al., 2006). Activated RICK mediates the 
ubiquitination of IKK&, leading to NF-kB activation (Abbott et al., 2004; Strober et 
al., 2006). The underlying mechanism of IKK& ubiquitination by RICK is not 
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known, although several potential regulators of NF-kB activity in the NOD-
dependent pathways have been identified to be involved, such as TAK1, TRIP-6, 
GRIM-19 and ERBIN (Werts et al., 2006). NODs can also activate MAP kinase 
pathways, for example, NOD2 has been shown to activate p38 and ERKs 
(Kobayashi et al., 2005), whereas NOD1 was implicated in JNK activation 
(Girardin et al., 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – Major signaling pathway of elicited upon NOD1 and NOD2 stimulation. 
NOD1 and NOD2 recruit TICK after recognition of their ligands (e.g. iEDAP and MDP, 
respectively). RICK in turn activates the IkB kinase (IKK) complex and nuclear factor NF-
kB sequentially, leading to the translocation of NF-kB to the nucleus and subsequent pro-
inflammatory cytokine transcription. Adapted from (Lee et al., 2007). 
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 In what concerns the NALP family of NLRs, several members have been 
involved in the activation of signal-induced multiprotein complexes called 
Inflammasomes (Martinon et al., 2002; Martinon et al., 2007a). Inflammasome 
complexes are involved in the activation of inflammatory Caspases, such as 
Caspase-1, that are essential for the processing of immature pro-inflammatory 
cytokines (pro-IL-1!, pro-IL-18 and possibly pro-IL-33) into their mature and 
secreted forms (reviewed in Tschopp et al., 2003; Martinon et al., 2009). At least 
two types of NALP Inflammasomes have been identified, the NALP1 and the 
NALP2/3 Inflammasomes. The NALP1 Inflammasome comprises NALP1, the 
adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD 
domain), Caspase-1 and Caspase-5 (Figure 7). NALP2/3 Inflammasomes 
composed of ASC, CARDINAL and Caspase-1, in addition to NALP2 or NALP3 
(Figure 7, Martinon, 2004; Martinon et al., 2007a). In both Inflammasomes, 
activated NALPs, via their PYD effector domains, recruit ASC (containing PYD 
and CARD domains), which in turn recruits Caspase-1 via CARD-CARD domain 
interaction. NALP1 also recruits Caspase-5 via its additional CARD effector 
domain at the C-terminus, whereas NALP3, lacking such a CARD domain, can 
recruit additional Caspase-1 via interaction with the CARD-containing adaptor 
protein, Cardinal. The close proximity of the Caspases in the Inflammasomes is 
thought to promote their cross-activation, thus leading to the maturation of the pro-
inflammatory cytokines (reviewed in Martinon et al., 2007a; Martinon et al., 
2009).  
 
 Members of the IPAF/NAIP family of NLRs have also been shown to be 
involved in the formation of Inflammasomes and therefore Caspase-1 activation, 
with subsequent IL-1! processing and release (Franchi et al., 2006; Miao et al., 
2006; Sutterwala et al., 2009). IPAF Inflammasome have been shown to be 
important in the generation of an inflammatory response to several pathogens, such 
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as S.typhimurium (Mariathasan et al., 2004; Franchi et al., 2006; Miao et al., 
2006), L. pneumophila (Amer et al., 2006; Zamboni et al., 2006), S.flexneri (Suzuki 
et al., 2007) and P.aeruginosa (Franchi et al., 2007; Sutterwala et al., 2007). The 
IPAF Inflammasome composition and role in IL-1! processing is quite similar to 
the other NALP Inflammasomes, although, since IPAF can interact directly with 
pro-Caspase-1 through CARD-CARD interaction (Figure 7), the role of the adaptor 
molecule ASC in IPAF-mediated Caspase-1 activation is unclear (reviewed in Lee 
et al., 2007; Martinon et al., 2009). More recently, another Inflammasome have 
been discovered, the AIM2 Inflammasome. This Inflammasome was shown to be 
activated upon the recognition of cytosolic dsDNA, and to recruit the ASC adaptor 
molecule to mediate activation of Caspase-1 (Burckstummer et al., 2009; 
Fernandes-Alnemri et al., 2009a; Hornung et al., 2009; Roberts et al., 2009). 
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Figure 7 - The different Inflammasomes and their compositions. The Inflammasome 
name is attributed according to the NLR involved. NALP3 Inflammasome is composed of 
NALP3, the adapter protein ASC and Caspase-1. Due to the lack of a CARD domain, 
NALP3 recruits ASC to mediate the interaction with Caspase-1. NALP1! and IPAF 
Inflammasomes composition is still controversial. Although NALP1! and IPAF contain a 
CARD domain, thus the requirement of the adaptor protein ASC to form an Inflammasome 
is not well defined. Upon Inflammasome activation by the different PAMPS/DAMPs 
recognized by the NLR, Caspase-1 is activated and processing of proIL-1!, proIL-18 and 
proIL-33 occurs. The mature forms of the cytokines are then secreted. Adapted from 
(Lamkanfi et al., 2009a). 
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   1.1.1.2.2.2 - Regulation 
 
 The mechanisms of NLR signaling pathways regulation are less 
understood than the TLR counterparts; however, several regulators of NLRs have 
also been described (Figure 8). These include ErbB2-interacting protein (ERBIN) 
that has been shown to bind specifically to NOD2 and therefore inhibiting NOD2 
dependent NF-kB and MAPK signaling (McDonald et al., 2005). A short isoform 
of NOD2, NOD2-s (which encodes only one CARD domain) has been shown to 
interact with NOD2 adaptor RICK and block NOD2 dependent NF-kB activation 
(Rosenstiel et al., 2006).  
The majority of NLR regulators described so far are related to the 
Inflammasome regulation, namely the CARD-containing proteins and PYD-
containing proteins (reviewed in Martinon, 2004; Stehlik et al., 2007; Martinon et 
al., 2009). The PYD-containing regulators are believed to exert its inhibitory effect 
due to PYD-PYD interaction between NALPS and the adaptor ASC. Among the 
PYD regulators are Pyrin, POP1, POP2 and viral PYDs (vPYDs). POPs and some 
vPYDs (e.g. poxviral gene M13L-PYD, Benedict et al., 2005) are short proteins 
that contain mainly a PYD domain, therefore the name POP (Pyrin Only Protein). 
Poxviruses deficient in vPYD show an enhanced activation of Caspase-1 and IL-1! 
secretion, further demonstrating a negative effect of vPYDs in Inflammasome 
activation (Benedict et al., 2005; Johnston et al., 2005; Dorfleutner et al., 2007). In 
a similar way it was shown that POP1 and POP2 modulate Inflammasome activity 
probably due to ASC-NALP interaction disruption (Bedoya et al., 2007; Stehlik et 
al., 2007). Pyrin, was initially identified as the product of the MEFV gene, which 
is mutated in patients with Familial Mediterranean Fever (FMF), was shown to 
interact with ASC, therefore blocking the recruitment of ASC and Inflammasome 
formation (consortium, 1997; Chae et al., 2003; Chae et al., 2006; Papin et al., 
2007). Several CARD-containing proteins have been described to inhibit 
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processing of IL-1! by preventing recruitment and/or activation of the Caspase by 
the adaptor ASC, due to homotypical CARD-CARD interactions. Iceberg, a highly 
similar protein to the CARD of Caspase-1 was shown to function as a decoy 
protein by sequestering Caspase-1 via its CARD domain, therefore preventing 
binding to activating adaptors (Humke et al., 2000; Druilhe et al., 2001). Other 
highly homolog proteins to the Caspase-1 CARD domain have been found to, by a 
mechanism similar to Iceberg, disrupt Caspase-1 activation, INCA and 
COP1/Pseudo-ICE respectively (Druilhe et al., 2001; Lee et al., 2001; Lamkanfi et 
al., 2004). Caspase-12 was recently identified as a negative regulator of the 
inflammatory cytokine response by binding to and inhibiting Caspase-1 (Saleh et 
al., 2004; Saleh et al., 2006). The pro-domain (a CARD domain) was shown to be 
sufficient for causing reduced cytokine secretion. Although, NOD2 precise role in 
Caspase-1 activation is still very controversial, it has been shown that although 
NOD2-S does not interact with Caspase-1 but with its adaptor RICK and competes 
with NOD2 for RICK binding, it results in impaired Caspase-1 activation 
(Rosenstiel et al., 2006). The NLR protein PYNOD (NALP10) interacts with ASC 
but lacks the ligand-sensing LRRs (Wang et al., 2004). Although removal of the 
LRR from NLRs usually renders them constitutively active, PYNOD associates 
with ASC without recruiting and activating Caspase-1 (Wang et al., 2004). One of 
the first identified Caspase-1 inhibitors was cytokine response modifier A (CrmA) 
from cowpox virus, which forms a complex with the catalytic center of Caspase-1 
(Ray et al., 1992).  Caspase-1 activity can also be blocked by Flightless-I (Li et al., 
2008) and the serpin protease inhibitor 9 (Pi9, Young et al., 2000). More recently, 
Bcl-2 and Bcl-xL were also suggested to influence NALP1 Inflammasome 
activation (Bruey et al., 2007). 
  
 
 
                                                                                                           Chapter 1 - Introduction          
 
39 
 
Figure 8 - Negative regulation of NLRs signaling pathways and Inflammasome. NOD 
signaling is inhibited by ErbB2-interacting protein (ERBIN) and the alternatively spliced 
isoform of NOD2 (NOD2s), which directly bind to NOD2 or compete with NOD2 for 
RICK binding, respectively, therefore inhibiting downstream signaling. Several CARD-
containing proteins (represented in violet) have been identified to inhibit NALP3 
Inflammasome by binding to ASC/Caspase-1 CARD domains. Among them are COP1, 
INCA, Caspase-12, Iceberg, PYNOD and NOD2s, however this last one is still under 
debate. PYD-containing proteins (depicted in green) that interact with PYD domains of 
NALP3 and ASC have also been reported to inhibit the Inflammasome. These include 
Pyrin, viral PYD-containing proteins (vPYDs), POP1 and POP2. Caspase-1 can be directly 
blocked by Flightless-I, the serpin protease inhibitor (Pi9) and the cowpox-virus encoded 
inhibitor of Caspase-1, vCrmA. Bcl-2 and Bcl-xl proteins have been shown to inhibit 
NALP1 Inflammasome oligomerization, by binding to NALP1. Adapted from (Martinon et 
al., 2009). 
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1.1.2 - The IL-1!  pathway: a PRR crosstalk 
 
 
Several types of PRR-PRR interplay have already been described. Many 
TLRs can influence the expression of other TLRs. For example, TLR3 and 4 
stimulation was shown to upregulate TLR2 expression on the surface of 
macrophages in a MyD88-independent manner, whereas TLRs 2, 7 and 9 do so in 
a MyD88-dependent way (Nilsen et al., 2004). TLR4 stimulation can upregulate 
TLRs 2, 4 and 9 mRNA expressions in DCs, in an ERK and NF-kB dependent 
manner (An et al., 2002a; An et al., 2002b). Although this upregulation of TLRs by 
other TLRs stimulation often results in an increased Immune response due to the 
engagement of several TLRs, the initial stimulation dose and the timing of 
stimulation by the second TLR agonist can influence the Immune response 
(Napolitani et al., 2005). For example, it has been shown that a strong first 
stimulation of the TLR can also induce TLR-signaling inhibitors expression, such 
as MyD88s (a short splice variant of MyD88 that acts as a dominant negative 
isoform of MyD88 dependent signaling pathway, Janssens et al., 2002).  
Certain TLRs can also diversify their recognition repertoire by interacting 
with other TLR/PRRs. As an example, TLR2 can form heterodimers with TLR6 
and TLR1 to recognize different lipopeptides (as shown in Figure 2), dyacil and 
tryacil lipopeptides, respectively (Takeuchi et al., 2001; Takeuchi et al., 2002). 
Furthermore, TLR2/6 complex can also interact with other PRRs, such as Dectin-1 
(a member of the C-type lectin family involved in the recognition of fungal cell 
wall components, such as !-glucans, Brown et al., 2001; Pyz et al., 2006) to 
recognize microbes and therefore to modulate an Immune response (Gantner et al., 
2003; Brown, 2006; Dillon et al., 2006).   
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Interplay between TLRs and NODs has also been described. For example, 
NOD1 and NOD2 agonists act cooperatively with LPS (a typical TLR4 agonist) to 
stimulate the production of inflammatory cytokines such as TNF" and IL-6, induce 
DC maturation (Fritz et al., 2005) and T cell differentiation (Tada et al., 2005). 
However the underlying mechanism(s) for the synergistic effect of NOD agonists 
on TLR-mediated cytokine production is largely not well understood. There are 
already some “hints” such as the increased expression of NOD2 and RICK upon 
TLR4 stimulation (Inohara et al., 2005) and the upregulation of MyD88 and 
TAK1 expression upon NOD2 and NOD1 stimulation, respectively (Inohara et al., 
2005; Masumoto et al., 2006). The classical example, and probably the best-
studied crosstalk between TLRs and other PRRs, is their joint action with NLRs 
leading to the secretion of mature IL-1! in an inflammatory response (Creagh et 
al., 2006; Dinarello, 2009; Martinon et al., 2009).  
 
 
1.1.2.1 - The IL-1!  pathway 
 
Interleukin-1! secretion is mainly described as a two-step process, that 
requires production of immature pro-IL-1! and a second processing step that leads 
to the maturation of this cytokine, prior to its release (reviewed in Eder, 2009; 
Dinarello, 2009; Martinon et al., 2009; Netea et al., 2010). While the first step 
required for IL-1! secretion, the production, is mainly TLR activation dependent, 
the second and processing step is NLR dependant (Figure 9, reviewed in Eder, 
2009; Dinarello, 2009). After stimulation, TLRs induce activation of the NF-kB 
pathway, leading to a strong IL-1! transcription (reviewed in Creagh et al., 2006; 
Lee et al., 2007; Dinarello, 2009; Martinon et al., 2009). However, several 
exceptions were already reported, as members of the NOD subclass of NLRs were 
also identified as important mediators of IL-1! production following different 
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stimuli, such as intracellular bacteria (Figures 6 and 9 , reviewed in Chamaillard et 
al., 2003; Delbridge et al., 2007; Franchi et al., 2007; Lee et al., 2007). The 
translation step, that generates the immature pro-IL-1!  occurs in the cytosol. 
Then, the processing, that leads to the effective production of mature IL-1! and its 
secretion depends on the activation of the Inflammasome complex (Figure 9, 
Martinon et al., 2002; reviewed in Martinon et al., 2009). Several major 
Inflammasomes involved in the activation of Caspase-1 and subsequent IL-1! 
processing have been described, but the NALP3 Inflammasome is by far the most 
studied (Figure 7, reviewed in Lamkanfi et al., 2009; Martinon et al., 2009). A 
large number of stimuli have been described to activate the NALP3 
Inflammasome, as described in Table 2, however the precise mechanism that leads 
to its activation is still unclear and several hypothesis have been drawn. A direct 
ligand-receptor interaction, between the LRRs of NALP3 and the activator, have 
been conceptually proposed to occur. This interaction would lead to a 
conformational change in the NLR, allowing oligomerization and Inflammasome 
formation, however no direct binding between NALP3 activators and the NLR 
itself have been found (reviewed in Martinon et al., 2009; Stutz et al., 2009). 
Another hypothesis relies on the necessity of low intracellular potassium 
concentrations to promote NALP3 Inflammasome activation (Pétrilli et al., 2007). 
This hypothesis is based in the evidences showing a need for potassium efflux for 
the activity of most, if not all, NALP3 Inflammasome stimuli (e.g. pore forming 
toxins, Perregaux et al., 1994; Walev et al., 1995; Pétrilli et al., 2007; Dostert et 
al., 2008). Others claim that ROS can act upstream of the NALP3 Inflammasome, 
therefore indirectly causing its activation (Cruz et al., 2007; Pétrilli et al., 2007; 
reviewed in Stutz et al., 2009). Phagosomal and lysossomal destabilization 
phenomenon as a mechanism of Inflammasome activation has also been proposed. 
Activation of NALP3 Inflammasome was observed upon phagosomal 
destabilization using crystals (e.g. silica) or by pharmacological disruption of 
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lysosomes (Hornung et al., 2008). According to this theory, NALP3 can sense 
phagosomal or lysosomal disruption as danger signals and thereby could indirectly 
sense excessive crystal phagocytosis or escape of microbes from the lysosomal 
compartments to the cytosol, therefore activating the processing and release of this 
pro-inflammatory cytokine (reviewed in Stutz et al., 2009; Shi et al., 2010). 
 
Figure 9 – IL-1! synthesis and processing, a classical example of TLRs and NLRs 
interplay. TLR stimulation induces strong transcription of IL-1! via activation of the NF-
kB transcription factor. NOD1 and NOD2 stimulation can also activate NF-kB pathway 
and therefore IL-1! transcription. IL-1! is produced as an inactive cytoplasmic precursor 
that is proteolytic processed by the inflammatory Caspase-1 to generate the mature secreted 
active form. Caspase-1 is also synthesized as an inactive form that requires processing by 
the Inflammasome to become active. Upon activation of NALP/IPAF NLR (e.g. NALP3) 
the Inflammasome complex is formed, and Caspase-1 activated, leading to the sequential 
maturation of IL-1! into its active secreted form. Adapted from (Lee et al., 2007). 
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The importance of TLRs in IL-1! pathway does not seem to be restricted 
to the production of a large quantity of the immature proIL-1! protein, it is far 
more complex than that. Several evidences suggest the involvement of TLR 
signaling in Caspase-1 activation itself. Costimulation of macrophages with 
extracellular ATP (a known inducer of potassium efflux) and LPS (TLR4 agonist) 
activates Caspase-1 efficiently, whereas extracellular ATP alone does not 
(Kahlenberg et al., 2005; Ferrari et al., 2006; Mariathasan et al., 2006). 
Kahlenberg et al. have shown that Caspase-1 activation by TLR is mediated by yet 
unknown protein(s) expressed as a result of NF-kB pathway activation upon TLR 
stimulation, but not of other signaling pathways such as MAPKs or PI-3K 
(Kahlenberg et al., 2005). In this context, activation of the NF-kB pathway by 
different ligands seems to be a critical checkpoint needed for cell priming prior to 
NALP3 Inflammasome activation by ATP (Bauernfeind et al., 2009; Franchi et 
al., 2009). 
Upon secretion, cytokines elicit their responses by binding to specific high 
affinity cell-surface receptors on target cells, initiating a series of intracellular 
signal transduction pathways. Interleukin-1! signals via the Type I IL-1 Receptor 
(IL-1RI, Sims et al., 1988; reviewed in O'Neill, 2008). The IL-1RI is a 
trasmembrane receptor, composed of three immunoglobulin domains in the 
extracellular part and a cytoplasmatic signaling TIR domain (reviewed in Gabay et 
al., 2010). The TIR domain shares some homology with the intracellular domain of 
the TLR family members, thus, eliciting similar signaling pathways (reviewed in 
O'Neill, 2000; O'Neill, 2008). Briefly, upon IL-1! binding, the IL-1R recruits the 
IL-1R accessory protein (IL-1RacP, Greenfeder et al., 1995). Then, in a similar 
way to the TLR signaling pathway, successive signaling events will culminate in 
transcription activation of several genes, mainly in an NF-kB dependent manner 
(Osborn et al., 1989; reviewed in O'Neill, 2000; O'Neill, 2008). 
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1.1.3 - IL-1!  (Dis)Regulation and Related Diseases 
 
 
  It is well established that a controlled inflammatory as response to 
infection or tissue damage is beneficial, however if not tightly regulated can show 
remarkable detrimental effects (reviewed in Medzhitov, 2008). As an example, the 
induction of IL-1! secretion shows remarkable beneficial effects against infection 
from a serious number of microbia, however, if not regulated, excessive circulant 
levels of IL-1! can be the cause of several autoinflammatory diseases (reviewed in 
Church et al., 2008; Martinon et al., 2009). Increased IL-1! levels have been 
related to atherosclerosis (Iida et al., 2009), type-2 Diabetes (Alexandraki et al., 
2006) and various autoimmune disorders, such as Crohn’s disease (Martinon et al., 
2009). Neurodegenerative diseases that are accompanied by inflammatory 
processes, such as Multiple Sclerosis, Alzheimer or Parkinson’s diseases, have also 
been characterized by augmented IL-1! levels (Allan et al., 2005; Simi et al., 
2007). Interleukin-1! has also been shown to facilitate tumor invasiveness (Apte et 
al., 2006) and promote tissue damage in the pathogenesis of a chronic 
Inflammation (Church et al., 2008; Martinon et al., 2009). Blocking IL-1! receptor 
with synthetic IL-1! receptor antagonists, such as Anankira (Fitzgerald et al., 
2005; Kalliolias et al., 2008; Lequerre et al., 2008), was found to reduce the 
severity of systemic-onset juvenile arthritis, acute pancreatitis and several 
autoinflammatory disorders, including the adult-onset Still’s disease, lupus 
arthritis, among others (Dinarello, 2005b; Burger et al., 2006; Martinon et al., 
2009). 
The important role of the Inflammasome and IL-1! in the inflammatory 
process is strongly supported by the genetic evidences that link the Inflammasome 
misregulation to several disorders, such as Family of Hereditary Periodic Fevers 
(HPFs, McGonagle et al., 2007; reviewed in Church et al., 2008; Stutz et al., 
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2009). Among the best described HPFs, is the cryopyrinopathy subfamily that 
include the Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells 
Syndrome (MWS) and the Chronic Infantile Neurological Cutaneous and Auricular 
Syndrome (CINCA/NOMID). All of these disorders are due to mutations in the 
third exon of the NALP3 gene, which lead to spontaneous oligomerization of 
NALP3 Inflammasome with subsequent Caspase-1 activation, giving rise to 
excessive and inappropriate IL-1! release (Agostini et al., 2004; Aksentijevich et 
al., 2007; Shinkai et al., 2008). Other autoinflammatory diseases, such as FMF, 
have also been associated with the NALP3 Inflammasome misregulation. FMF is 
an autossomal-recessive disorder caused by mutation in the Pyrin gene, leading to 
a reduced ability to moderate IL-1! processing and release (Gumucio et al., 2002; 
Papin et al., 2007). Mutations in other NLRs have also been found to be the 
causative effect or to increased susceptibility to several inflammatory diseases 
(such as Crohn’s disease and Hereditary Fever Syndrome, reviewed in McGonagle 
et al., 2007; Martinon et al., 2009; Stutz et al., 2009; Gabay et al., 2010). Mutated 
NOD2 gene have been found to be associated with increased susceptibility to 
Crohn’s disease, a chronic and relapsing inflammatory disease of the bowel 
(Ogura et al., 2001, Maeda et al., 2005), while several mutations in the NALP12 
gene have been associated with hereditary periodic fever syndromes (Jéru et al., 
2008). 
Because of its potency, extensive functions and the increased number of 
diseases associated with excessive circulant levels of IL-1!, it became clear the 
necessity of a tight regulated mechanism of IL-1! secretion in order to avoid 
excessive inflammatory conditions leading to disease.  
The process that leads to IL-1! secretion is the outcome of a two-step 
mechanism where TLRs are involved primarly in the first step and NLRs in the 
second. Consequently, all the regulators mentioned reported previously to be 
involved in the regulation of either TLR or NLR signaling pathways, can exert 
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similar functions in the regulation of IL-1! secretion. As an example, known 
inhibitors of the Inflammasome, such as Iceberg or Pyrin, were shown to be able to 
modulate IL-1! secretion (consortium, 1997; Humke et al., 2000; Druilhe et al., 
2001; Chae et al., 2003; Chae et al., 2006; Papin et al., 2007). In a similar manner, 
known regulators of TLR signaling pathway were shown to be able to regulate the 
secretion of this cytokine (e.g. MyD88s, Janssens et al., 2002).   
 
 
1.1.3.1 - Alternative Splicing and the Regulation of IL-
1! secretion 
 
 A functional Immune system utilizes a wide range of proteins produced by 
Immune cells to adapt and respond to the rapidly changing environmental 
conditions. Thus, the massive functional changes required to respond to the diverse 
challenges the Immune System has to face, several mechanisms of gene regulation 
are required to achieve diversity and flexibility of functions (Lynch, 2004; Miosge 
et al., 2005). Alternative Splicing (AS) has emerged recently as a major regulatory 
process that contributes to the biological complexity and diversity required by a 
competent Immune system. Alternative Splicing can direct the inclusion or 
exclusion of regulatory sequences located in the 5’ or 3’ untranslated regions, 
therefore capable of controlling mRNA stability, cellular distribution and 
translation efficiency (Chapter 1.2, reviewed in Black, 2003; Chen et al., 2009). In 
addition, AS can alter the structure of the gene product by the insertion or deletion 
of novel protein coding parts, therefore allowing a single gene to generate more 
than one messenger RNA molecule (mRNA), so-called isoforms (reviewed in 
Black, 2003; Wang et al., 2008; Chen et al., 2009). As a matter of fact, an 
increasing amount of studies focus AS as one of the most important protein 
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diversity generator mechanisms involved in the regulation of several cellular 
functions, where Immune responses are obviously included (reviewed in Black, 
2000; Lynch, 2004; Leeman et al., 2008; Wang et al., 2008; Sahoo et al., 2010). 
In the past years, in an attempt to unveil the mechanisms involved in the 
regulation of Inflammation and other Immune responses, diverse isoforms of 
important key-molecules in different signalling pathways were found to recurrently 
be involved in their regulation (reviewed in Lynch, 2004; Litman et al., 2007; 
Leeman et al., 2008; Mourich et al., 2009). As an example, splice variants have 
been detected in several genes expressed in T cells, with functional consequences 
(reviewed in Lynch, 2004). One example is the Splicing of the cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), where either a transmembrane or 
soluble forms are generated by AS in response to T cell activation (Magistrelli et 
al., 1999; Oaks et al., 2000). Another example is the Splicing of protein tyrosine 
phosphatase CD45. It was shown that different AS generated isoforms of CD45 are 
present in naïve and active T cells (Trowbridge et al., 1994; Lynch et al., 2000; 
Oberdoerffer et al., 2008).   
Several genes involved in IL-1! secretion and Inflammation have also 
been shown to be regulated by AS (Figure 10, reviewed in  Leeman et al., 2008; 
Krieg et al., 2009; Matsushita et al., 2009a;!Sahoo et al., 2010). An Alternatively 
spliced isoform of the MyD88, MyD88s, was reported to be able to modulate TLR 
signaling pathway activation and IL-1! secretion (Janssens, 2002). This short 
isoform was reported to be induced in monocytes after 16 hr of LPS challenge. 
Despite the capabillity of MyD88s to bind the IL-1R and IRAK, it is defective in 
its ability to induce IRAK phosphorylation and NF-kB activation, therefore 
behaving as a dominant negative inhibitor of IL-1! secretion upon LPS challenge 
(Janssens, 2002; Burns et al., 2003; Janssens, 2003). Similar to MyD88s, 
alternatively spliced isoforms of other important molecules involved in the IL-1! 
pathway have been found to be able to regulate this pathway, such as: NOD2s, a 
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short isoform of NOD2 (Rosenstiel et al., 2006; Leung et al., 2007); IRAK2 
isoforms (Hardy et al., 2004) and more recently an ASC isoform was also 
identified, vASC, also capable of modulating IL-1! secretion (Matsushita et al., 
2009a). Alternative Splicing isoforms of the IL-1R antagonist (IL1-RA) were also 
reported to exist, namely a secreted (sIL-1RA) and two intracellular (icIL-1RaI, 
icIL-1RaII) isoforms (Malyak et al., 1998; reviewed in Sahoo et al., 2010). The 
endogenous expression or exogenous administred IL-1RA isoforms antagonize the 
IL-1! pro-inflammatory effects, therefore being capable of modulating this 
Immune response (reviewed in Dinarello, 2009). The expression of IL-1! and its 
receptor, IL-1R was also demonstrated to be regulated by AS (reviewed in Sahoo 
et al., 2010). Three isoforms of IL-1RI were reported in primary cultures of rat 
hepatocytes. Two of the membranar isoforms were related to increased 
transcription and mRNA stability of the inducible Nitric Oxide Synthase, whereas 
the soluble isoform decreased the IL-1! induced Nitric Oxide production (Yamada 
et al., 2007). Several isoforms of IL-1! were identified in different cell types and 
organisms. In rainbow trout, three IL-1! isoforms of incompletely spliced variants, 
containing intron 5 or introns 4 and 5, were detected in gills, kidney, liver and 
spleen tissue from bacterially challenged fish but only the fully spliced transcript 
was detectable in blood (Sahoo et al., 2010). In equine peripheral blood 
mononuclear cells, an isoform of IL-1! not containing the exon 5 region necessary 
for normal maturation of the cytokine by Caspase-1 was also identified (Kato et 
al., 1996). Moreover, the expression of the different IL-1! isoforms is sometimes 
linked with the appearance of disease. For example, increased expression of the IL-
1! splice variant 1 (IL-1!sv1) in the myocardium of dogs is linked with a severe 
heart failure due to a chronic degenerative valvular disease (Kiczak et al., 2008). 
  
 
 
 
“Identification of Splicing Factors with a role in IL-1! secretion”              
 
 
50 
 
Figure 10 - Alternative Splicing regulation of IL-1!  secretion. Several genes involved 
in the regulation of IL-1! secretion pathway have been shown to be regulated by AS. These 
genes are marked with an asterisk. Adapted from (Leeman et al., 2008; Krieg et al., 2009; 
Matsushita et al., 2009a). 
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In sum, as represented in Figure 10, the expression of a large number of 
genes involved in IL-1! secretion pathway were already described to be regulated 
by AS. Despite the identification of the different isoforms of important molecules 
involved in this pathway, not much is known about the mechanisms involved in the 
regulation of their expression and their roles in the regulation of IL-1! secretion. 
All these information lead us to investigate impact of AS in the regulation of 
Inflammation, namely the regulation of IL-1! secretion.  
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Chapter 1.2 - Alternative Splicing 
 
 
 “A number of genes in higher organisms and in their viruses appear to be 
split… they have nonsense stretches of DNA interspersed within the sense DNA. 
The cell produces a full RNA transcript of this DNA…and then appears to splice 
out the nonsense sequences before sending the RNA to the cytoplasm.” 
 
 
                  Francis Crick, 1979 
 
 
 In Eukaryotes, gene expression involves several steps that start with 
transcription. After transcription, where DNA is transcribed into a precursor 
messenger RNA (pre-mRNA) by the RNA polymerases (RNA pol), several 
processing steps (e.g. 5’capping, Splicing, 3’end processing and editing)  occur in 
the cell nucleus before the export of the mature messenger RNA (mRNA) to the 
cytoplasm, where it serves as template for the synthesis of a protein (reviewed in 
Orphanides et al., 2002). However, it is now accepted that some of these steps 
occur simultaneously as a part of a continuous process, and not in an independent 
successive mechanism as it was thought in the past (reviewed in Cramer et al., 
2001; Orphanides et al., 2002; Licatalosi et al., 2010). For example, coupling 
between transcription and the capping step of pre-mRNA processing (reviewed in 
Shatkin et al., 2000; Cramer et al., 2001; Proudfoot et al., 2002) and between 
transcription and pre-mRNA Splicing (reviewed in Cramer et al., 2001; Fong et 
al., 2001; Kornblihtt et al., 2004). 
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 Several RNA polymerases were identified, however, the majority of 
eukaryotic genes are transcribed by RNA pol II transcription machinery (reviewed 
in Cramer et al., 2001). The primary transcripts synthesized by the RNA pol II, 
pre-mRNA, undergo several specific modification steps before being transported to 
the cytoplasm, namely: 5’capping, Splicing, 3’ processing and editing (reviewed in 
Cramer et al., 2001; Orphanides et al., 2002).  
 A capping step at the 5’ end occurs soon after the RNA poll II transcribes 
the first 25-30 nucleotides (reviewed in Proudfoot et al., 2002). This 5’ cap 
minimizes its degradation by the nucleases and allows the interaction with proteins 
involved in export of mRNA into the cytoplasm (reviewed in Cramer et al., 
2001;Proudfoot et al., 2002).  
 The pre-mRNA Splicing is an essential step in the regulation of gene 
expression due to the nature of eukaryotic genes. An eukaryotic gene is 
characterized by a very large interruption of the coding sequence with large non-
coding sequences, which have to be removed during this step of RNA biogenesis 
in order to place the coding sequences in a protein-reading frame (discussed further 
in greater detail, reviewed in Orphanides et al., 2002; Soller, 2006).  
 At the 3’end, the majority of  RNA pol II transcripts are cleaved and a 
polyadenosine, poly(A), tail of about 200-250 adenosines is added, providing 
binding sites for a major class of regulatory factors, the poly(A)-binding proteins 
(PABPs,Orphanides et al., 2002; Soller, 2006 ). These PABPs exert several 
function in the gene expression pathway, such as: polyadenylation, mRNA export, 
translation and turnover of the transcripts to which they are bound (reviewed in 
Mangus et al., 2003). 
 Until recently, the step of RNA editing was known to occur only in a few 
number of transcripts and was largely understimated due to the difficulty to detect 
the editing sites (reviewed in Skarda et al., 2009). This step is characterized by 
single nucleotides changes at the pre-mRNA level, either insertions or deletions of 
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nucleotides or by nucleic acid bases substitutions. These modifications can affect 
both coding and non-coding sequences, therefore this editing event can change both 
the sequence and the secondary structure of RNA molecules, with important 
consequences for both the final proteins and regulatory RNAs (reviewed in Keegan et 
al., 2001; Skarda et al., 2009).  
 Once processed, the mRNA is exported by binding to factors in the 
nucleus that direct the mRNA molecules into the cytoplasm through interactions 
with proteins that line the nuclear pores (reviewed in Reed et al., 2002; Cole et al., 
2006b; Cole et al., 2006a; Carmody et al., 2009). 
 In the cytosol, protein biosynthesis, or so-called translation, occurs on the 
ribosome, a large RNA-protein complex (reviewed in Ramakrishnan, 2002; Dunkle 
et al., 2010; Jackson et al., 2010). The mRNA translation, is a highly coordinated 
mechanism involving many proteins and RNAs, which is generally divided into 
three steps: initiation, elongation, and termination. Translation initiation can be 
subdivided into three steps: the binding of the specific start codon (AUG) 
ribosomal subunit; binding of the resulting complex to an mRNA and locating the 
initiation codon; and third, joining of the large ribosomal subunit to generate a 
translation-competent ribosome (reviewed in Ramakrishnan, 2002; Sonenberg et 
al., 2003; Dunkle et al., 2010; Jackson et al., 2010). The elongation process is a 
much simpler step that only requires to maintain the reading frame, select and 
deliver the correct aminoacyl-tRNAs to the ribosome, and form peptide bonds 
(reviewed in Groppo et al., 2009; Van Der Kelen et al., 2009). Upon the 
recognition of the stop codons, UAA, UAG or UGA, translation is termined 
(reviewed in Groppo et al., 2009; Van Der Kelen et al., 2009). Then, the nascent 
polypeptide undergoes folding and post-translational modification to give rise to 
the final active protein (reviewed in Daggett et al., 2003; Groppo et al., 2009). 
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1.2.1 - Splicing  
 
 
The term “Splicing” was probably used for the first time in the 1970s, 
when Francis Crick defined Splicing as the “mechanism by which a single 
functional RNA molecule is produced by the removal of one or more internal 
stretches of DNA during the processing of the primary transcript” (Figure 11, 
Crick, 1979). The Splicing discovery was achieved when a simple comparison of 
the mRNA sequence and its corresponding nuclear DNA revealed that long 
stretches of DNA were removed during the processing of the longer precursor 
(Berget et al., 1977; Chow et al., 1977). Gilbert et al. defined these long stretches 
of “DNA” not included in the final mRNA as “introns” (intervening sequences), 
and named “exons” (expressed sequences) the sequences of “DNA” that end up 
expressed in the final mRNA (Gilbert, 1978). Nowadays, it is known that the 
process of intron removal occurs at an RNA processing step and not at the DNA 
level, as suggested by Gilbert. However, since then, the terminology intron/exon is 
still used to define those regions excluded and included in the mRNA, respectively 
(reviewed in Black, 2003).  
 
 
Figure 11 - RNA Splicing schematics. The gene is encoded by 3 exons (1, 2 and 3) and 2 
introns (A and B). In the final mRNA just the exons are expressed and the introns were 
spliced out. Adapted from (Crick, 1979). 
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In the early times of RNA Splicing studies, four mechanisms of Splicing 
were proposed. First, the DNA rearrangement mechanism, where the cell would 
rearrange its own DNA in order to displace or eliminate the sequences that were 
not needed. Second, the process where DNA would remain unaltered, but the RNA 
polymerase would “jump” along the DNA sequence, skipping the introns and 
including only the exons in the mature RNA. The third mechanism proposed that 
each exon would be transcribed separately, and the pieces joined together to form 
the mature RNA. Finally, the fourth mechanism where the RNA polymerase would 
make a primary transcript of the whole region, including exons and introns. This 
transcript would then be processed so that the introns were removed and the exons 
joined together (reviewed in Crick, 1979). Nowadays, it is accepted that the 
Splicing mechanism occurs in a two-step fashion (Figure 12), both involving single 
transterification reactions. In the first step, the 2’-hydroxyl group of an A residue at 
the branch point attacks the phosphate at the 5’ splice site. This process will lead to 
the cleavage of the 5’ exon from the intron and the concerted ligation of the intron 
5’ end to the branch point 2’-hydroxyl, producing two reaction intermediates, a 
detached 5’ exon and an intron/3’-exon fragment in a lariat configuration 
containing a branched A nucleotide at the branch point. The second 
transterification reaction is the attack on the phosphate at the 3’end of the intron by 
the hydroxyl of the detached exon. This ligates the two exons and releases the 
intron, still in the form of a lariat (reviewed in Black, 2003).  
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Figure 12 – Splicing reaction. The Splicing reaction takes place in two transterification 
steps. The first step results in two reaction intermediates: the detached 5’exon and an 
intron/3’ exon fragment in a lariat structure. The second step ligates the two exons and 
releases the intron lariat. Adapted from (Burge, 1999). 
 
 
1.2.1.1 - At the Splicing Locus 
 
The RNA Splicing, like other events of gene expression is tightly 
regulated. Pre-mRNA Splicing regulation is achieved by the interplay between the 
cis-acting RNA sequence elements, and protein and/or RNA trans-acting factors 
that recognize these sequences. The position and composition of the cis-acting 
elements help to define the splice sites through the recruitment of the Spliceosome 
complex (Smith et al., 2000; Black, 2003). The Spliceosome is normally defined as 
a large multiprotein complex composed of five small nuclear ribonucleoproteins 
(snRNPs, U1, U2, U4, U5 and U6) and more than 50 non-snRNPs that recognize 
and assemble on the exon-intron processing of the pre-mRNA (reviewed in 
Makarov et al., 2002; Black, 2003; Jurica et al., 2003) 
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  1.2.1.1.1 - Splicing Machinery - The Spliceosome 
assembly and its dynamics 
 
The Spliceosome complex is not static, it is a highly dynamic molecular 
machinery whose composition is also not static and whose structure undergoes 
multiple rearrangements during each Splicing cycle. Spliceosome assembles onto 
the pre-mRNA through a series of complexes (Figure 13). During the assembly, 
the U1 snRNP binds to the 5’ splice site via base pairing between the splice site 
and the U1 snRNA, whereas the 3’ splice site elements are initially bound by a 
special set of proteins. SF1/BBP binds to the branch point (A) and the U2 snRNP 
auxiliary factor (U2AF), a heterodimer composed of a large (U2AF65) and a small 
(U2AF35) subunits, binds to the polypyrimidie tract (Py). The earliest defined 
complex in Spliceosome assembly, the E complex, contains the U1 and U2AF 
bound at the two intron ends. The E complex is then joined by the U2 snRNP, 
whose snRNA base pairs at the branch point, to form the A complex. This A 
complex then recruits the pre-formed U4/U6.U5 tri-snRNP, to form the mature 
Spliceosome, also called complex B. The conversion of the mature Spliceosome 
into a complex capable of catalyzing Splicing, named the activated Spliceosome or 
complex B*, unveils a major structural change in which the U1 snRNP interaction 
at the 5’ splice site is replaced with the U6 snRNP and both the U1 and U4 snRNPs 
dissociate from the complex. Subsequently, the activated Spliceosome catalyzes 
the first transesterification step of Splicing and complex C is formed. After the 
second step of Splicing, the mRNA is released and the post-spliceosomal complex, 
containing the excised intron and the U2, U5 and U6 snRNPs, disassembles. The 
snRNPs are then recycled for new rounds of Splicing (reviewed in Makarov et al., 
2002; Black, 2003; Jurica et al., 2003). 
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Figure 13 – Spliceosome assembly and dynamics. The Spliceosome contains five small 
nuclear ribonucleoproteins (U1, U2, U4, U5 and U6) that assemble to the intron (light 
blue).  The presence of auxiliary non-snRNPs is required for Spliceosome assembly and 
intron removal (represented in dark blue). Adapted from (Makarov et al., 2002; Black, 
2003; Jurica et al., 2003). 
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  1.2.1.1.2 - Splice site choice - The exon/intron 
definition 
 
 
The regulation of Splicing involves both cis and trans “players’, which are 
sequences in the pre-mRNA and cellular factors (RNA or protein), respectively. 
The relative functional strength of the splice sites influences the frequency of 
which an exon is included or excluded. Although, a pair of “strong” splice sites is 
not sufficient to define an exon. Many pseudo-exons that are flanked by predicted 
splice sites are not spliced at all (Sun et al., 2000; Wang et al., 2008b). This rises 
the point that other factors are important in exon definition. Additional elements 
known as Silencers or Enhancers have been shown to be key players in the 
definition of an exon (Blencowe, 2000).   
Cis acting auxiliary elements are highly variable in sequence but are 
extremely important in the exon/intron definition. These sequences occur within 
both exonic and intronic regions and can either promote recruitment of the 
Spliceosome and exon inclusion (Splicing Enhancers) or disrupt assembly of the 
Splicing machinery and cause exon skipping (Splicing Silencers). They are 
normally named according to their location and activity as Exonic Splicing 
Enhancers (ESEs) and Exonic Splicing Silencers (ESSs), when located in an exon; 
and Intronic Splicing Enhancers (ISEs) and Intronic Splicing Silencers (ISSs), 
when located in an intron, as can be seen in Figure 14 (reviewed in Matlin et al., 
2005). 
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Figure 14 – Splicing auxiliary elements. In addition to the splice-site consensus 
sequences, a number of auxiliary elements can influence Alternative Splicing. These 
include Exonic Splicing Enhancers and Silencers (ESE and ESS, respectively), and Intronic 
Splicing Enhancers and Silencers (ISE and ISS, respectively). Enhancers can activate 
adjacent splice sites or antagonize Silencers, whereas Silencers can repress splice sites or 
antagonize Enhancers. Silencers are represented in red and Enhancers in blue. Adapted 
from (Matlin et al., 2005). 
 
While a few regulatory sequences have been shown to function by directly 
creating RNA secondary structures that alter splice site recognition (Buratti et al., 
2004; Lim et al., 2004), the majority act primarily as platforms for binding of non-
snRNP regulatory proteins (reviewed in Matlin et al., 2005). Although the binding 
of each individual protein to cis elements on the RNA is weak, a high specificity is 
achieved through interactions of multiple RNA elements with proteins that can 
interact with other RNA-binding proteins (House et al., 2007). As a result, exons 
are recognized with a remarkable fidelity through combinatorial control of 
different proteins (Smith et al., 2000). Probably the best characterized of the 
regulatory elements, ESEs, bind a family of proteins known as SR proteins. In 
contrast, ESS typically function to repress exon inclusion by recruiting members of 
the hnRNP family of proteins (reviewed in Stamm, 2002; Shin et al., 2004; House 
et al., 2007). 
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  1.2.1.1.3 - The SR and hnRNP families of 
Splicing regulators 
 
 The two more prominent families of non-snRNP Splicing factors consist of 
serine - arginine (SR) proteins and heterogeneous nuclear ribonucleoproteins 
(hnRNPs). 
The SR proteins constitute perhaps the best-studied family of Splicing 
regulators. They are named SR due to their high Serine (S) and Arginine (R) 
contents. Members of this family of proteins have multiple functions in the pre-
mRNA Splicing reaction. All SR proteins have a modular organization and contain 
an N-terminal RNA-binding domain (RRM) that interacts with the pre-mRNA and 
a C-terminal RS domain that functions as a protein interaction domain, as can be 
seen in Figure 15. The modular structure of the SR proteins, allows that different 
modules can be exchanged among different family members maintaining their 
activity. For example, the RNA-binding domains can be exchanged between SR 
proteins (Chandler et al., 1997; Mayeda et al., 1999) and still bind the RNA in the 
absence of the RS domain (Caceres et al., 1993; Zuo et al., 1993; Mayeda et al., 
1999). The RS domains can also be exchanged among different SR proteins 
(Chandler et al., 1997; Wang et al., 1998b) and was also found to be possible to 
function when fused to hnRNP RNA binding proteins (Graveley et al., 1998). 
 
Figure 15 - Schematic diagram of human SR proteins. The domain structures of some of 
the human SR protein family members. RRM: RNA recognition motif; RRMH: RRM 
homology and RS: arginine/serine-rich domain. Adapted from (Graveley, 2000). 
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 In the cell, SR proteins migrate from speckles - subnuclear domains that 
may function as storage sites for certain Splicing factors - to sites of active 
transcription (Misteli et al., 1997; Misteli et al., 1998b; Misteli et al., 1999) and 
some SR proteins have been found to shuttle in and out of the nucleus (Caceres et 
al., 1998). The subcellular localization of SR proteins can be modulated by their 
phosphorylation state (Misteli et al., 1998a; Misteli et al., 1998b). A number of 
studies have shown that the serine residues within the RS domains of SR proteins 
are extensively phosphorylated (Gui et al., 1994a; Misteli et al., 1998a). The 
phosphorylation state of these proteins is involved not only in their distribution 
within the cell but also in the interactions among the different SR proteins (Gui et 
al., 1994a; Wang et al., 1998a; Xiao et al., 1998), both of which may change the 
ability of SR proteins to function in Splicing. It has been reported that both hyper- 
and hypo- phosphorylated SR proteins are unable to support Splicing (Prasad et 
al., 1999; Sanford et al., 1999), showing that the SR proteins activity is tightly 
regulated by their phosphorylation state (reviewed in Fluhr, 2008). Several kinases 
have been identified that can phosphorylate RS domains in vitro. These include the 
SR protein kinase family (SRPK1 and SRPK2), that only phosphorylates SR 
proteins (Gui et al., 1994b; Wang et al., 1998a), the dual specificity kinase Clk/Sty 
family (Colwill et al., 1996) and the DNA topoisomerase I (Rossi et al., 1996; 
Labourier et al., 1998). Evidence for a role of phosphorylation in alternative 
splice-site selection has come from the observation that overexpression of Clk/Sty 
kinase results in a shift of selected splice sites of cellular Clk1 and adenovirus pre-
mRNAs in vivo (Duncan et al., 1997) and that dephosphorylation induces a splice-
site switch in late adenoviral infection (Kanopka et al., 1998). 
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 Mechanisms of Splicing repression are normally associated with the 
hnRNP family of Splicing factors. In a simplistic way, hnRNP proteins directly 
antagonize the SR proteins function. HnRNP family is composed of more than 20 
proteins that associate with high-molecular-weight nuclear RNA. The members of 
this family contain RRM-type and KH-type RNA binding domains (Krecic et al., 
1999; Valverde et al., 2008), as well as auxiliary domains that are often involved in 
protein-protein interactions. Many hnRNPs are abundant nuclear proteins that 
shuttle between the nucleus and cytoplasm (Dreyfuss et al., 1993; Nakielny et al., 
1997). hnRNPs interact avidly with themselves and other factors forming the so 
called hnRNP complexes (reviewed in Krecic et al., 1999). Besides the function of 
hnRNPs in pre-mRNA Splicing, other functions have been attributed to this family 
of Splicing factors, such as transcriptional regulation (Michelotti et al., 1996; Du et 
al., 1998), telomere length maintenance and biogenesis (Ishikawa et al., 1993; 
LaBranche et al., 1998), polyadenylation (Bagga et al., 1998) and translation 
control (Ostareck et al., 1997; Collier et al., 1998). As the SR proteins, hnRNP 
proteins can also be modified post-translationally. Among the best-described 
modifications is phosphorylation (Mayrand et al., 1993; Xie et al., 2003) and 
methylation (Bedford et al., 2005). Other post-translational modifications have 
been reported, although less extensively, such as SUMOylation (Vassileva et al., 
2004) and acetylation (Kim et al., 2006).  
While much remains to be understood with respect to the mechanism by 
which these post-translational modifications of SR, hnRNP and other Splicing 
proteins change in response to extracellular stimuli and the influence in specific 
Alternative Splicing patterns, many studies already correlated changes in the 
phosphorylation states of these proteins with signal-induced regulation of several 
Alternative Splicing events (reviewed in!Black, 2003). 
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1.2.2 - Alternative Splicing 
  
 
“…from the very limited experimental data at present available to us, is that a 
chromosomal gene only produces a single protein, whereas a stretch of DNA in 
virus may produce more than one protein, depending on which way the primary 
transcript is spliced...” 
“…in most cases this is because viruses are short of DNA and, by various devices, 
their limited amount of DNA is made to code for more proteins than would 
otherwise be possible.” 
 Francis Crick, 1979 
  
 
 As Francis Crick observed in 1979 (Crick, 1979), several genes show 
different patterns of Splicing, therefore coding for more than one protein. This was 
probably one of the first observations of AS and of its importance in the generation 
of proteomic diversity. Interestingly, an analogy can be made with the Human 
Genome Project, where it was found that fewer genes exist than it was initially 
predicted (Lander et al., 2001; Venter, 2001), and the necessity of protein diversity 
generator mechanisms in the cell, where AS plays a major role (reviewed Black, 
2000; Maniatis et al., 2002; Kazan, 2003; Blencowe, 2006). However this cannot 
be attributed exclusively to AS, the use of multiple transcription sites and various 
post-translational modifications also play a role in the production of proteome 
complexity (reviewed in Quelle et al., 1995; Banks et al., 2000) 
 Probably the first report of a gene that undergoes AS dates from 1980, 
when David Baltimore and colleagues findings showed the generation of distinct 
isoforms, secreted and membrane bound, of the immunoglobulin gene (Alt et al., 
1980). If for a long time it was thought that this mechanism only occurred in 
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exceptional cases, the recent estimates indicate that the expression of 
approximately 93% of the Human multi-exon genes involves AS (Pan et al., 2008; 
Wang et al., 2008; Wahl et al., 2009). A typical multiexon pre-mRNA, can 
undergo multiple Splicing patterns, generating multiple mRNA isoforms of a 
single gene, therefore generating diversity. There are at least 5 distinct Alternative 
Splicing patterns described (Figure 16): inclusion or skipping of a cassette exon, 
selection of an alternative 5’ splice site, selection of an alternative 3’ splice site, 
inclusion of only one of two mutually exclusive cassette exons and intron 
retention.  Additional layers of complexity can be added when different 5’ and 3’ 
ends of mRNA are generated by the use of alternative promoters and alternative 
polyadenylation signals present in different exons (Cartegni et al., 2002; Black, 
2003). These complex combinations of exons and alternative segments show 
consequently different protein coding sequences.  
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Figure 16 – Patterns of Alternative Splicing. Constitutive sequences present in all final 
mRNAs are depicted as black boxes. Alternative RNA segments that can either be included 
or excluded from the final mRNA are represented by light grey and light blue boxes. 
Retained introns represented as burgundy boxes. a) a cassette exon can either be included 
or excluded in the mRNA. b) and c)  alternative 5’ and 3’ splice sites allow lengthening or 
shortening of particular exons. d) two adjacent cassette exons can be included or excluded 
from the mRNA in a mutually exclusive manner. e) an intron can be retained in the final 
mRNA. Adapted from (Cartegni et al., 2002). 
 
 Besides the major role AS plays as proteome diversity generator, its 
importance as a regulatory process that contributes to biological complexity 
through other mechanisms rather than just increasing proteomic complexity has 
becoming more evident (reviewed in Lareau et al., 2004). Alternative Splicing can 
regulate gene expression at different levels. A common case occurs when specific 
domains required for the activity of a certain gene are altered, generating non-
functional isoforms, therefore compromising specific gene functions (reviewed in 
Vilardell et al., 2000; Lareau et al., 2004; Resch et al., 2004;). Another mechanism 
of gene expression regulation is achieved when AS leads to the production of 
mRNA isoforms containing premature termination codons, targeting the transcripts 
for degradation via nonsense-mediated mRNA decay, therefore not available for 
translation (reviewed in Lewis et al., 2003; Hillman et al., 2004; Lejeune et al., 
2005). In addition, the production of specific spliced isoforms where protein-
coding regions are not changed may also regulate protein functions . As an 
example,  the generation of different isoforms where the removal or insertion of 3’ 
untranslated region (UTR) regulatory elements can alter mRNA subcellular 
localization, stability and translation efficiency (reviewed in Wickens et al., 2002; 
Bratu et al., 2003; Lareau et al., 2004). Alternative mRNAs differing in the 5’ 
UTR are also common and their expression may be regulated through alternative 
promoter usage (Zhang et al., 2004). 
  The increasing number of AS related studies have unveilled a great 
diversity of biological processes where this mechanism plays an important role 
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such as sex determination, programmed cell death and cell excitation and 
contraction (reviewed in Black, 2003; House et al., 2007). A classical example of 
AS regulated cellular process, is the regulation of apoptosis (Jiang et al., 1999; 
Paronetto et al., 2007). The antiapoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL 
play important roles in inhibiting mitochondria-dependent extrinsic and intrinsic 
cell death pathways. Alternative Splicing of the Bcl-x gene originates two 
isoforms, a long (Bcl-xl) and a shorter (Bcl-xs) isoforms with opposite functions, 
anti- and pro-apoptotic, respectively (Boise et al., 1993;!Youle et al., 2008). The 
mechanism of Bcl-x Splicing has been extensively studied and several Splicing 
factors (SF) have been implicated in the regulation of Bcl-x Splicing. Paronetto et 
al. (Paronetto et al., 2007) have shown that by modulating the concentration of 
several SFs, such as Sam68 and hnRNPA1, or by inducing mutations of “key” 
aminoacid residues, they would induce changes in the Splicing balance of Bcl-x 
from an non-apoptotic to an apoptotic isoform, thus showing the importance of a 
tight regulation of this process. As mentioned before in Chapter 1.1.3, a large 
number of Immune relevant genes, either in the Adaptative or Innate Immune 
systems, have also been shown to be regulated by AS (reviewed in Lynch, 2004; 
Wells et al., 2006; Leeman et al., 2008). 
  As a major regulator of different cellular functions, the tight regulation of 
AS modulates the physiological requirements of a cell. If the control of Alternative 
Splicing is disrupted, the result can be a failure to meet cellular and tissue 
requirements resulting in dysfunction and disease. In the past years several 
diseases have been associated with defects in RNA Splicing (reviewed in Tazi et 
al., 2008; Cooper et al., 2009). Where defects in general Splicing machinery are 
usually not compatible with life, changes in Alternative Splicing machinery can be 
normally tolerated by the organism, but sometimes being a cause of a disease. 
Although the majority of disease causing mutations has been observed either in cis 
and trans Splicing regulatory elements, mutations in core elements of the Splicing 
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machinery have also been reported. For example, an autosomal dominant form of 
retinitis pigmentosa is caused by a mutation in the Splicing factors PRPF31/U4-
61k and PRP8 (Vithana et al., 2001; Boon et al., 2007; Wilkie et al., 2008). Several 
diseases have been reported to be caused by point mutations in regulatory 
sequences (e.g. Spinal muscular atrophy, Zhang et al., 2008), changes in the ratio 
of protein isoforms generated by AS (e.g. Tauopathies, Andreadis, 2005; 
Andreadis, 2006), mutations leading to activation of cryptic splice sites (e.g. 
Hutchinson-Gilford proegeria syndrome, De Sandre-Giovannoli et al., 2006), 
mutations in the 5’splice site (e.g. Thalassemias, Birgens et al., 2007). Among the 
different pathologies where Splicing is playing a role, a recent report by Xiong et 
al. (Xiong et al., 2006) shows that in patients with inflammed muscle, the 
expression of the Splicing Factor ASF/SF2 is downregulated. Moreover, it was 
shown that this downregulation can be induced by a pro-inflammatory stimuli, 
such as TNF-a (Xiong et al., 2006; Balkwill, 2009).  Therefore, the increasing 
connection between alterations in AS patterns and disease, and the increased 
number of cellular processes regulated by AS, strongly suggests that the 
importance of a tight regulation of this process in different physiological 
conditions.  
We have decided to study the impact of AS regulation in the context of an 
inflammatory response, namely the secretion of IL-1! after a bacterial challenge. 
Our objective was to identify molecules involved in Splicing regulation (SFs) that 
can be implicated in the regulation of IL-1! secretion and their mechanism of 
action. 
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Chapter 2 - The Method and Experimental 
proceedings 
 
 
 
 
 
 
 
 
 
“No amount of experimentation can ever prove me right; a single 
experiment can prove me wrong.” 
 
Albert Einstein 
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2.1 - The method - RNA Interference  
 
 
 
 
 
“Andy introduced siRNAs as these small interfering RNAs, as we call 
them; the little chunks of RNA that go on and silence genes” 
 
 
Craig Mello, Nobel Prize lecture 2006 
 
 
 
RNA interference (RNAi) originally referred to the ability of exogenously 
introduced double-stranded RNA (dsRNA) molecules to trigger silencing of 
complementary messenger RNA sequences in the nematode Caenorhabditis 
elegans (Fire et al., 1998).  RNAi is an evolutionary conserved defense mechanism 
whereby genes are specifically silenced through degradation of messenger RNAs. 
It became clear that RNAi is mechanistically related to several other conserved 
RNA silencing pathways, which are involved in the cellular control of gene 
expression and in protection of the genome against mobile repetitive DNA 
sequences, such as retroelements and transposons (reviewed in Dykxhoorn et al., 
2005; Grimm, 2009; Moazed, 2009).  
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2.1.1 - The mechanism  
 
 
The mechanism by which dsRNA induces gene silencing involves a two-
step process. First, RNAi and related gene-silencing pathways are initiated by the 
production of small RNAs (20-30 nucleotides, Elbashir et al., 2001a; Elbashir et 
al., 2001b). Several classes of small regulatory RNA described, among them are 
short interfering RNAs (siRNAs), microRNAs (miRNAs) and PIWI-interacting 
RNAs (piRNAs, reviewed in Tolia et al., 2007; Moazed, 2009). Short interference 
(siRNAs) and miRNAS are 21-25 nucleotide molecules, which are generated from 
longer dsRNA precursors by Dicer, a ribonuclease III (RNase III) enzyme 
(Bernstein et al., 2001; Ketting et al., 2001). These small RNAs subsequently 
associate with members of the Argonaute family of proteins, which function as the 
core components of a diverse set of protein-RNA complexes called RNA-induced 
silencing complexes (RISCs, reviewed in Dykxhoorn et al., 2003; Tolia et al., 
2007; Hutvagner et al., 2008). RISCs use the small RNAs as guides for the 
sequence-specific silencing of messenger RNAs that contain complimentary 
sequence through inducing the slicing of the mRNAs or repressing their 
translation. After slicing, the cleaved target RNA is released, and the RISC is 
recycled for another round of slicing (Figure 17, reviewed in Dykxhoorn et al., 
2003; Dykxhoorn et al., 2005; Tolia et al., 2007).  
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Figure 17 – RNAi interference pathway, shRNA and synthetic siRNA delivered. The 
effector molecules that guide mRNA degradation are small 21-25 nucleotide dsRNA, 
termed short interfering RNA (siRNA), produced by the cleavage of long dsRNA. These 
siRNA are produced by the cytoplasmic Dicer family of RNase III-like enzymes, resulting 
in a characteristic 21-23 nucleotides dsRNA duplex with 2-3 nucleotide overhangs. The 
siRNAs are taken up into a multi-subunit ribonucleoprotein complex called RNA-induced 
silencing complex (RISC). The antisense (guide) strand of the siRNA directs the 
endonuclease activity of RISC to the homologous (target) site on the mRNA, resulting in 
mRNA slicing and RISC recycling for posterior rounds of silencing. RNAi can be induced 
by the introduction of synthetic short interfering RNA (siRNA) or by intracellular 
generation of siRNA from vector driven expression of the precursor short hairpin RNA 
(shRNA). In the latter method, upon delivery of the shRNA expression vector into the 
cytoplasm (e.g. using lentiviruses), the viral RNA is reverse transcribed into 
complementary DNA (cDNA), by the viral Reverse Transcriptase. cDNA is then integrated 
into the host cell genome, and posterior transcribed by the RNA polymerase II or III. The 
primary transcript generated by the RNA polymerase contains a hairpin like stem-loop 
structure therefore named shRNA.  This shRNA is then exported to the cytosol where it 
follows the natural RNAi pathway, processed by Dicer, loaded on RISC and further 
promoting complimentary mRNA degradation. Adapted from (Jinek et al., 2009). 
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2.1.2 - RNAi as a research tool. Screening Era 
 
 
Since its discovery, RNAi have been extensively used as a tool to 
understand gene function in vitro and in vivo. RNAi is an extremely powerful 
research tool to perform reverse genetic studies, which focus in undermining the 
function of a certain gene by its disruption. Silencing of target genes can be 
mediated by introducing synthetic siRNAs or by vector systems (e.g. lentiviral 
vectors, Stewart et al., 2003)) that encode short hairpin RNAs (shRNA) that are 
processed intracellular into siRNAs (Figure 17, reviewed in Dykxhoorn et al., 
2003; Manjunath et al., 2009; Rao et al., 2009). Typically, RNAi mediated 
silencing is incomplete, i.e. it is a “knockdown” and not a “knockout”, although in 
some cases, the targeted mRNA is undetectable even with very sensitive PCR 
assays (Song et al., 2003; Rao et al., 2009). However, the incomplete silencing 
performed by RNAi might be useful in certain studies, where the complete 
silencing of a gene would compromise the survival of the cell/organism and 
therefore not possible to knockout (e.g.ASF/SF2, Cooper, 2005). The progress in 
genome sequencing and annotation, as well technological advances that allow 
biological assays to be executed and analyzed in high throughput manner, triggered 
an increasing interest in genome-wide RNAi based screens, where the effects of 
gene silencing on biological phenotypes can be systematically explored. This 
approach has been pursued most extensively in simpler organisms, such as 
C.elegans, and more recently in Drosophila and human cells (reviewed in Fraser 
et al., 2000; Berns et al., 2004; Boutros et al., 2004; Kittler et al., 2004; 
Kolfschoten et al., 2005; Pelkmans et al., 2005; Westbrook et al., 2005; Friedman 
et al., 2007; Oberdoerffer et al., 2008).  Cell-based RNAi screens can be 
performed either using arrays of individual RNAi constructs in high-throughput 
screening protocols, or by using pools of different RNAi constructs, termed 
  
 
 
                                                         Chapter 2 – The Method and Experimental proceedings             
 
77 
arrayed or pooled screens, respectively (Moffat et al., 2006; Sharma et al., 2009). 
Pooled screens have the advantage that a large set of RNAi molecules, perhaps 
targeting an entire genome, can be delivered to bulk populations of cells, thereby 
allowing rapid evaluation of large gene sets and/or parallel analyses of multiple 
cell types. This type of screen is typically less expensive and more practical to do 
in a standard lab space, whereas arrayed screening normally requires specialized 
high-throughput equipment and is more expensive. However, the deconvolution 
process of the putative “hits” can be really laborious, being a disadvantage of the 
pooled screen. In other hand, in arrayed screens, each unique RNAi construct 
(targeting a single gene) is delivered to a cell subset, therefore allowing the rapid 
identification of the gene responsible for the phenotype observed, with a lower 
extent of false negatives when compared to the pooled screens (Root et al., 2006).  
Several libraries to perform gene silencing in a different number of 
organisms, such as mouse and human, have already been built and used 
successfully (Berns et al., 2004; Kittler et al., 2004; Paddison et al., 2004; Silva et 
al., 2005; Moffat et al., 2006). Among those libraries, is the The RNAi Consortium 
(TRC) lentiviral library that covers the entire human and mouse genomes, with 
multiple constructs targeting each gene (reviewed in Moffat et al., 2006; Root et 
al., 2006).  
 
 
 
2.1.2.1 - TRC lentiviral library 
 
The TRC library was designed to cover entire human and mouse genome, 
with a five-fold coverage, meaning that has an average of five shRNA constructs to 
target each gene (reviewed in Moffat et al., 2006; Root et al., 2006). This library 
allows high-efficiency delivery of the shRNA and enables stable long-term gene 
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suppression in a broad range of cell types, including primary cells (Boehm et al., 
2007; Oberdoerffer et al., 2008; Savina et al., 2009), cell lines (Boehm et al., 
2007), dividing and nondividing cells (Moffat et al., 2006). Briefly, the library was 
cloned into a lentiviral vector, pLKO.1, which drives shRNA expression from a 
human U6 promoter and carries the puromycin-resistance gene, allowing the 
selection of transduced cells (Figure 18). Like other third-generation lentiviral 
vectors (Dull et al., 1998), viruses are generated using a three-plasmid packaging 
system, separating the HIV gag, pol and rev genes, and the gene encoding the 
Vesicular stomatitis virus (VSV)-G coat onto separate vectors, therefore producing 
self-inactivating viruses, minimizing the possibility of recombination to create 
replication-competent viruses (Moffat et al., 2006; Root et al., 2006). Upon 
infection of the target cell, viral genome is integrated into the host cell genome. 
After integration, the cassette produces an shRNA molecule that will be processed 
by the RNAi machinery and target the degradation of the complimentary mRNA, 
as described above (Figure 17). 
 
Figure 18 – Map of the TRC lentiviral vector pLKO.1.  Expression of the shRNA 
cassette is driven by the human U6 RNA polymerase II promoter (hU6). The lentiviral 
vector also contains the mammalian selection marker puromycin resistance gene (PAC) 
under the control of the PGK promoter, allowing the selection of transduced cells. 
Ampicilin resistance gene (AmpR) allows for colony selection upon bacterial 
transformation with the lentiviral vector. Adapted from (Root et al., 2006). 
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2.1.2.1.1 - TRC library subsets 
 
 RNAi based screenings can be performed in a genome-wide fashion, 
targeting the organism entire genome, or in a more accessible manner, by targeting 
specific gene subsets, such as kinases, phosphatases, NLRs, Splicing factors, 
among others. A Splicing related subset was reorganized from the main TRC 
library, encoding all known Splicing factors, Splicing regulators and proteins 
shown to interact with Spliceosome components, according to was known in the 
literature (Grabowski et al., 1985; Krecic et al., 1999; Sanford et al., 1999; 
Longman et al., 2000; Makarov et al., 2002; Maniatis et al., 2002; Zhou et al., 
2002; Barbosa-Morais, 2005; Wang et al., 2006).  A similar approach was 
performed to compile the Caspases, CARD containing proteins and NLRs shRNA 
collections (Earnshaw et al., 1999; Elkon, 1999; Martinon, 2004; Inohara et al., 
2005; Kufer et al., 2005; Martinon et al., 2005; Ting et al., 2005; Kersse et al., 
2007; Mariathasan et al., 2007; Martinon et al., 2007b; Park et al., 2007). The 
complete lists of the genes that compose each collection are shown in chapter VIII-
1 and VIII-2 (Tables S1 and S2). 
 
2.1.2.1.2 - RNAi based screening outline 
 
THP-1 cells were infected with the shRNA-containing vector, as described 
in the lentiviral infection procedure (chapter II-2.4). After the 3 days of puromycin 
selection, plates were divided into 2. In one of the plates cell number was assayed 
by Alamar Blue® cell viability assay (Invitrogen®), according to manufacturer’s 
protocol. On the other plate, cells were stimulated with 4% PFA fixed DH5! E.coli 
at a Multiplicity of Infection (MOI) of 20 bacterial cells per THP-1 cell. Twenty-
four hours after stimulation, cell supernatants were collected and submitted to 
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ELISA assay for the quantification of IL-1! and IL-8 cytokines, according to 
ELISA protocol present at chapter II-2.5. Cytokine concentration was then 
calculated per cell number. A schematic view of the RNAi based screening outline 
can be seen in Figure 19. 
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Figure 19 – Lentiviral production and RNAi based screening outline. TRC library is 
kept in glycerol stocks at -80ºC. Bacterial stocks transformed with the pLKO.1 plasmids 
were incubated at 37ºC and plasmid was purified by a high-throughput plasmid purification 
protocol (as described in chapter 4.2). 293T cells were transfected with library pLKO.1 and 
the packaging plasmids to produce the lentiviral vectors (as described in chapter 4.3). 
Lentiviruses were used to transduce THP-1 cell line. Briefly, lentiviral infection was 
performed by 90 minutes spinoculation (2200 RPM at 37ºC) of THP-1 cells with the 
lentiviral vectors. After spinoculation, media was replenished and cells incubated for 48 hr. 
In order to select the transduced cells, puromycin was added and cells incubated for 72 hr. 
After puromycin selection, each 96 well plate was divided into 2 to be able to perform an 
Alamar Blue ® cell viability assay and to stimulate the remaining plate with 4%PFA fixed 
E.coli. After 24 hr E.coli stimulation, cell supernatants were collected and assayed for 
cytokine concentration by ELISA (as described in chapter II.2.5). 
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2.2 - Experimental proceedings 
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2.2.1 - Cell culture 
 
 THP-1 cells (ATCC TIB-202) were grown in R10- RPMI media 1640 
(GIBCO ®) supplemented with 10% (v/v) Fetal Bovine Serum (GIBCO ®), 1% 
(v/v) Penicillin-Streptomycin (GIBCO ®), 1% (v/v) Pyruvate (GIBCO ®), 1% (v/v) 
L-Glutamine (GIBCO ®), 1% (v/v) Non-essential aminoacids (GIBCO ®), 1% (v/v) 
Hepes buffer (GIBCO ®) and 2-Mercaptoetanol (GIBCO ®) to a final concentration 
of 0.05M, as recommended by the American Tissue Culture Collection (ATCC). 
HEK 293T cells (ATCC CRL-11268) were grown in Dulbecco’s modified Eagle’s 
medium (DMEM, GIBCO ®) supplemented with 10% (v/v) Fetal Bovine Serum 
(GIBCO ®), 1% (v/v) Penicillin-Streptomycin (GIBCO ®) and 2-Mercaptoetanol 
(GIBCO ®) to a final concentration of 0.05M. Cells were kept at 37ºC under a 5% 
carbon dioxide (CO2) atmosphere. 
 
 
2.2.2 - hairpin-pLKO.1 Plasmid preparation 
 
 Plasmids were prepared according to TRC proceedings listed at 
(https://www.broadinstitute.org/genome_bio/trc/publicProtocols.html). 96 deep 
well sterile growth plates (Corning ®) were pre-filled with 1.2 mL of Terrific broth 
(TB, Invitrogen ®) media containing 100 ug/mL Carbenicillin (Sigma-Aldrich®). 
The hairpin-pLKO.1 containing bacterial glycerol stocks were inoculated on the 
TB pre-filled 96 deep well plates and grown for at least 16 hours at 37ºC under 
agitation, 300 rpm. After incubation, plates were centrifuged for at 1500 g for 8 
minutes at 4ºC, and supernatants discarded. Bacterial cell pellets were 
ressuspended in 200 uL of RNase A containing Ressuspension buffer (50 mM 
Tris-HCl, 10 mM EDTA pH 8.0 and 0.1 mg/mL RNase A) and further lysed in 210 
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uL fresh Alkaline Protease containing lysis buffer (200 mM NaOH, 1% (w/v) SDS 
and 25 units/mL of Alkaline Protease) for 4 minutes at room temperature. Bacterial 
cell lysates were neutralized by adding 300 uL Neutralization buffer (3.75 M 
Guanidinium Hydrochloride, 0.9 M KOAc and 1.4 M HOAc, pH4.35). After 30 
minutes 4ºC centrifugation at 3000g, lysates were transferred to a clarification 
filter plate (Whatman®) and centrifuged at 3000g for 5 minutes at 4ºC. Clarified 
lysates were then incubated at 70ºC for 30 minutes. After incubation, lysates were 
transferred to a pDNA binding plate (Whatman®), centrifuged at 1800g for 2 
minutes at 4ºC and supernatants were discarded. Two washes were performed by 
centrifuging the pDNA binding plates at 1800g for 2 minutes at 4ºC in the 
presence of 600 uL of Wash buffer (480 mL of 100% ethanol added to a 120 mL of 
a solution containing 15 mM NaCl, 40 mM Tris-HCl and 25 mM Tris, pH 6.65). 
Plasmid DNA was eluted from the pDNA binding plates by centrifuging at 1800g 
for 5 minutes at 4ºC after an incubation of 10 minutes with 140 uL of Elution 
buffer (10 mM Tris-HCl, pH 8.0). Plasmid DNA concentration was assayed by 
spectrophotometry in a Tecan Infinite® 200 equipment using Quant-iT™ 
PicoGreen® dsDNA reagent (Invitrogen®) following manufacturer’s protocol, and 
further stored at -80ºC. 
 
 
2.2.3 - Lentivirus production 
 
 Lentiviruses were produced according to TRC lentiviral proceedings 
present at the RNAi Consortium website 
(https://www.broadinstitute.org/genome_bio/trc/publicProtocols.html). Briefly, 
HEK 293T cells were seeded at a density of 2.2x105 cells/mL (100 uL per well in 
96 well plates) in DMEM media without Penicillin-Streptomycin. After 24 hr 
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incubation at cell culture normal conditions, cells were transfected with a mixture 
of the 3 plasmids, the packaging plasmid (100 ng of pCMV-dR8.91), the envelope 
plasmid (10 ng of VSV-G/pMD2.G) and 100 ng of the shRNA containing 
pLKO.1-puro vector, using TransIT-LT1 transfection reagent (Mirus Bio ®) in 
Optimem medium (GIBCO ®), following TRC transfection proceedings. After 18 
hours of incubation, media was replaced with 170 uL of high serum growth media 
(30% FBS (v/v) DMEM). Twenty-four hours after media replacement, viruses 
were harvested (150 uL) and fresh media (150 uL) was added to the cells. The 
second viral collection was performed 24 hours later and harvested viruses were 
pooled with the previous day collection and stored at -80ºC. 
 
 
2.2.4 - Lentiviral infection 
Lentiviral infection was performed according what is described at the 
RNAi Consortium website 
(https://www.broadinstitute.org/genome_bio/trc/publicProtocols.html). Briefly, 10 
uL of viruses were plated per well in a 96 well plate. THP-1 cells were 
ressuspended in R10 medium containing 8 ug/mL of Polybrene (Sigma-Aldrich ®) 
at a density of 1.25x106 cells/mL, and 40 uL were added on top of the virus 
containing wells. Plates were spun for 90 minutes at 2200 RPM at 37ºC. After 
spinoculation, media was removed and replaced with 200 uL of fresh R10, and 
cells incubated at 37ºC under normal cell culture conditions. After 2 days, 
transduced cell selection was performed by adding 50 uL of R10 containing 
Puromycin (Calbiochem®) to a final concentration of 5 ug/mL. Cells were kept 
under Puromycin selection for 3 days and then were ready to be used in further 
assays. 
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2.2.5 - ELISA Assay 
 
 
  Cytokine concentration (IL-1! and IL-8) in cell supernatants were assayed 
by Enzyme-linked immunosorbent assay (ELISA) using Human IL-1 beta/IL-1F2 
DuoSet® and Human CXCL8/IL-8 DuoSet® (R&D Systems ®), respectively, 
according to company’s protocol. Briefly, 96 well plates (Nunc®) were coated with 
50 uL of 4 ug/mL capture antibody diluted in PBS and incubated overnight at 4ºC. 
Plates were washed 3 times with 0.1% PBS-T previous to 1 hour room temperature 
blocking step with 100 uL of I-Block™ Protein-Based Blocking Reagent (Applied 
Biosystems®). After blocking, plates were washed 3 times with 0.1% PBS-T and 
50 uL of samples were added to each well, including the respective standard 
controls at different concentrations ([IL-1!]=0-250 pg/mL and [IL-8]=0-2 ng/mL), 
and incubated for 1 hour at room temperature. Three more washes were performed 
with 0.1% PBS-T and 50 uL of respective detection antibodies diluted in I-Block™ 
Protein-Based Blocking Reagent (100 ng/mL and 20 ng/mL, for IL-1! and IL-8 
detection, respectively) were applied to each well and plates were incubated for 1 
hr at room temperature. Fifty microlitres of Streptavidin (R&D Systems ®) diluted 
in PBS (1:200 (v/v)) was added to the plates after the 3 washes with 0.1% PBS-T. 
After 30 minutes of incubation with streptavidin, plates were washed for another 3 
times with 0.1% PBS-T, developed with of 50 uL of Pierce® Soluble TMB 
Substrate. The developing reaction was stopped by adding 50 uL of 2 N H2SO4. 
Plates were read at 450 nM using a Tecan Infinite® 200 equipment.  
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2.2.6 - Quantitative RT-PCR 
 
 Total RNA was extracted using TRIzol® reagent (Invitrogen®) and final 
RNA quality and concentration determined by spectrophotometry using Nanodrop 
2000c equipment (Thermo Scientific®). Complementary DNA (cDNA) synthesis 
was carried out using Superscript II Reverse Transcriptase (Invitrogen®) according 
to manufacturer’s directions. Quantitative RT-PCR (qRT-PCR) was performed in 
the presence of Power SYBR® green PCR Master Mix (Applied Biosystems®) and 
the amplification protocol was performed on a Rotor-Gene 6000 (Corbett®). All 
samples were normalized against the expression of the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and the relative expression 
of each gene was calculated using Pfaffl’s method (Pfaffl, 2001). The primers were 
designed using different online softwares, namely Primer3  
(http://frodo.wi.mit.edu/primer3/), MGH/Harvard Primer bank 
(http://pga.mgh.harvard.edu/primerbank/) and Primer-blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The complete list of primer 
sequences is shown in Table S5.   
 
 
2.2.7 - Western-blot  
 
 THP-1 cells from the different experiments were collected and washed 
twice with cold Phosphate Buffered Saline (PBS) solution. Cells were lysed for 15 
minutes at 4ºC using RIPA buffer (50 mM Tris-HCl at pH=7.4, 1% NP-40, 0.25% 
Sodium Deoxicholate, 150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4, 1 mM NaF in 
the presence of proteases inhibitor cocktail (Roche®)). Lysed cells were 
centrifuged at 14000 RPM for 15 minutes at 4ºC, and supernatants kept at -20ºC. 
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Cell lysates were denatured at 95ºC for 10 minutes in the presence of Laemli buffer 
(Biorad®) before loaded on 10% / 12% Sodium Dodecyl Sulfate (SDS)-PAGE 
gels. Electrophoresis was performed at 110 V for 2 hours, and gels transferred to 
nitrocellulose membranes (Whatman®) at 220 mA for 1 hour. Membranes were 
blocked in a solution containing 5% Milk for one hour and incubated with primary 
antibodies for one hour at room temperature, just for "-actin antibody, or overnight 
at 4ºC, for all the other antibodies (complete list of antibodies and dilutions used, 
in Table S3). Before applying the secondary antibody, membranes were washed 3 
times with 0.1% PBS-T (PBS plus 0.1% Tween20 (Sigma-Aldrich®)). Secondary 
antibody incubations were performed for 1 hour at room temperature, followed by 
3 times 10 minutes washes with PBS-T, before developing with ECL plus reagent 
(GE Healthcare®). Membranes were developed in an AGFA Curix 60® equipment.  
 
 
2.2.8 - Caspase-1 activity assay by FACS 
 
 Caspase-1 activity was measured using the Carboxyfluorescein FLICA 
Detection kit for Caspase Assay (Immunochemistry Technologies, LLC®) 
following the reagent instructions. Briefly, cells from the different assays 
performed were incubated for 1 hour at 37ºC with 30X FLICA solution at a 1:30 
ratio, protecting the cells from light exposition. Cells were collected into FACS 
tubes (BioRad®) and washed 3 times using the provider’s wash buffer. The washes 
were performed by adding 500 uL of wash buffer and tubes centrifuged at 400g for 
5 minutes at room temperature. After the final wash, cells were ressuspended in 
150 uL of wash buffer and immediately assayed by Flow citometry, using a 
FACSCalibur system (BD biosciences®). The data collected was further analysed 
using FlowJo software (Tree Star Inc®). 
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2.2.9 - Construction of overexpressing lentiviral 
vectors  
 
Lentiviral vectors for protein overexpression were constructed using the 
Gateway® pENTRTM11 vector and pLenti6/V5-DEST Gateway® Vector kit from 
Invitrogen®. SFRS1, SFRS3, IL-1! and IL-18 were amplified from THP-1 cells 
cDNA by PCR reaction using specific primers and annealing temperatures as 
mentioned at Table 2.  All PCR reactions were performed with Phusion® High-
Fidelity DNA Polymerase (Finnzymes®) and using the following cycle conditions: 
initial denaturating step for 5 minutes at 95ºC; 40 cycles (30 seconds at 95ºC, 1 
minute at annealing temperature (mentioned on Table 3), extension step for 1 
minute at 72ºC and a final elongation step at 72ºC for 7 minutes.   
Table 3- Primers used for cloning of SFRS1, SFRS3, IL-1! and IL-18. 
Gene Primers 
Annealing 
(ºC) 
Amplicon 
(bp) 
cloneSFRS1_Fw- 
ATAGGATCCTTATGTCGGGAGGTGGT 
SFRS1 
cloneSFRS1_Rw- 
TTGCGATATCTTGTACGAGAGCGAGA 
52.9 766 
cloneSFRS3_Fw- 
ATCGGATCCTTATGCATCGTGATTCC 
SFRS3 
cloneSFRS3_Rw- 
GCGCGATATCTTTTCCTTTCATTTGACCT 
64.1 514 
cloneIL-1!_Fw- 
ATAGGATCCTTATGGCAGAAGTACCT 
 
IL-1! 
cloneIL-1!_Rw- 
TATTGATATCTGGAAGACACAAATTG 
52.9 829 
cloneIL-18_Fw- 
ATAGGATCCTTATGGCTGCTGAACCA 
IL-18 
cloneIL-18_Rw- 
TGCCGATATCTGTCTTCGTTTTGAAC 
52.9 601 
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After amplification, PCR products were purified from agarose gel using 
QIAquick Gel Extraction Kit (Qiagen®). Purified products and empty pENTR11 
vector (Invitrogen®) were digested for 90 minutes at 37ºC using EcoRV and 
BamHI restriction enzymes (New England Biolabs®). After digestion, pENTR11 
vector was dephosphorylated for 30 minutes at 37ºC in the presence of Antartic 
Phosphatase enzyme (New England Biolabs®). A ligation step was performed 
using T4 DNA ligase enzyme (New England Biolabs®) for 75 minutes at room 
temperature, followed by 10 minutes at 65ºC. Ligation products were used to 
transform DH5! competent bacterial cells (Invitrogen®). Transformed bacteria 
were inoculated in Lysogeny Broth (LB, Invitrogen®) agar plates in the presence of 
50 ug/mL Kanamycin (Calbiochem®) and incubated overnight at 37ºC. Colonies 
were inoculated in 50 ug/mL Kanamycin containing TB media and incubated 
overnight at 37ºC under agitation, 300 rpm. Plasmid extraction and purification 
was performed using PureYield™ Plasmid Miniprep System (Promega®) following 
manufacter’s protocol. Purified plasmids were sequenced using the following 
primers (Seq_Fw-TTTCTACAAACTCTTCCTGTTAGTTAGT and Seq_Rw-
GTAACATCAGAGATTTTGAGACAC). A map of pENTR11-SFRS1 plasmid 
can be seen in Figure 20, all the others are in shown in Figure S2.  
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Figure 20 – pENTR11-SFRS1 map.  SFRS1 gene was cloned into a BamHI and EcoRV 
sites in the multiple cloning site of the pENTR11® vector. Two restriction sites can be used 
to check insert orientation after the ligation step, NheI and KpnI. After transformation into 
bacterial cells, kanamycin selection can be performed due to a kanamycin resistance gene 
(Kan(R)) present in the final vector. Sequencing primers were designed in the outside of 
the multiple cloning site, therefore can be used for all the constructs performed. 
 
 
 
 
 pENTR11 vectors were then recombined into a lentiviral vector, the 
pLenti6/V5-DEST Gateway® Vector (Invitrogen®) following the company’s 
protocol. Briefly, pENTR11 vectors were recombined with pLENTI6/V5-DEST in 
the presence of Gateway® LR Clonase® II enzyme mix (Invitrogen®) at 25ºC for 
150 minutes, followed by 10 minutes of Proteinase K (Roche®) treatment at 37ºC. 
Stbl3™ competent E.coli cells (Invitrogen®) were transformed with the 
recombined vector, inoculated on LB agar plates in the presence of 100 mg/mL of 
Ampicillin (Calbiochem®) and incubated for 16 hours at 37ºC. Bacterial colonies 
were inoculated in 100 ug/mL Ampicillin TB media and incubated for 16 hours at 
37ºC. pLENTI6/V5-DEST DNA encoding the gene of interest was purified using 
PureYield™ Plasmid Miniprep System (Promega®) and concentration measured by 
spectophotometry in a Nanodrop 2000c equipment (Thermo Scientific®). 
pLENTI6/V5-DEST-SFRS1 map can be seen in Figure 21, all the others are in 
shown in Figure S2. Lentiviruses were produced using the same protocol as 
described for the expression of pLKO.1 vector.
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Figure 21 – pLenti6/V5-DEST-SFRS1 map. pENTR11-SFRS1 was recombined into a 
pLenti6/V5-DEST Gateway® Vector (Invitrogen®). The expression of SFRS1 is driven by 
the Human cytomegalovirus (CMV) immediate early promoter, which allows high-level 
and constitutive expression of the gene of interest (Boshart et al., 1985). A PPGK promoter 
allows high-level expression of the Blasticidin resistance gene, allowing for transduced 
cells selection (Kimura et al., 1994). Ampicillin resistance gene allows selection of the 
plasmid in E. coli, while pUC origin permits high-copy replication and maintenance in 
E.coli cells. Several restriction sites such as KpnI can be used to digest the plasmid and 
check for insert orientation and expression. Insert expression in mammalian cells can be 
visualized by the detection of the V5 epitope. 
 
 
 
 
 
 
2.2.10 - Microarray analysis and validation 
 
 Microarray data was analyzed in collaboration with Ana Grosso (UBCe, 
IMM) using R software and suitable packages available from CRAN® (Team, 
2009) and Bioconductor (Gentleman et al., 2004). The raw data for the Affymetrix 
GeneChip Exon microarray data sets was normalized and summarized using 
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FIRMA method (Purdom et al., 2008) implemented in aroma.affymetrix package 
(Bengtsson et al., 2008). The statistical significance from the gene and exon 
expression alterations was assessed using linear models and empirical Bayes 
methods (Smyth, 2004) implemented in limma package (Smyth, 2005). Graphical 
representation of Firma scores for each probe set or probe selection region (PSR) 
was based on annotated exons from ExonMine (Mollet et al., 2009). 
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Chapter 3 - Results  
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“If it can't be expressed in Figures, it is not science, it is opinion.” 
 
Lazarus Long 
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3.1 - Human monocytic cell line (THP-1) as a 
model to study regulation of IL-1! secretion  
 
 
3.1.1 - E.coli challenge induces IL-1!  secretion  
 
 
 The Human monocytic cell line (THP-1) has been extensively used in a 
number of studies addressing different Innate Immune responses to several 
PAMPs, namely the mechanisms of Inflammasome activation and regulation 
(Martinon et al., 2002; Agostini et al., 2004; Bruey, 2004; Damiano et al., 2004). 
In fact, the Inflammasome discovery was performed using THP-1 cells (Martinon 
et al., 2002). The ability of THP-1 cells to produce IL-1! was demonstrated by 
different independent studies, however the kinetics of IL-1! production and 
processing has not been assessed before in response to PFA-fixed E.coli. We 
stimulated THP-1 cells with 4%PFA-fixed E.coli and collected cells and 
supernatants at different time points after the bacterial challenge. Increased IL-1! 
mRNA expression was observed after challenge, detected by qRT-PCR analysis 
(Figure 22-a). Moreover, it is already highly induced at 4 hours after bacterial 
stimulation.  
 In order to verify if increased IL-1! mRNA expression is related with 
augmented cytokine secretion, we quantified the secreted levels of IL-1! in the cell 
supernatants by ELISA. As can be seen in Figure 22-b, IL-1! secretion is already 
detected at 2 hours of E.coli challenge. The secretion of this cytokine keeps raising 
even at 24 hours after challenge, peaking at around 48hr post-stimulation (data not 
shown). 
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a)     b)  
  
Figure 22 – Kinetics of IL-1! mRNA expression and secretion after E.coli stimulation. 
THP-1 cells were challenged with 4% PFA-fixed E.coli. Cells and supernatants were 
collected at different time points post-stimulation. a) IL-1! mRNA expression was assayed 
by qRT-PCR. b) IL-1! secretion were assayed in cell supernatants by ELISA. IL-1! 
mRNA expression and secretion is induced in THP-1 cells by E.coli challenge. 
 
 
 
 In addition to IL-1!, we decided to evaluate the expression of other pro-
inflammatory mediator, the Interleukin-8 (IL-8). Interleukin-8 belongs to a 
chemotactic cytokine family and is responsible for the chemotactic migration of 
neutrophils and other cell types (such as monocytes) to the sites of Inflammation 
(reviewed in Miller et al., 1992; Feghali et al., 1997). Interleukin-8 is produced by 
a wide variety of cell types, however, like IL-1!, monocytes and macrophages 
typically represent the principal cellular source. Multiple stimuli have been shown 
to induce the secretion of IL-8, including LPS and live bacteria (Standiford et al., 
1990; reviewed in Remick, 2005). In opposition  to IL-1!, IL-8 is actively secreted 
into the extracellular space following stimulation of cell with no processing 
requirements (reviewed in Remick, 2005). As can be seen in Figure 23, increased 
IL-8 mRNA expression and secretion is observed following E.coli stimulation of 
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THP-1 cells. However, in comparison with IL-1! secretion, IL-8 secreted levels 
peak at a much earlier time point after the bacterial challenge. This can be 
explained by the requirement of IL-1! to be processed in order to be secreted, 
whereas IL-8 processing is not needed, therefore peaking earlier (Martinon et al., 
2002; Remick, 2005; Dinarello, 2009). 
 
a)     b) 
 
Figure 23 – Kinetics of IL-8 mRNA expression and secretion after E.coli stimulation. 
THP-1 cells were challenged with 4% PFA-fixed E.coli. Cells and supernatants were 
collected at different time points post-stimulation. a) IL-8 mRNA expression was assayed 
by qRT-PCR. b) IL-8 secreted levels were assayed in cell supernatants by ELISA. IL-8 
mRNA expression and secretion is induced in THP-1 cells by E.coli challenge. 
 
  
 The expression of both pro-inflammatory cytokines can be detected after 
challenging THP-1 cells with E.coli, therefore we have decided to use this cell line 
to study IL-1! regulation. We used the 24 hr challenge with E.coli as the main  
time point for the following studies. 
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3.1.2 - IL-1!  secretion is Caspase-1 dependent 
 
 
 
As described in Chapter 1.1 (Figure 1), IL-1! release is dependent on the 
processing of its inactive form (pro-IL-1!) into a mature form.  The processing 
step is mainly mediated by Caspase-1, however several other proteases have been 
shown to be able to process IL-1! (reviewed in Netea et al., 2010). Therefore we 
used different strategies, either knocking-down Caspase-1 expression by RNAi or 
blocking Caspase-1 activation using specific inhibitors, in order to test this 
dependency on Caspase-1 for IL-1! release following E.coli challenge. 
 As can be seen in Figures 24 (a, b and c), knocking-down Caspase-1 by 
RNAi almost completely abolished IL-1! secretion after 24 hr E.coli challenge. 
Similar results were obtained when using drugs that inhibit Caspase-1 activity. 
These drugs have been extensively used to block Caspase-1 activity in different 
experimental sets using different cell lines (Margolin et al., 1997; Watson et al., 
1998; Gurcel et al., 2006; Keller et al., 2008), and were shown to compete with the 
common substrates of Caspases for the binding to the catalytical site in a reversible 
or irreversible manner, therefore inhibiting its activity. As can be seen in Figure 
24-d, the secretion of IL-1! is reduced in the presence of all inhibitors tested, either 
using the broad Caspase inhibitors (Z-VAD and Z-DEVD) or a more specific 
Caspase-1 inhibitor (Z-YVAD). Thus, these data confirms the previous results 
showing that Caspase-1 and its processing activity are required to process pro-IL-
1! into the mature secreted form. 
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a)     b) 
 
c)  d)      
 
 
 
 
 
 
 
 
Figure 24 – Caspase-1 dependent IL-1! secretion. IL-1! secretion is dependent on its 
pro-form processing by Caspase-1. a) Caspase-1 knockdown by RNAi almost completely 
abolish IL-1! secretion after 24 hr E.coli challenge. b,c) Caspase-1 knockdown efficiency 
was assayed by qRT-PCR (b) - to measure its mRNA expression upon knockdown ; and by 
western-blot (c)- to measure knockdown efficiency at the protein level. (d)Targeting 
Caspase-1 with different inhibitors (Z-VAD, Z-DEVD and Z-YVAD) decreased IL-1! 
secreted levels. !-actin was used as a protein loading control (t-student: *p<0.05, 
***p<0.0001). 
 
 
Several methods have been described to measure Caspase-1 activity, 
although propably the most sensitive relies on using analogs of Caspase-1 
substrates that irreversibly bind to the active Caspase-1 catalytical site. These 
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analogs can be fused to fluorophores (such as Carboxyfluorescein, FAM) and its 
fluoresence can be measured by spectophotometry or by FACS analysis. By using 
one of these comercial available probes for Caspase-1 activity detection (FLICA® 
from Immunochemistry®), we have measured Caspase-1 activity by FACS at 
different time points upon E.coli challenge. Figure 25a clearly shows that Caspase-
1 activation increases over time after E.coli challenge. In order to unveil if 
Caspase-1 expression is also induced after an E.coli stimuli, we have measured 
Caspase-1 mRNA expression by qRT-PCR. Augmented Caspase-1 mRNA 
expression is detected after E.coli challenge, as shown at Figure 25-b.  
 
a)     b) 
 
Figure 25 – Caspase-1 mRNA expression and activity. a) Caspase-1 activity measured 
by FACS using Caspase-1 substrate (FLICA). Caspase-1 activity is increased over time 
following an E.coli challenge. b) Caspase-1 mRNA expression is induced upon E.coli 
challenge, as measured by qRT-PCR.  
 
These results confirm that Caspase-1 is required for IL-1! secretion upon 
E.coli challenge. As demonstrated using Caspase-1 inhibitors, its activity is 
mandatory in order to process IL-1! into its mature form. In addition, increased 
Caspase-1 mRNA expression and activity was indeed detected in THP-1 cells upon 
E.coli challenge. 
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3.1.3 – Identification of the Inflammasome involved 
in IL-1! secretion 
 
 
We have previously shown that in order to be secreted, IL-1! needs to be 
processed by Caspase-1. However, as discussed in Chapter 1.1, Caspase-1 itself 
needs to be activated by the Inflammasome in order to become an active protease 
(Martinon et al., 2002; reviewed in Martinon et al., 2009). Several Inflammasome 
complexes have been identified, such as the NALP3, IPAF, AIM2 (Figure 7), as 
being activated by different PAMPs (reviewed in Martinon et al., 2009). Thus, to 
better characterize our model of study, we decided to develop several experiments 
to identify the major Inflammasome involved in IL-1! secretion following an 
E.coli challenge. 
 
However, before performing such experiments, we decided to look if other 
stimuli, in addition to E.coli, are required for maximum IL-1! secretion after an 
E.coli challenge. Several studies report the different Inflammasome activation 
requirements by using either monocytes or macrophages, such as the usage of 
extracellular ATP in the case of macrophages studies (Walev et al., 1995; 
Kahlenberg et al., 2004; Pelegrin et al., 2006; Duncan et al., 2007; Netea et al., 
2008). Furthermore, Netea et al. reported that THP-1 cells, in order to be able to 
secrete IL-1!, require an additional stimulus induced by ATP (reviewed in Netea et 
al., 2008; Netea et al., 2010). However, in our previous studies, as shown in Figure 
22-b, we have observed IL-1! secretion by THP-1 cells after E.coli challenge, with 
no need to add extracellular ATP. Even though, we decided to test that hypothesis. 
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 3.1.3.1 - Extracellular ATP addition is not required for 
IL-1! secretion 
 
The early observations by Hogquist, Perregaux and Griffiths (Hogquist et 
al., 1991; Perregaux et al., 1994; Griffiths et al., 1995) clearly show that ATP is a 
strong IL-1! releasing agent. Moreover, a massive efflux of potassium (K+) is 
triggered by ATP, strongly suggesting that ATP activates the Inflammasome by 
decreasing intracellular K+ levels (Perregaux et al., 1994; Pétrilli et al., 2007). 
Exogenous added ATP-driven maturation and release of IL-1! was then identified 
to be specifically mediated by an P2X7 receptor dependant manner (Ferrari et al., 
1997; Solle et al., 2001). 
In order to assess the role of ATP in our model we have decided to 
perform an experiment where in addition to 24 hr E.coli challenge, THP-1 cells 
were also stimulated with 3 mM of extracelullar ATP. As can be observed in 
Figure 26, using ATP, in addition to E.coli. showed an increase in the amount of 
IL-1! secreted, although not statistically significant.  
In addition to the role of ATP, the role of the P2X7 receptor in 
Inflammasome activation induced by E.coli challenge was also assessed. Using a 
known P2X7 receptor inhibitor, KN-62 (Baraldi et al.,2003; Friedle et al., 2010), 
a remarkable decrease in IL-1! secretion was observed in treated cells, when 
compared to IL-1! levels secreted by non-treated cells (Figure 26). Therefore we 
could conclude that P2X7 receptor plays a role in IL-1! secretion after E.coli 
challenge, however no extracellular ATP addition is needed in our model. 
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Figure 26 - Role of ATP and P2X7 in IL-1! secretion after 24 hr E.coli challenge. 
THP-1 cells were challenged with E.coli for 24 hr either in the presence or absence of a 
P2X7 receptor inhibitor (KN-62) or extracellular ATP. IL-1! secretion was assayed by 
ELISA. Cells that were challenged with E.coli and then exogenously treated with 3 mM of 
ATP (for 30 min before the end of the assay) showed an increase in IL-1! secretion, 
although not statistically significant. In opposition, THP-1 cells treated with KN-62 showed 
a statistically significant decrease in IL-1! secretion after 24 hr of E.coli challenge. (t-
student: *p<0.05) 
 
 
3.1.3.2 - NALP3 Inflammasome regulates IL-1! 
secretion 
 
In order to identify the major Inflammasome involved in Caspase-1 
activation and subsequent IL-1! secretion upon E.coli challenge, we decided to 
perform an RNAi targeted screen. We used a subset of the TRC library enriched in 
shRNAs that target all the NLRs described so far and several CARD-containing 
proteins (Table S1). Briefly, as described in Chapter 2 (Figure 19), we infected 
THP-1 cells with a lentiviral vector encoding the shRNA of interest. After 
selection of the infected cells, we split the total cells into two, in order to evaluate 
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the number of cells by Alamar Blue® assay and to challenge the remaining cells 
with the 4% PFA-fixed E.coli. After challenge, cell supernatants were assayed for 
the presence of secreted IL-1! by ELISA. All concentrations were then normalized 
by the number of cells and then compared with the IL-1! secreted levels obtained 
with control (Scramble) shRNA (as represented in the equation below).   
 
 
 
 
 
 
 
The z-score values can then be represented in a more visual “friendly” way 
if organized from the lowest to the highest z-score values (Figure 27). As can be 
seen in Figure 27, the values follow a continuous curve, where the lowest values 
are depicted for positive regulator candidates and the highest values for negative 
regulator candidates. A candidate was considered a negative regulator (represented 
in blue box) if at least 2 out of 5 shRNA targeting the same gene showed a score 
higher than 1.8 standard deviations above the average of the control. In opposition, 
a positive regulator candidate (represented in red box) was depicted if at least 2 out 
of 5 shRNA targeting the same gene showed IL-1! secreted levels inferior to 1.8 
Standard deviations to the average of the control. All the candidates are listed on 
Table 4. Since we were interested in the identification of the major Inflammasome 
activated after E.coli challenge, we have looked more carefully to the positive 
regulator candidates, as the ones where knocking down showed decreased IL-1! 
secretion. 
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Figure 27 - Identification of NLRs and CARD domain containing proteins with a role 
in IL-1! secretion. 29 NLR/CARDs genes were targeted in THP-1 cells by lentiviral 
shRNA delivery, with an average of five-fold coverage per gene. After 24 hr E.coli 
challenge, IL-1! secretion was measured by ELISA. After normalization of IL-1! secreted 
levels, several genes showed a clear phenotype either by increasing or decreasing IL-1! 
secretion, therefore named negative (in blue) and positive regulators (in red), respectively. 
 
Table 4 – List of NLR/CARD candidates to play a role in IL-1! secretion after E.coli 
challenge obtained from the RNAi based screen. 
 
Positive Regulators Negative Regulators 
ASC NALP4 
CARMA1 NALP9 
NALP12  
NALP3  
NALP8  
VISA  
 
Among the positive regulator candidates, NALP3 and ASC, two key 
components of NALP3 Inflammasome (reviewed in Martinon et al., 2009), 
showed the strongest phenotype. The levels of IL-1! secreted after knocking down 
NALP3 and ASC and posterior 24 hr E.coli challenge are represented at Figure 28-
a. In order to validate the results, the levels of knockdown of NALP3 and ASC 
were evaluated. As depicted in Figure 28-b, a remarkable decreased mRNA 
expression of both, NALP3 and ASC, was measured upon targeting these two 
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genes by RNAi. In addition, the protein levels of these two major components of 
the NALP3 Inflammasome were also assayed. Decreased expression of both 
proteins is also observed after knockdown by RNAi (Figure 28-c).   
a) 
 
b) 
 
c)  
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Figure 28 – NALP3 Inflammasome regulates IL-1! secretion. THP-1 cells were 
infected with lentiviral vectors encoding shRNA specific for NALP3 or ASC. a) IL-1! 
secretion after 24 hr E.coli challenge. Decreased IL-1! secretion after knockdown of 
NALP3 and ASC. The efficiency of knockdown of the candidates was assayed by qRT-
PCR (b) and by Western-blot (c). !-actin was used as a protein loading control (t-student: 
***p<0.0001). 
 
 
 In sum, our results show that the NALP3 Inflammasome plays a major role 
in IL-1! secretion by THP-1 cells following an E.coli challenge. However, we 
cannot exclude that other Inflammasomes may be involved in the regulation of this 
Inflammatory response. Further experiments would be required to prove this 
assumption. 
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3.2 - Alternative Splicing and the regulation of 
IL-1! secretion 
 
 Alternative Splicing has gained an extraordinary attention with the 
completion of the Human Genome Project, where fewer genes were found to exist 
than it was initially predicted (Lander et al., 2001; Venter, 2001). This process has 
been extensively studied in the past years due to its role in the generation of 
proteome diversity and in the regulation of several cellular processes (reviewed in 
Black, 2000; Smith et al., 2000; Graveley, 2001). As described extensively on 
Chapter 1.2, the number of genes known to undergo AS has been increasing over 
time, and at the moment it is estimated that around 92-94% of the genes are 
alternatively spliced (Pan et al., 2008; Wang et al., 2008). Simultaneously, the 
number of cellular processes regulated by AS has also increased. Focusing on the 
IL-1! pathway, different isoforms of several genes are already reported to play 
important roles in the regulation of this Inflammatory response (Figure 10, 
reviewed in Chapter 1.1.3). However, besides the identification of numerous 
isoforms of “key-components” of this response, little is still known about the total 
number of genes regulated by AS and their functions in the regulation of IL-1! 
secretion. 
 As extensively mentioned in Chapter 1.2.1.1, AS is tightly regulated, 
where different cellular pathways and molecules have been unveiled as important 
regulators of this process. Subtle variations in the regulation of Splicing have been 
described to be involved in different, and sometimes opposite, outcomes of certain 
cellular responses, and in certain cases leading to disease (reviewed in Black, 2003; 
Tazi et al., 2008; Cooper et al., 2009).  As an example, the work by Paronetto et 
al. elegantly shows that modulating the concentration of several SFs, different 
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isoforms of the Bcl-x gene are generated (Paronetto et al., 2007). Furthermore, the 
different isoforms have completely opposite effects in the regulation of apoptosis, 
from an anti-apoptotic to a pro-apoptotic effect if the long or the short isoforms are 
generated, respectively (reviewed in Boise et al., 1993;!Youle et al., 2008). Thus, 
we have decided to follow a similar concept, changing the expression of different 
SFs and evaluating the impact in IL-1! secretion. 
 
 
3.2.1 - Identification of Splicing Factors with a role in 
IL-1! secretion 
 
 In an attempt to identify the SFs that could play a role in the secretion of 
IL-1! after E.coli challenge, we have performed an RNAi-based screen. We 
screened 425 genes (listed at Table S2) that were previously reported to be 
important players either in Spliceosome assembly, Splicing or proteins found to 
interact with Spliceosome components (Longman et al., 2000). The screening 
outline and the analysis performed was similar to what was already described in 
Chapter 3.1.3, although, in spite of normalizing the values with the control shRNA, 
values were normalized against the mean of IL-1! per cell in all the constructs for 
all the genes assayed in each plate tested. A similar type of analysis was already 
performed in other published studies (Oberdoerffer et al., 2008).  
 The screening results are shown in Figure 29. Genes were considered 
candidates if at least 2 out of 5 shRNA targeting the same gene showed IL-1! 
secretion superior or inferior to 1.5 Standard Deviations to the average of the 
control. After a secondary screen, and several rounds of phenotypic validation, 30 
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genes were considered candidates, 20 positive regulators and 10 negative 
regulators of IL-1! secretion (Table 5).  
 
 
 
Figure 29 - Identification of Splicing Factors with a role in IL-1! secretion by RNAi 
based screen. 425 Splicing Factors (SFs) were targeted in THP-1 cells by lentiviral shRNA 
delivery, with an average of five-fold coverage per gene. After 24 hr E.coli challenge, IL-
1! secretion was measured by ELISA. Several of the genes tested showed a clear 
phenotype either by increasing or decreasing IL-1! secretion upon knockdown, therefore 
named negative (in blue) and positive regulators (in red), respectively. 
 
 
 
 As a representative example of two SF candidates that play a role in IL-1! 
secretion, Figure 30 shows the phenotypes observed for a positive and a negative 
regulator candidates, HMGB1 and SFRS3, respectively. As can be seen, there are 
at least 2 out of 5 shRNA constructs with a similar phenotype upon knockdown, 
either increasing or decreasing IL-1! secretion, therefore negative (in blue) and 
positive (in grey) regulators candidates, respectively. All the other candidates are 
listed on Table 5. 
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Figure 30 – Splicing Factor candidates to play a role in IL-1! secretion. Five different 
shRNA were used to target each SF candidate in THP-1 cells. If at least 2 out of 5 showed 
an increase or decrease in IL-1! secretion over the 1.5 StDev, it was considered a 
candidate. Therefore, as an example, HMGB1 was depicted as a positive regulator 
candidate (in grey) and SFRS3 as a negative regulator candidate (in blue) due to their 
decreased/increased effect in IL-1! secretion upon knockdown and posterior 24 hr E.coli 
challenge, respectively.   
 
 
Table 5 – List of Splicing Factor candidates to play a role in IL-1! secretion obtained 
from the RNAi based screen. 
Positive Regulators Negative Regulators 
CLK1 AKAP8 
CLK4 GNB2L1 
CUGBP2 HYPC 
CWF19L1 MFAP1 
DDX54 PPIE 
DHX38 PPIH 
EIF3S10 SFPQ 
GTF2LI SFRS1 
HMGB1 SFRS3 
HNRPM TET1 
KHSRP  
KIN  
LSM7  
PABPN1  
SF3A3  
SFRS2  
SFRS12  
SKIV2L2  
SNIP1  
ZC3H13  
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3.2.1.1 - Validation of candidates obtained in the RNAi-
based screen 
 
 
 After performing the RNAi-based screen, in order verify if the phenotypes 
observed were really due to the knockdown of a certain gene, mRNA expression of 
all the target genes was evaluated by qRT-PCR analysis. The knockdown 
efficiency was then calculated by comparing the expression of the gene of interest 
in cells infected with the control shRNA and the shRNA targeting the gene of 
interest. A candidate was considered validated if at least 2 out of 5 shRNA 
targeting each gene, that showed a phenotype in IL-1! secretion, have a 
knockdown efficiency over 50% at mRNA level . The total list of validated genes 
is present at Table 6 and their respective mRNA expression and IL-1! secretion 
profiles are present in Figures 31-a and b, respectively. Therefore, according to the 
criteria defined, the rate of validation of the SF candidates was 63%. 
 
 
Table 6– List of the validated Splicing Factor candidates  
 
Positive Regulators Negative Regulators 
CUGBP2 GNB2L1 
CWF19L1 MFAP1 
DDX54 PPIE 
DHX38 SFPQ 
EIF3S10 SFRS1 
HMGB1 SFRS3 
HNRPM TET1 
KHSRP  
PABPN1  
SF3A3  
SFRS12  
ZC3H13  
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a) 
 
 
b) 
 
Figure 31 - Knockdown validation of SF candidates obtained from the shRNA screen. 
THP-1 cells were infected with a lentiviral vectors encoding the shRNA molecules specific 
for each SF candidate. a) The knockdown efficiency of the SF candidates was assayed by 
qRT-PCR. The expression of a certain gene was normalized with the expression of the 
same gene in the control. b) IL-1! secretion phenotype, after 24 hr E.coli challenge, of the 
different shRNAs used to target each SF candidate. IL-1! secreted levels were normalized 
with the levels observed in the control shRNA. 
 
  
 From all the 19 candidates validated, we selected 2 of the Negative 
Regulators (SFRS1 and SFRS3) and the Positive regulator, High-mobility group 
box-1 (HMGB1), for further studies. 
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 SFRS1 and SFRS3 are two “bona-fide” members of the SR protein family of 
SFs (reviewed in Chapter 1.2.1.1 and  reviewed in Long et al., 2009). SFRS1 
(ASF/SF2) was the first SF to be identified (Krainer et al., 1990a) and is probably 
one of the most studied SFs (reviewed in Long et al., 2009). SFRS1 has been 
shown to play a role in several cellular processes, such as constitutive and 
alternative splicing (Ge et al., 1990; Krainer et al., 1990b) transcription (Li et al., 
2005a; Li et al., 2007), translation (Michlewski et al., 2008; reviewed in Li et al., 
2005a;Long et al., 2009). Moreover, the role of SFRS1 in several diseases has also 
been studied in great detail, such as cancer (Fischer et al., 2004; Karni et al., 2007; 
Stickeler et al., 1999), AIDS (Asang et al., 2008), and more recently it was shown 
that SFRS1 may play a role in Inflammation (Xiong, 2006). The work from Xiong 
et al. shows that patients with an Inflammatory condition, inflamed muscle, have a 
remarkable decreased ASF/SF2 expression (Note: ASF/SF2 is the protein encoded 
by the SFRS1 gene). In addition, in vitro stimulation of Mouse C2C12 skeletal 
muscle myoblasts with a pro-inflammatory mediator, TNF-", showed a similar 
phenotype, thus unveiling a possible role of ASF/SF2 in the regulation of an 
Inflammatory response. The other SR protein, SRp20 (Note: SRp20 is the protein 
encoded by the SFRS3 gene) is far less studied than ASF/SF2. However besides its 
role in Splicing, SRp20 have also been demonstrated to be important in other 
cellular processes, such as nucleocytoplasmic export of mRNA (Huang et al., 
2001; Huang et al., 2003; Huang et al., 2004) or in translation (Bedard et al., 
2007). The IL-1! secretion phenotype observed after knockdown this SF was one 
of the most remarkable and consistent found during the RNAi based screen (Figure 
31-b). Therefore we decided to further study its role in the regulation of IL-1! 
secretion, in addition to SFRS1. 
 In Figure 32 are represented, for each gene, the different values (knockdown 
and IL-1! secretion) for the shRNA construct used on further studies. In addition 
to the mRNA knockdown validation,  the protein levels of these 2 SF was also 
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assayed by Western blot. As can be seen in Figure 32-e, in agreement to what was 
observed at the mRNA level, the protein levels of both SF are decreased upon 
knockdown. In addition, knocking-down one SF did not show any impact in the 
expression of the other candidate (Figure 32-f). 
a)       b) 
 
c)       d) 
 
e)  
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f)  
 
 
 
 
    
 
    
 
 
Figure 32 – Knockdown validation of SFRS1 and SFRS3. THP-1 cells were infected 
with Lentiviral vectors encoding shRNAs to target SFRS1 and SFRS3. The efficiency of 
knockdown of the SF candidates was assayed at mRNA level by qRT-PCR (a and c) and at 
protein level (e), by Western-blot. b, d ) IL-1! secretion phenotype for the shRNA used to 
target each SF candidate after 24 hr E.coli challenge. f) SRp20 protein expression upon 
ASF/SF2 knockdown and vice-versa. SRp20 and ASF/SF2 are the proteins encoded by the 
genes SFRS3 and SFRS1, respectively. !-actin was used as a protein loading control (t-
student: ***p<0.0001). 
 
  In addition to the Negative Regulator SF candidates, we decided to 
further validate the Positive Regulator SF candidate HMGB1. The role of HMGB1 
in Splicing or Splicing Regulation have not yet been unveiled, however it was 
found as a putative Splicing Regulator protein during a Proteomic Analysis of the 
Spliceosome (Barbosa-Morais, 2005). In opposition, an important role in 
Inflammation has been attributed to this candidate. The HMGB1 has been 
identified to be actively secreted by stimulated macrophages and monocytes and to 
act as potent pro-inflammatory mediator (Wang et al., 1999; reviewed in 
Erlandsson Harris et al., 2004). Furthermore, a report by Mouri et al. shows that 
HMGB1 can regulate IL-1! production by the transactivation of its promoter 
(Mouri et al., 2007). In a similar manner to what was performed for SFRS1 and 
SFRS3, HMGB1 mRNA and protein expression was evaluated upon knockdown. 
Targeting THP-1 cells with the lentiviral vectors encoding an HMGB1 specific 
shRNA reduced its expression at mRNA (Figure 33-a) and protein levels (Figure 
33-c), and showed a clear reduction in IL-1! secretion upon 24 hr E.coli challenge 
(Figure 33-b). 
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a)       b) 
 
c) 
 
 
 
Figure 33– Knockdown validation of HMGB1. 
THP-1 cells were infected with  a Lentiviral vector 
encoding a shRNAs to target HMGB1. The 
efficiency of HMGB1 knockdown was assayed at 
mRNA level by qRT-PCR (a) and at protein level 
(c), by Western-blot. b) IL-1! secretion phenotype 
for the shRNA used to target HMGB1 after 24 hr 
E.coli challenge. !-actin was used as a protein 
loading control (t-student: ***p<0.0001).  
 
  
 
3.2.2 - Validation of SFRS1 and SFRS3 as Negative 
Regulators of IL-1! secretion 
 
 
 In an attempt to validate the Negative roles of SFRS1 and SFRS3 in the 
regulation of IL-1! secretion after a bacterial challenge, we performed other 
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complimentary studies, either using drugs to target the two SFs or by 
overexpression experiments. 
 
 
 3.2.2.1 – Drugs targeting SFRS1 and SFRS3 show a 
similar Negative Regulator phenotype 
 
 The strong connection between Splicing and disease has “boosted” the 
interest of finding drugs that may be used to modulate certain cellular responses by 
targeting some key-components in Splicing, such as SFs. One such example is the 
work of Keriel and colleagues (Keriel et al., 2009) where several drugs were 
screened for their suppressive effect in the production of ASF/SF2 Splicing 
dependent retroviral proteins, therefore promoting protection against retrovirus 
pathogenesis. Other study, by Stoilov et al. (Stoilov et al., 2008), have identified 
Digoxin as a compound capable of modulating microtubule-associated protein tau 
(MAPT) exon 10 Splicing by decreasing the expression of SRp20. Therefore, to 
confirm the phenotypes observed by RNAi, we have used drugs that inhibit 
ASF/SF2 dependent Splicing, kindly provided by Dr. Jamal Tazi, and Digoxin to 
target SRp20. Briefly, THP-1 cells were treated with drugs or DMSO (as control) 
and further challenged with E.coli for 24 hr. Supernatants were collected and IL-1! 
concentration assayed by ELISA. Inhibiting ASF/SF2 dependent Splicing using 
BO-3 and BO-26 compounds, increased the levels of IL-1! secreted after 24 hr 
E.coli challenge, when compared with control (Figure 34-a). A similar result was 
found when SRp20 expression was decreased using Digoxin (Figure 34-b). Indeed, 
to confirm the downregulation of SRp20 expression upon digoxin treatment, an 
immunoblot was performed in Digoxin treated cell lysates. As can be seen in 
Figure 34-d, SRp20 expression is decreased upon treatment; moreover, the positive 
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effect of digoxin treatment on IL-1! secretion is inversely correlated with SRp20 
expression (Figures 32 c and d). 
 
a)       b) 
 
c)      d) 
 
 
 
 
 
Figure 34 – The effect of drugs targeting SFRS1 and SFRS3 on IL-1! secretion. a) 
BO-3 and BO-26, two compounds that abolish SFRS1 dependent Splicing events were used 
to treat THP-1 cells previous to E.coli challenge. Increased IL-1! secretion was observed 
upon targeting SFRS1 using both drugs. b) In a similar way, Digoxin treatment increased 
IL-1! secretion after 24 hr E.coli challenge. c) Moreover, the increased IL-1! secretion is 
dependant on the digoxin dose used. d) Digoxin treatment reduces the expression of SRp20 
in a dose dependant manner. SRp20-protein encoded by SFRS3. !-actin was used as a 
protein loading control (t-student: *p<0.05,**p<0.005,***p<0.0001). 
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 3.2.2.2 – Overexpression of SFRS1 and SFRS3 decreases 
IL-1!  secretion 
 
 
 The results obtained using RNAi or drugs targeting SFRS1 and SFRS3, 
clearly show that either decreasing both SFs expression or impairing their Splicing 
dependent reactions, increased IL-1! secretion. Thus, in an attempt to counteract 
this phenomena and further prove the negative regulator effect of these two SFs, 
we decided to overexpress both candidates and evaluate the impact of the 
overexpression in IL-1! secretion. We have generated lentiviral vectors (Figures 
20, 21, S1 and S2) to promote the overexpression of these SFs and then analyze 
their role in IL-1! secretion induced by E.coli challenge. Briefly, as mentioned in 
Chapter 2.2.9, SFRS1 and SFRS3 were cloned into a lentiviral vector (pLenti6/V5-
DEST) and viruses were produced in 293T cells. The lentiviruses generated were 
then used to infect THP-1 cells. After selection with Blasticidin®, the infected cells 
were challenged with E.coli for 24 hr and supernatants were collected and assayed 
for IL-1! levels by ELISA. As can be seen in Figure 35, overexpressing SFRS1 or 
SFRS3 resulted in a remarkable decrease in IL-1! secretion, as compared with the 
control. The overexpression was confirmed by immunoblot to detect the V5 
epitope that is fused to the protein of interest (Figures 21 and S2) as shown in 
Figure 35-b. 
 Thus, these results further substantiate the role of SFRS1 and SFRS3 as 
negative regulators of IL-1! secretion.  
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a)      b) 
  
Figure 35 – Overexpression of SFRS1 and SFRS3. Lentiviruses were used to 
overexpress SFRS1 and SFRS3 in THP-1 cells. After infection cells were challenged with 
E.coli and IL-1! concentration was measured in the supernatants by ELISA. a) 
Overexpression of SFRS1 and SFRS3 decreased IL-1! secretion after 24 hr E.coli 
challenge, as compared to control. b) Western blot detection V5-epitope tagged SFRS1 and 
SFRS3 proteins. pSFRS1 and pSFRS3 are the lentivirus encoding the SFRS1 and SFRS3 
V5 tagged proteins. Lanes 1 and 3-control non-infected cells. Lanes 2 and 4 cells 
overexpressing ASF/SF2 or SRp20, respectively. !-actin was used as protein loading 
control (t-student: ***p<0.0001). 
 
 
 
3.2.3 - SFRS1 and SFRS3 effects on IL-1! secretion 
pathway 
 
  Interleukin-1! secretion is the outcome of a two-step mechanism, 
Production and Processing, as described in Chapter 1.1.2 (Figure 9, reviewed in 
Creagh et al., 2006; Dinarello, 2009; Martinon et al., 2009). To dissect the 
contributions of SFRS1 and SFRS3 in the regulation of both steps required for IL-
1! secretion we have developed several assays. We have measured IL-1! mRNA 
expression after SFRS1 and SFRS3 knockdown, as a quantitative method to 
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observe the impact in the Production step. To elucidate their role in the Processing 
step, we took advantage of an indirect method to detect Inflammasome activation, 
by measuring Caspase-1 activity. 
 
 
 
 3.2.3.1 - SFRS1 and SFRS3 regulate IL-1! mRNA 
expression 
 
 One of the key elements in the production of IL-1! is the activation of the 
NF-kB transcription factor (Dinarello, 2009). Upon activation, NF-kB is 
translocated into the nucleus and promotes the transcription of several pro-
inflammatory cytokines, such as IL-1! and IL-8 (Dinarello, 2005; Remick, 2005). 
In addition to IL-1!, IL-8 expression and secretion in THP-1 cells was already 
mentioned to be induced upon E.coli challenge (Figures 22 and 23). Therefore, we 
decided to measure both cytokines mRNA expression as an indirect, however 
quantitative method, of NF-kB activation and IL-1! production.  
 Interleukin-1! and IL-8 mRNA expression was measured by qRT-PCR at 
different time points after THP-1 challenge with E.coli. Once more we could 
observe that the mRNA expression of both cytokines is induced by E.coli 
challenge (Figure 36). However, upon SFRS1 and SFRS3 knockdown, their 
mRNA  expression is much higher when compared with control (Figure 36). 
Moreover, the increased mRNA expression of both IL-1! and IL-8 is much higher  
in cells targeted for SFRS3 than in SFRS1 knocked-down cells (Figure 36). This 
observation correlates with the higher secretion of IL-1! in SFRS3 knocked-down 
cells as compared with cells with decreased SFRS1 expression (Figures 32-b and 
d; S4-a and S4-b).  
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 Interleukin-1! concentration was also measured in the cell supernatants at 
the different time points following E.coli challenge. Increased IL-1! secretion is 
already detected 4hr post-challenge upon SFRS1/SFRS3 knockdown as compared 
with control cells (Figures S4-a and b). 
 
a) 
 
b) 
 
Figure 36 – Kinetics of IL-1! and IL-8 mRNA expression upon SFRS1/SFRS3 
knockdown.  THP-1 cells were infected with lentiviral vectors encoding specific SFRS1 or 
SFRS3 shRNA. After infection cells were challenged with E.coli for different times. a) 
Increased IL-1! mRNA expression, detected by qRT-PCR, in cells where SFRS1 and 
SFRS3 were down regulated. Higher induction was found in SFRS3 knocked-down cells, 
as compared with control and SFRS1 RNAi targeted cells. b) Similar to the results obtained 
for IL-1!, IL-8 mRNA expression was also increased in SFRS1 and SFRS3 knocked-down 
cells, with higher values in the last one. 
  
 
 
 
“Identification of Splicing Factors with a role in IL-1! secretion”              
 
 
128 
 The Positive Regulator candidate HMGB1 has been recently reported to be 
an endogenous Danger Signal (DAMP), therefore capable of inducing 
Inflammation (reviewed in Erlandsson Harris et al., 2004; Klune et al., 2008). 
Moreover, it was shown that HMGB1 can act as a transactivator of IL-1! 
promoter, therefore being involved in IL-1! production (Mouri et al., 2007). As a 
proof of principle, we  performed  a similar approach to what was done previously, 
for SFRS1 and SFRS3, to measure IL-1! mRNA expression upon HMGB1 
knockdown. The results confirmed the positive role of HMGB1 in IL-1! 
production, as can be seen in Figures 37 and S4-c, where decreased IL-1! mRNA 
expression and secretion occurs in HMGB1 RNAi targeted cells.  
 
 
Figure 37 - Kinetics of IL-1! mRNA 
expression in HMGB1 knockdown 
cells. THP-1 cells were infected with 
lentiviruses encoding a specific 
HMGB1 shRNA. Infected cells were 
further challenged with E.coli for 
different time points. qRT-PCR 
analysis shows that IL-1! mRNA 
expression is decreased in cells where 
HMGB1 was knocked-down, as 
compared with control. 
 
  
 
 All these results prompted us to, besides validating our approach to find SFs 
with a role in IL-1! secretion, to conclude that SFRS1 and SFRS3 are negative 
regulators of IL-1! expression.  
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3.2.3.2 - SFRS3 regulates IL-1! processing 
 
The second step necessary for IL-1! secretion is the Processing by the 
Inflammasome, in a Caspase-1 dependent manner, as shown in Figure 24 and 
extensively reviewed in Chapter 1.1.  
Using Caspase-1 activity as an indirect method of Inflammasome 
activation detection, we have studied the role of both SFs in the second step of IL-
1! secretion pathway. Briefly, as described in Chapter 3.1.2, Caspase-1 activity 
can be measured by FACS using FLICA, a fluorophore labeled Caspase-1 
substrate that irreversibly binds to the catalytical center of active Caspase-1. We 
assayed Caspase-1 activity in cells knocked-down for SFRS1 or SFRS3 and further 
challenged with E.coli for 24 hr. The results obtained by FACS analysis were then 
normalized with the Caspase-1 activity measured in control infected cells 
stimulated with E.coli. As presented in Figure 38, SFRS1 does not play a role in 
this second step necessary for IL-1! secretion, as the levels of Caspase-1 activity 
are almost equal to control. In opposition, SFRS3 was found to be a negative 
regulator of Caspase-1 activation since increased levels of activation were detected 
upon knocking down this SF. 
 
 
Figure 38 – Caspase-1 activity in 
SFRS1/SFRS3 RNAi targeted cells. 
THP-1 cells were infected with lentiviral 
vectors encoding specific SFRS1/3 
shRNAs and further challenged with 
E.coli for 24 hr Caspase activation was 
measured by FACS. Cells knocked-down 
for SFRS3 showed an increased 
activation after 24 hr E.coli challenge, as 
compared with control and SFRS1 RNAi 
targeted cells. (t-student: ***p<0.0001). 
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 These data showed that SFRS1 does not have an impact in this second step 
necessary for IL-1! maturation and release. In opposition, the increased Caspase-1 
activity observed after knocking-down SFRS3, strongly suggests that this SF is 
involved in the regulation of the Inflammasome, however by an unknown 
mechanism.  
 
  3.2.3.2.1- SFRS3 regulates Caspase-1 mRNA 
expression 
 
 In order to study the underlying mechanism of SFRS3 regulation of 
Caspase-1 activity, we have measured the expression of the NALP3 Inflammasome 
components, to check if the augmented Caspase-1 activation could be related with 
increased expression of these molecules. In addition, we developed a preliminary 
approach to evaluate if other Inflammasome complexes are being activated upon 
SFRS3 knockdown. 
 The increased Caspase-1 activation observed upon knockdown of SFRS3, as 
compared with the control or SFRS1 knockdown suggested that Caspase-1 
expression might be increased in cells targeted for SFRS3. qRT-PCR assays were 
performed to evaluate Caspase-1 mRNA expression kinetics in cells knocked-
down for SFRS1, SFRS3 and in control infected cells. As can be seen in Figure 39 
there is an increase in Caspase-1 mRNA expression in SFRS3 knocked-down cells, 
as compared to the expression levels in either SFRS1 and control cells. The 
increased levels are more striking 24 hr post-E.coli challenge, approximately 5-
fold higher than in control-infected cells. This increased Caspase-1 mRNA 
expression in SFRS3, and not in SFRS1, RNAi targeted cells, correlates with the 
increased Caspase-1 activation observed, thus, suggesting that the increased 
Caspase-1 activity could indeed be due to increased Caspase-1 availability.  
  
 
 
                                                                                                                   Chapter 3 – Results          
 
131 
 
Figure 39 – Kinetics of Caspase-1 mRNA 
expression upon SFRS1 and SFRS3 
knockdown. THP-1 cells were infected 
with lentiviral vectors encoding specific 
shRNAs targeting SFRS1 or SFRS3. Cells 
were further challenged with E.coli for 
different time points. Increased levels of 
Caspase-1 mRNA are found in cells 
knocked-down for SFRS3, as compared 
with SFRS1 RNAi targeted and control 
cells.  
   
  
 The expression of the other two-components of the NALP3 Inflammasome, 
ASC and NALP3, was also tested. As can be observed in Figure 40, the expression 
of ASC and NALP3 was not significantly altered upon SFRS3 knockdown. 
Moreover, 24 hours after challenge a reduced expression of NALP3 is observed in 
SFRS3 targeted cells, thus suggesting that the increased Caspase-1 activation is not 
due increased expression of ASC or NALP3. 
a)     b) 
 
Figure 40 - Kinetics of ASC and NALP3 mRNA expression upon SFRS3 knockdown. 
THP-1 cells were infected with lentiviral vectors encoding specific shRNAs targeting 
SFRS1 or SFRS3. Cells were further challenged with E.coli for different time points. a) 
ASC mRNA expression kinetics is not altered upon SFRS3 knockdown. b) NALP3 mRNA 
expression is not dramatically affected upon SFRS3 knockdown. Small increase can be 
observed at 1 and 2 hr after E.coli challenge. At 24 hr after bacterial challenge, NALP3 
expression is reduced in SFRS3 knocked-down cells. 
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  3.2.3.2.2 - The regulation of different 
Inflammasomes by SFRS3  
 
In the past years, several Inflammasomes have been reported to exist, and 
to be important in the processing of IL-1! in response to different stimuli (Figure 
7,  reviewed in Franchi et al., 2009; Martinon et al., 2009). In Chapter 3.1.3.2, we 
have reported that the NALP3 Inflammasome is the major Inflammasome involved 
in the generation of IL-1! response to an E.coli challenge. However, we cannot 
rule-out the possibility that by knocking-down SFRS3, we might be activating 
different Inflammasomes, and consequently an increased Caspase-1 activation.  
To answer this question, we performed double knockdown experiments 
targeting the 3 major Inflammasomes described (NALP3, NALP1 and IPAF), the 
common adaptor ASC, and at the same time SFRS3. After infection, cells were 
challenged with E.coli for 24 hr. Interleukin-1! secretion was measured in the cell 
supernatants by ELISA. The results present at Figure 41 show that the increased 
IL-1! secretion observed upon SFRS3 knockdown, can be partially reverted if a 
double knockdown with NALP3 or NALP1 is performed. Suggesting that these 
two Inflammasome platforms might be negatively regulated by SFRS3. In 
opposition, IPAF does not seem to play a role in the increased IL-1! secretion 
upon SFRS3 knockdown, since the same levels of IL-1! are secreted when double 
knockdowns were performed for SFRS3/IPAF. Double knockdowns of SFRS3 and 
the Inflammasome(s) adaptor ASC, remarkably decreased the IL-1! secretion, 
therefore confirming the important role of ASC in IL-1! secretion, as was shown 
previously. 
These results thus suggest that the increased IL-1! secretion upon SFRS3 
knockdown might be also due to activation of different Inflammasome platforms, 
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in addition to the increased Caspase-1 expression shown in the previously. 
However, further experiments are required to confirm this assumption. 
 
 
 
 
Figure 41 – The role of different Inflammasomes in IL-1! secretion upon SFRS3 
knockdown. Several key-components of the different Inflammasomes and SFRS3 were 
double knockdown in THP-1 cells, either in the presence of Scramble shRNA (Control) or 
SFRS3. The increased IL-1! secretion observed in the double knockdown Control/SFRS3 
situation is reverted if in addition to SFRS3 kd, NALP3 or NALP1 are also knocked-down. 
Double knockdown of SFRS3/IPAF does not decrease IL-1! secretion as compared to the 
Control/SFRS3 double knockdown. The double knockdown of SFRS3 and the adaptor 
protein ASC, shows a remarkable decreased IL-1! secretion after 24 hr E.coli challenge. (t-
student:**p<0.005, ***p<0.0001). 
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3.2.4 - SFRS1 and SFRS3 Regulation upon E.coli 
challenge 
 
 
As reported previously, ASF/SF2 expression was shown to be 
downregulated in inflamed muscle and in the presence of a pro-inflammatory 
cytokine (Xiong, 2006). Thus, these results prompted us to look for the expression 
of SFRS1 and SFRS3 in our model system, THP-1 cells challenged with E.coli.  
Concerning the expression of SFRS1, Figure 42-a shows that its mRNA 
expression is down regulated after E.coli challenge, already 1 hr post-challenge. 
This result seems to be in agreement with the involvement of SFRS1 in 
Inflammation as described by Xiong et al. (Xiong, 2006). In opposition, SFRS3 
mRNA expression is not remarkably changed along the stimulation. Although, at 
24 hr after E.coli challenge, it seems to be down-regulated, but not to similar levels 
as compared with SFRS1 (Figure 42-b). 
 The expression and activity of several SFs have also been shown to be 
regulated at post-transcriptional levels (e.g. by miRNAs, Boutz et al., 2007) and at 
post-translational levels (such as phosphorylation, as described in Chapter 1.2.1.1).  
Since we were interested in studying the role of SFRS3 in the regulation of IL-1! 
secretion, in addition to SFRS1, we decided to go further and look for possible 
SRp20 alterations induced by an E.coli stimulus. As can be seen in Figure 42-c, 
SRp20 expression is down regulated at the protein level after E.coli challenge.  
In sum, we can conclude that the expression of these two SFs is altered 
upon E.coli challenge. The underlying mechanism that regulates their expression is 
not yet known, however is now under study. 
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a)     b) 
  
c) 
Figure 42 – SFRS1 and SFRS3 expression 
after E.coli challenge. a), b) SFRS1 and 
SFRS3 mRNA expression was assayed by 
qRT-PCR in THP-1 cells challenged with 
E.coli at different time points. SFRS1 
mRNA expression is decreased upon E.coli 
challenge, whereas SFRS3 mRNA 
expression is almost unaltered. An exception can be observed at 24 hr post challenge where 
SFRS3 mRNA expressed levels are lower, although not at the same extent as SFRS1. c) 
THP-1 cells challenged with E.coli show decreases SRp20 expression over time, as 
detected by Western Blot. !-actin was used as protein loading control. 
 
  
 
 
3.2.5 – Alternatively Spliced Genes involved in the 
regulation IL-1! secretion 
 
As discussed in Chapter 1.1.3a, numerous isoforms of important genes 
involved in the IL-1! secretion pathway have been found over time (reviewed in 
Leeman et al., 2008; Krieg et al., 2009; Matsushita et al., 2009a;! Sahoo et al., 
2010). However, a lot is still unknown about the true extent of Alternative Splicing 
events (ASE) that are involved in the regulation of this Inflammatory response. In 
an attempt to identify possible Splicing events that occur upon E.coli challenge, the 
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Splicing patterns of several genes already described to play a role in IL-1! 
secretion were tested.  In addition to the already identified isoforms, we extended 
our AS analysis to other  putative isoforms and genes that could be involved in the 
regulation of IL-1! secretion. We have based our search on published data and 
using a bioinformatic tool, the Exonmine online database 
(http://www.imm.fm.ul.pt/exonmine/), that predicts the different isoforms each 
gene may present. According to the different isoforms already published and the 
putative isoforms predicted by the Exonmine database, we have designed the 
primers that would allow us to identify the most interesting Splicing patterns of the 
genes in study (listed at Table 7). Alternative Splicing patterns were then analyzed 
by RT-PCR followed by agarose gel electrophoresis. However, besides the greater 
number of genes tested, no conclusive results were obtained in what concerns the 
possible isoforms induced by an E.coli challenge. 
 
 
Table 7 – List of genes tested for ASE upon E.coli challenge of THP-1 cells. 
 
GENE GENE GENE GENE 
APAF1 CASP2 MDM2 P2X7 
ASC CASP8 MEFV2 PANX1 
BCL-2 CASP9 MKNK2 PANX2 
BCL-X CD45 MyD88 PANX3 
BCL10 COP1 NALP1 PTEN 
BCL2A1 ICEBERG NALP1" RIPK2 
BIN1 IL1RN NALP3 RPS6KB 
CARD9 INCA NLRX1 SERPINB2 
CASP1 MALT1 P2X4 SFRS1 
 
Similar experiments were performed in THP-1 cells previously targeted 
with control, SFRS1 and SFRS3 specific shRNAs. With this approach we 
attempted to identify possible alterations in the Splicing patterns of these genes, 
that could be regulated by the two SFs. Moreover, as described in previous 
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Chapters, knocking-down the expression of the SFs can also affect gene 
expression, as demonstrated by the increased Caspase-1 mRNA expression upon 
SFRS3 knockdown. Therefore, we have extended our approach to identify possible 
alterations at gene expression levels, in addition to the different isoforms. 
However, once more, no conclusive results were obtained using this approach (data 
not shown).  
Thus, we decided to perform a high-throughput analysis of ASE and 
differences of Gene Expression (DEG) using the GeneChip® Human Exon 1.0 ST 
Arrays platform by Affymetrix®.  
 
 
3.2.5.1 - Exon-array analysis  
 
The GeneChip® Human Exon 1.0 ST Arrays platform by Affymetrix® is 
designed to have approximately four probes covering each exon, and roughly 40 
probes per gene, therefore enabling two complementary levels of analysis, gene 
expression (differences in gene expression, DEG) and Alternative Splicing events 
(ASE), The existence of several probes for the same exon enables “exon-level” 
analysis, therefore allowing to distinguish differentially expressed isoforms of the 
same gene. In addition, the large number of probes covering the same gene also 
makes this platform a good method to evaluate the expression levels of a certain 
gene (http://www.affymetrix.com/products_services/arrays/specific/exon.affx). 
In order to perform this analysis, THP-1 cells were infected with lentivirus 
encoding an shRNA targeting SFRS1 or Control. After puromycin selection, cells 
were challenged for 4 hr with E.coli. Total RNA was extracted and cell 
supernatants were assayed for IL-1! secretion by ELISA. As can be seen in Figure 
43-a, 4 after E.coli challenge, SFRS1 knocked-down cells show increased IL-1! 
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secretion, similar to what was observed 24 hr post-challenge. SFRS1 knockdown 
was validated at mRNA (Figure 44-b) and protein levels (data not shown). 
 
a)      b) 
 
Figure 43 – Validation of SFRS1-kd phenotype in IL-1! secretion. THP-1 cells were 
infected with lentiviral vectors encoding an shRNA to target SFRS1. a) IL-1! secretion was 
assayed in the cell supernatants after 4 hr of E.coli challenge. The values were normalized 
against the IL-1! secreted levels measured in control-infected cells. An increase in IL-1! 
secretion was observed in SFRS1 knocked-down cells. b) The efficiency of SFRS1 
knockdown was assayed by qRT-PCR and normalized against the expression of SFRS1 in 
control infected cells. (t-student: **p<0.005). 
 
 
The RNA extracted was sent to the Genomics Core Facility at The 
European Molecular Biology Laboratory in Heidelberg, Germany (EMBL) for 
hybridization in the GeneChip® Human Exon 1.0 ST Arrays 
(http://www.embl.de/services/core_facilities/genecore/index.html).  After the 
hybridization protocol, the data generated was analyzed in collaboration with Ana 
Grosso at the Unit of Cellular Biology (UBCe) at Instituto de Medicina Molecular 
(IMM) in Lisbon, Portugal, as described in Chapter 2.2.10. Twelve hybridizations 
were performed: Control cells stimulated and non-stimulated with E.coli, Control-
S and Control-NS, respectively; and SFRS1-kd cells stimulated (shSF2-S) and 
non-stimulated with E.coli (shSF2-NS, all in triplicate). Two types of analysis 
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were performed for the different replicate samples, differences in gene expression 
(DEG, Chapter 3.2.5.1.1) and in Splicing patterns (ASE, Chapter 3.2.5.1.2). 
 
 
 
 3.2.5.1.1- Differentially Expressed Genes (DEG) 
 
 
The Human Exon 1.0 ST Arrays platform allows the identification of DEG 
due to the high number of probes covering each gene, as mentioned before. Three 
comparison analyses were performed with the data generated: Control-NS vs 
Control-S, shSF2-NS vs Control-NS and shSF2-S vs Control-S (Figure 44). The 
complete list of genes DEG in the different analysis performed can be seen on 
supplementary data.  
 
 
Figure 44– DEG obtained in the different comparison analysis. After bioinformatics 
analysis of the data generated by the Human Exon 1.0 ST Arrays, the expression of several 
genes was shown to be changed in the different conditions, either upregulated (in blue) or 
down regulated (in red). 
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In order to validate the results obtained by the bioinformatics analysis, 
qRT-PCR experiments were performed for 33 of the genes found to be 
differentially expressed in the different comparisons (the validated genes are listed 
at Table 8). On Figure 45 are shown the results obtained in the qRT-PCR 
experiments (in blue) in comparison to the fold inductions determined by the array 
analysis (in white). The results obtained in the Control-S vs Control-NS analysis 
are represented in Figure 45-a, whether the shSF2-Ns vs Control-NS analysis is 
shown in Figure 45-b. The primers used for the validations are listed in Table S5. 
Among the genes tested only SERPINB2 was not validated (as can be seen in 
Figure 45). The rate of validation was 96.9%.  
a) 
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b) 
 
 
Figure 45 – Validation of the DEG obtained by bioinformatic analysis of the array 
data. qRT-PCR experiments were performed to detect differences at gene expression levels 
of some differently expressed candidates, obtained by bioinformatic analysis of the Exon 
arrays. In the Figure are represented the fold inductions predicted by the array (in white) 
and the fold inductions obtained in qRT-PCR analysis (in blue). a) Control-S vs Control-
NS analysis validation-All the genes show a similar profile in the qRT-PCR analysis when 
compared to the predicted by the array, with the exception of the SERPINB2 gene, 
therefore not validated. b) shSF2-Ns vs Control-Ns analysis validation-All the genes 
analyzed were validated. 
 
Table 8 – List of DEG genes validated by qRT-PCR in the different analysis. 
 
Control-S 
vs 
Control-NS 
Control-S 
vs 
Control-NS 
shSF2-NS 
vs 
Control-NS 
CCL2 NFE2 P2RX1 
CCL20 NUDT7 RIPK3 
CCL4 P2RX1 SFRS1 
CCL4L2 P2RY2 TBC1D30 
CX3CR1 RIPK3 TNF 
CXCL10 SCAMP5  
CXCR4 SELPLG  
ERLIN1 SFRS1  
HMOX1 SOD2  
ICAM1 TBC1D30  
IL-1! TNF  
IL-8 TNFAIP6  
IL8RB VLDLR  
LAMP3   
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In agreement to what was already presented previously, IL-1! and IL-8 
mRNA expression is induced after E.coli challenge. As can be seen in Figure 45-a, 
SFRS1 mRNA expression is down-regulated after an E.coli challenge, further 
proving the results presented before.  
A preliminary bioinformatic analysis was performed using the Ingenuity® 
Pathway analysis software (INGENUITY® Systems) in order to evaluate the major 
pathways and cellular functions that are either activated or inhibited in the different 
conditions (E.coli challenge or SFRS1 knockdown). As can be seen in Figure 46-a 
several cellular functions (such as Cell death and Inflammatory response) and 
pathways (Figure 46-b) are “altered” when challenging  THP-1 cells with E.coli. 
Among the pathways induced, is the NF-kB pathway, which was already described 
to be important, either for the production of IL-1! and in the Inflammatory 
response in general, therefore validating this approach. Additionally, several genes 
in the NF-kB pathway are either up- (in red) or down regulated (in green), as can 
be seen in Figure 46-c.  This preliminary approach will be extended in the future to 
the other analysis in an attempt to find important genes which expression is altered 
that could have an impact in the regulation of IL-1! secretion after an E.coli 
challenge. 
a) 
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b) 
 
 
 
 c) 
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Figure 46 – Ingenuity Pathway analysis of the DEG obtained in the Control-S vs 
Control-NS Exon array analysis. a,b) Several cellular function and pathways are induced 
after 4 hr E.coli challenge. In b is represented the percentage of the known genes in 
different pathways that are either up- or down regulated. Among the different pathways 
altered is the NF-KB pathway. c) Close look to the genes in the NF-KB pathway that are 
altered after 4 hr E.coli challenge. Up and down regulated genes are represented in red and 
green, respectively. 
 
 
 
 3.2.5.1.2 - Alternative Splicing Events (ASE) 
 
 
In an attempt to identify possible changes in the Splicing pattern of 
different genes upon E.coli challenge and/or SFRS1 knockdown by shRNA, 
several comparison analysis were performed with the data originated by the 
Human Exon 1.0 ST Arrays for each sample, namely Control-S vs Control-NS, 
shSF2-NS vs Control-NS and shSF2-S vs Control-S, as described previously for 
the case of DEG. The complete list of ASE found to occur in the different analysis 
performed is present on Chapter 7. In order to validate the results, PCR analysis 
were performed using specific primers to detect the ASE events predicted by the 
Exon array. The primers (listed on Table S4) were designed in accordance to the 
different isoforms predicted by the array and by different isoforms of the same 
gene already listed at the Exonmine online database 
(http://www.imm.fm.ul.pt/exonmine/). An example of a validated and a non-
validated ASE is present on Figure 47, for OS9 and SPPL3 genes, respectively. 
The list of ASE tested is present at Table 9. All the validated ASE are depicted in 
bold, therefore, the rate of validation was 78% for the Control-S vs Control-NS, 
and 67% for the shSF2-NS vs Control-NS.  
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a)     b) 
  
 
c)     d) 
 
                                
 
 
Figure 47 – ASE validation. ASE predicted by the Exon array analysis were validated by 
PCR. a,b) Schematic representation of the ASE predicted by the array for 2 of the genes, 
OS9 and SPPL3, respectively. The numbers correspond to the number of the exon listed on 
the Exonmine database. The primers and the respective annealing sites are represented in 
grey as forward (Fw) and reverse primers (Rw). In the case of OS9, exon 13 is excluded 
upon ASF/SF2 knockdown, generating a shorter isoform of 126 bp when compared to the 
control situation, 291 bp. For SPPL3, exon 3 is excluded upon ASF/SF2 knockdown, 
originating a 112 bp isoform. c,d) PCR validation of the array predictions. c) After 
ASF/SF2 knockdown, there is an increase of the shorter band (126 bp) as predicted by the 
array, therefore validating the ASE. In the case of SPPL3 (d), the prediction by the array 
suggested that a shorter isoform of 112 bp would be amplified in cells targeted to ASF/SF2 
knockdown. No differences in isoforms were seen, therefore not validating this ASE. 
 
Table 9 – List of tested and validated (in bold) ASE in the different analysis. 
Control-S 
vs 
Control-NS 
shSF2-NS 
vs 
Control-NS 
ATP2B4 ALAS1 
CD44 IRF7 
EIF4H OS9 
IL-32 PVRL2 
RET SPPL3 
RGS8 STAT5A 
SHD  
STAT5A  
TNFAIP2  
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 In a similar way to what was done in the previous Chapter for the DEG, a 
preliminary bioinformatic analysis using Ingenuity® software was performed for 
the ASE. As can be seen in Figure 48-a several immune functions are altered at an 
“Alternative Splicing” level, for example the Inflammatory response. Several 
signaling pathways are also altered, such as the expected NF-kB pathway (Figure 
48-b). Numerous genes in the NF-kB pathway were already reported to be 
regulated by AS and to play a role in the regulation of this pathway (reviewed in 
Leeman et al., 2008). Furthermore, some of the isoforms identified in this pathway 
(e.g. MyD88s) were already reported to be induced by an Inflammatory stimulus, 
such as LPS (Janssens et al., 2002; Janssens, 2003), thus validating our approach. 
In Figure 48-c are represented the ASE in the NF-KB pathway found by the Exon 
array analysis. In red and green are represented exon inclusion and exclusion 
events, respectively.  
 We decided to intersect the list of genes that undergo AS listed by Leeman 
and Gilmore (Leeman et al., 2008) and the events collected by our Exon Array 
analysis (Control-S vs Control-NS). Doing this, we observed that 36% of the genes 
listed in the report were among the ASE detected by the array (represented by 
asterisk in Figure 48-c and shown in Table 10).  
  In addition, a similar approach was performed to determine which ASE 
predicted by the Exon array were already described in TLR signaling cascade by 
Wells et al. (Wells et al., 2006). As presented in Table 10, several ASE predicted in 
our analysis were already reported, such as NFKB1 or NFKB2, among others 
(approximately 20% of the already described ASE were found in our analysis). 
 We therefore hypothesize that this approach can be extended in the future 
to find new important genes in the Inflammatory response that are regulated by 
AS.  
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a) 
              
 
 
b) 
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c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48 – Ingenuity Pathway analysis of the ASE obtained in the Control-S vs 
Control-NS Exon array analysis. a,b) Several cellular functions and pathways are altered 
at AS level after E.coli challenge. In b) is represented the percentage of the genes in the 
different pathways that undergo AS by exon array analysis prediction, c) Close look to the 
genes in the NF-KB pathway that undergo AS after E.coli challenge. Exon exclusion events 
in green, and exon inclusion events in red. The genes marked with asterisk (*) are the genes 
that were already reported, by Leeman and Gilmore (Leeman et al., 2008), to undergo AS 
in the NF-kB pathway. 
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A similar approach was also performed, by crossing the events already 
described in the two mentioned reports and the ASE predicted by the remaining 
analysis (shSF2-NS vs Control-NS and shSF2-S vs Control-S), however, as 
expected showing a decreased level of intersection (Table 10). 
 
Table 10 - Intersection of the ASE predicted by the different Exon Array analysis and 
ASE already reported in similar studies. 
 
Comparison Genes in common with 
Leeman report  
(Leeman et al., 2008) 
Genes in common with 
Wells report   
(Wells et al., 2006) 
Control-S vs Control-NS 
IL1RN, IRAK1, IRAK2, 
MyD88, NFKB1, NFKB2, 
NFKBIZ, REL, RELB 
CCL5, CXCL10, IL12B, 
NFKB1, NFKB2, 
NFKBIA, RAC2, TNF 
shSF2-NS vs Control-NS NFKBIB  
shSF2-S vs Control-S IRAK1, REL, TLR4, RAC2 
 
 
 Recently, seminal work from different groups have been focused in the 
identification of the genes that could be regulated by different SFs, such as the 
ASF/SF2. In 2008, Sanford et al. identified, by Cross-Linking 
Immunoprecipitation (CLIP), 326 binding sites for SF2/ASF in RNA transcripts 
from 180 protein coding genes (Sanford et al., 2008). A more recent paper, also 
from Sanford et al., using a Cross-linking Immunoprecipitation and high-
throughput sequencing technique (CLIP-seq), allowed the identification of 
numerous binding sites for the ASF/SF2 in the transcriptome of cultured 
embryonic kidney cells (Sanford et al., 2009). Therefore, due to the available 
CLIP-seq data for ASF/SF2, we decided to perform a bioinformatic approach to 
check which of the ASE that were found to occur by the Exon array analysis, 
would be present in those set of genes already published by Sanford. et al. 
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(Sanford et al., 2009), listed in Tables 11 and S18. Several of the genes identified 
by the ASF/SF2 CLIP-seq assay, were predicted by the Exon array analysis to have 
altered Splicing events once targeting this SF by RNAi. We are at the moment 
choosing the most interesting candidates to play a putative role in the regulation of 
the IL-1! secretion for further studies.  
 
Table 11 – List of the common genes identified in the ASF/SF2 CLIP-seq analysis 
(Sanford et al., 2009) and the ASE observed in the shSF2-NS vs Control-NS analysis. 
 
 
Common ASE of shSF2-S vs Control-S analysis and ASF/SF2 CLIP-seq  
(Sanford et al., 2009) 
ABCE1 HDLBP PHPT1 SLC6A8 
ACADVL HGS PI4KB SMPD4 
ADCK4 HMGA1 PNPO SOLH 
ADNP HNRNPD POLR1D SPATA5L1 
AHSA1 KIAA0515 POMP SRP9 
APLP2 KIAA1191 PPIE SRRM2 
ARHGAP17 LEPRE1 PPIH STAU1 
ARL17 MYL6 RAB5C STK40 
C7orf27 NDUFB8 RAD54L TAP2 
CDC2L5 NMT1 RBM3 TMEM109 
CDC42SE1 NOMO2 RPL28 TRIM37 
CHAF1A OS9 RPL35 UBAP2L 
COX11 PBX4 RPN2 UCHL1 
FAM128B PCBP2 RPS21 YWHAB 
GEMIN7 PEA15 RRP1 ZNF202 
H2AFX PFKP RRP12  
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Chapter 4 - Discussion  
!
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!
“Professionals know that they have to produce theory after theory 
before they are likely to hit the jackpot.” 
 
Francis Crick 
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The Inflammation process is thought to have been first reported by Celsus, 
in the first century A.D., with the description of the four signs of Inflammation 
(reviewed in Rocha e Silva, 1978; Rocha e Silva, 1994; Medzhitov, 2010). Along 
the years, several other descriptions have been made, however, perhaps the biggest 
advances in the knowledge of this Immune Response, started to arise in the 
nineteenth century by Virchow, Cohnheim, Weigert, Metchnikoff, among others 
(Virchow, 1871; Cohnhein, 1873; Weigert, 1889; Metchnikoff, 1892; Rocha e Silva, 
1978) 
 
“He (Metchnikoff) put forward the principle that Inflammation was a reaction of 
mesodermal cells against an external agent and that Inflammation was a curative 
reaction.” (Turk, 1991)  
 
Since then, several important discoveries have outlined the importance of a tight 
regulation of Inflammation in the outcome of a microbial infection and several 
other inflammatory conditions where the microbe presence is not mandatory 
(reviewed in Medzhitov, 2008). Along the past years, several new “highways” of 
research have been “opened”, namely after the discovery of the release of pro-
inflammatory mediators by immune cells (such as cytokines, Menkin, 1944), the 
concept of Immune PRRs by Janeway’s (Janeway, 1989) and more recently with 
the discovery of the Inflammasome (Martinon et al., 2002).  
  
 The IL-1! was one of the first cytokines to be identified and represents one 
of the most important mediators of Inflammation and host responses to infection 
(reviewed in  Dinarello, 2004). The strong connection between misregulation of 
IL-1! release and the appearance of inflammatory diseases, made this cytokine one 
of the “hotspots” of intensive research (reviewed in O'Neill, 2008). A large number 
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of diseases have been reported to be caused by a misregulation of this 
inflammatory response, for example, several mutations in key-components of this 
response have been linked to the appearance of such diseases, such as the case of 
Familial Cold Autoinflammatory Syndrome or the Muckle-Wells Syndrome that 
are linked with mutations in NALP3 (Ogura et al., 2001; Maeda et al., 2005; 
McGonagle et al., 2007; Church et al., 2008; Martinon et al., 2009). Nowadays, 
certain diseases are already being treated successfully using IL-1! receptor 
antagonists, such as Anankira, or other methods to decrease IL-1! concentrations, 
for example using monoclonal anti-IL-1! antibodies (Fitzgerald et al., 2005; 
Kalliolias et al., 2008; Lequerre et al., 2008; Martinon et al., 2009). However, 
despite several years of intensive research, the mechanisms involved in the 
regulation of IL-1! secretion are not fully known, therefore, still of extreme 
importance to be studied.  
 
 The discovery of the Inflammasome, and other studies focused on the 
regulation of IL-1! secretion, have been performed using the THP-1 monocytic 
cell line (Martinon et al., 2002; Sarkar et al., 2006; Burckstummer et al., 2009; 
Fernandes-Alnemri et al., 2009). In some of the studies researchers differentiated 
the monocytic cells into macrophages by different methods, such as using phorbol 
12-myristate 13-acetate (PMA, Martinon et al., 2002; Dostert et al., 2008; Vinzing 
et al., 2008). We have decided to perform our studies in non-macrophage 
differentiated THP-1 cells. The usage of PMA has been reported by DeCoursey et 
al. (DeCoursey et al., 1996) to modify the expression of several K+ ion channels in 
THP-1 cells. The already reported involvement of K+ and K+ channels in 
Inflammasome activation (Pétrilli et al., 2007) and consequently in IL-1! release 
(reviewed in Ferrari et al., 2006), strongly suggested us to use a more 
homogeneous population of undifferentiated cells to perform our high-throughput 
analysis, where little cell-to-cell changes that would occur upon the differentiation 
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step would increase the “noise” obtained in the assays. Thus, we performed pilot 
assays to verify if the non-macrophage differentiated THP-1 cell line would be a 
good model to study the inflammatory response to an E.coli challenge. After 
bacterial stimulation, as early as 1 hour post E.coli challenge, induction of IL-1! 
expression was detected in THP-1 cells. The active and secreted form of IL-1! was 
detected in THP-1 supernatants already 2 hr post-challenge and kept raising till 48 
hours after bacterial stimulus. The results obtained show that differentiation of 
THP-1 cells into a macrophage like cells is not mandatory to study IL-1! secretion 
upon E.coli challenge. 
 A number of studies report different activation requirements by monocytes 
or macrophages, such as the usage of extracellular ATP in the case of macrophages 
studies, in order to achieve maximum IL-1! secretion (Walev et al., 1995; 
Kahlenberg et al., 2004; Pelegrin et al., 2006; Duncan et al., 2007; Netea et al., 
2008). Exogenously added ATP is thought to induce stronger IL-1! secretion by 
decreasing intracellular potassium levels, in a P2X7 receptor dependant manner 
(Perregaux et al., 1994; Ferrari et al., 1997; Pétrilli et al., 2007; Solle et al., 
2001). As mentioned previously, we used THP-1 cells in a monocytic cell state, 
therefore we decided to test the necessity of adding extracellular ATP and the role 
of the P2X7 receptor in our assays. We observed that exogenously added ATP 
induced higher IL-1! secretion, although not statistically significant. 
Consequently, we decided not to use exogenously added ATP in our assays. In 
opposition, cells that were treated with a known P2X7 inhibitor, KN-62 (Baraldi et 
al. 2003; Friedle et al., 2010), showed a remarkably decrease in IL-1! secretion, 
hence showing the importance of this receptor in the release of this cytokine by 
THP-1 cells. So far, the only known P2X7 receptor agonist is ATP, therefore we 
hypothesize that THP-1 cells do need ATP for complete IL-1! release, still, 
exogenously ATP addition is not required for its release upon E.coli challenge. 
These results are in agreement with a previous study by Piccini et al. 
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demonstrating that ATP can be released by monocytes upon different PAMPs 
stimulation, therefore inducing IL-1! secretion in an autocrine manner (Piccini et 
al., 2008; Orellano et al., 2009).  
 
 As mentioned in Chapter 1, processing of pro-IL-1! into its mature and 
active form is necessary to its secretion (reviewed in Martinon et al., 2009). 
Numerous reports show that the processing step can be mediated by different 
proteases (reviewed in Netea et al., 2010). However, it is generally accepted that it 
is mainly Caspase-1 processing dependant (reviewed in Lamkanfi et al., 2009; 
Martinon et al., 2009; Netea et al., 2010). We performed a number of assays to 
confirm the Caspase-1 dependency of IL-1! secretion after challenging THP-1 
cells with E.coli. Interleukin-1! secretion is diminished either by decreasing the 
expression of Caspase-1 by RNAi or by blocking its activation with known 
inhibitors, confirming the necessity of Caspase-1 processing of IL-1! in order to be 
released. In addition, the expression of Caspase-1 and its activity after E.coli 
challenge was also evaluated. Both, expression and activity were increased after 
the bacterial challenge. The sum of these results confirm that after an E.coli 
challenge, THP-1 cells secrete IL-1! in a Caspase-1 processing dependant manner, 
as already described previously by other studies (reviewed in  Lamkanfi et al., 
2009; Martinon et al., 2009; Netea et al., 2010). 
 Caspase-1, as IL-1!, is synthesized in an inactive form that needs further 
processing in order to be active. This processing step is mediated by the 
Inflammasome complex (Martinon et al., 2002). Since the discovery of the NALP1 
Inflammasome (Martinon et al., 2002), several years of intensive research unveil 
the existence of other Inflammasome complexes, such as the NALP3, IPAF and 
more recently the AIM2 Inflammasomes (reviewed in !Martinon et al., 2009; Stutz 
et al., 2009; Latz, 2010; Schroder et al., 2010a). The different Inflammasomes 
were shown to assemble in response to several stimuli, such as PAMPS or 
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DAMPs, leading to the activation of Caspase-1. In an attempt to identify the most 
important Inflammasome involved in IL-1! secretion upon E.coli challenge, we 
performed an RNAi-based screen targeting all NLRs described so far and CARD-
containing proteins. Knocking-down NALP3 and ASC showed the highest impact 
in IL-1! secretion after 24 hr E.coli challenge. Since these two proteins are the 
“key-components” of the NALP3 Inflammasome, in addition to Caspase-1 
(reviewed in Ogura et al., 2006; Martinon et al., 2009), we concluded that the 
NALP3 Inflammasome is the major Inflammasome involved in IL-1! secretion 
upon E.coli challenge of THP-1 cells. A similar approach was also successfully 
performed in another study by our group, in collaboration with the group of Prof. 
Elsa Anes at the “Faculdade de Farmácia da Universidade de Lisboa”, where we 
identified the components of the Mycobacterium tuberculosis (M.tb) that lead to 
higher Caspase-1 activation and IL-1! secretion, upon infection of THP-1 cells. In 
that study, we have also identified the NALP3 Inflammasome as the major 
Inflammasome activated during an M.tb infection (Mishra et al., 2010). The 
NALP3 Inflammasome is the most studied Inflammasome, as can be clearly seen 
by the high number of PAMPS and DAMPS already identified to be involved in its 
activation. Several mechanisms of NALP3 Inflammasome activation and 
regulation have been proposed, however, no unifying theory is yet known and 
accepted (reviewed in Schroder et al., 2010b; Tschopp et al., 2010). The 
appearance of certain disease states have been linked with Inflammasome 
disregulation (reviewed in Martinon et al., 2009). As an example, mutations in 
NALP3 are associated with the appearance of the Hereditary Periodic Fevers, such 
as Muckle-Wells Syndrome or Familial Cold Autoinflammatory Syndrome 
(Hoffman et al., 2001; Stutz et al., 2009). Mutations in other Inflammasomes and 
molecules involved in the IL-1! secretion pathway have also been described to be 
involved in disease generation (reviewed in McGonagle et al., 2007; Church et al., 
2008; Martinon et al., 2009; Stutz et al., 2009). Consequently, it urges the 
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identification of the underlying mechanisms and regulatory elements involved in 
the regulation of IL-1! secretion.  
 
 A large number of immune relevant genes, either in the Adaptative or Innate 
Immune Systems, have been shown to be regulated by AS (reviewed in  Lynch, 
2004; Litman et al., 2007; Mourich et al., 2009). Several studies have already 
reported the Splicing of some genes in the NF-kB pathway, such as MyD88 
(Janssens et al., 2002), IRAK1 (Jensen et al., 2001), TAB1 (Ge et al., 2003), 
among others (reviewed in  Leeman et al., 2008; Sahoo et al., 2010), therefore 
regulating this pathway, IL-1! secretion and an inflammatory response in general. 
Taken this into account, we decided to study the impact of AS in the regulation of 
Inflammation. In particular, we focused in the identification of Splicing related 
genes (SF) that play a role in the secretion of IL-1!, after an E.coli challenge. To 
approach that question, we performed an RNAi-based screen targeting 425 SF. 
After screening validation, 19 genes were considered candidates to play a role in 
the regulation of IL-1! secretion after 24 hr E.coli challenge, 12 as positive 
regulator and 7 as negative regulator candidates. Among the candidate genes, two 
of the most studied SR proteins were identified, SFRS1 and SFRS3 (reviewed in  
Long et al., 2009). SFRS1, which encodes ASF/SF2 protein, was indeed the first 
SF to be identified by Krainer et al. (Krainer et al., 1990a) and has been shown to 
play a role in different cellular processes besides Splicing, such as RNA 
transcription and protein translation (reviewed in Sanford et al., 2008; Zhong et al., 
2009). In the past years, ASF/SF2 and SRp20 (protein encoded by SFRS3) have 
been implicated in several diseases such as cancer (Stickeler et al., 1999; Fischer et 
al., 2004; Karni et al., 2007), AIDS (Asang et al., 2008) and more recently SFRS1 
has been implicated in Inflammation (Xiong, 2006). Therefore, we decided to focus 
our work in trying to address the role of ASF/SF2 and SRp20 in the regulation of 
IL-1! secretion.  
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 In order to validate the results obtained by the RNAi based screening, we 
have decided to overexpress these two SFs and check the impact in IL-1! 
secretion. Overexpressing both SFRS1 and SFRS3 lead to decreased IL-1! 
secretion after 24 hr E.coli challenge, in opposition to what was verified upon 
knockdown of these two SF. In addition, we also cloned and overexpressed IL-1! 
and IL-18 (Figures S1 and S2), in an attempt to rule out indirect effects in IL-1! 
secretion governed by increased cytosolic total protein concentration. Interleukin-
18 have also been shown to be processed by the Inflammasome, in order to be 
secreted (Gracie, 2003; Martinon et al., 2009) . Moreover, unpublished results by 
our group show that THP-1 cells do not highly express IL-18 even after an E.coli 
challenge, thus, overexpressing IL-18 in THP-1 cells can be used to perform other 
experiments in the future, regarding Inflammasome activation. Overexpressing IL-
1!, lead to increased secretion of this cytokine, whereas IL-18 overexpression did 
not show any impact in IL-1! secretion (Figure S3). Accordingly, these results 
confirmed the previous data obtained by the RNAi based screen, showing the 
negative role of these two SFs in the regulation of IL-1! secretion. 
 The increased correlation between Splicing defects and disease focused the 
attention of pharmaceutical companies and researchers to the identification of 
drugs that would modulate certain cellular responses by targeting some key 
Splicing components, such as the case of these two SFs. A study performed by 
Stoilov et al. has identified Digoxin as a modulator of SRp20 dependent Splicing, 
by decreasing its protein levels (Stoilov et al., 2008). Other study, performed by 
Keriel et al. has identified several drugs capable of inhibiting ASF/SF2 dependant 
Splicing of retroviral proteins (Keriel et al., 2009). We have then decided to use 
these drugs to confirm the role of these two SFs in the outcome of an inflammatory 
response elicited by E.coli challenge. Targeting ASF/SF2 by either BO-3 or BO-26 
drugs (kindly provided by Dr. Jamal Tazi), elicited a higher IL-1! secretion after 
24 hr E.coli challenge, when compared to control treated cells. Similar results were 
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obtained upon decreasing SRp20 expression using Digoxin. The results obtained 
with these assays further complement and confirm the results obtained in the 
screen and overexpression experiments, as unveiling a role of SFRS1 and SFRS3 
as negative regulators of IL-1! secretion. Moreover, the notion of modulating IL-
1! secretion and an inflammatory response using drugs targeting specific SFs can 
be of extreme importance in the future. An increasing number of researchers are 
now focused in the identification of compounds capable of modulating the activity 
of certain SF, and some already proved to be successful in certain disease 
conditions (Keriel et al., 2009). Perhaps, in the future, similar set of studies can be 
performed targeting the identified SFs to control severe inflammatory diseases. 
 
 Interleukin-1! secretion is normally defined as a “two-step” mechanism that 
requires the Production, mainly NF-kB dependant, and the Processing by the 
Inflammasome (reviewed in Creagh et al., 2006; Lee et al., 2007; Dinarello, 2009; 
Martinon et al., 2009). In order to evaluate the role of the two SFs candidates 
ASF/SF2 and SRp20 in the two-steps necessary for IL-1! secretion, several 
experiments were performed. In addition to IL-1!, we decided to evaluate the 
production of IL-8 by THP-1 cells after an E.coli challenge. Interleukin-8 is also an 
important pro-inflammatory mediator (reviewed in Miller et al., 1992; Feghali et 
al., 1997). Upon stimulation, IL-8, as IL-1!, is mainly produced in an NF-kB 
dependant manner, however, in opposition to IL-1!, it is produced in its active 
form where no further processing steps are required in order to be secreted 
(Standiford et al., 1990; reviewed in Remick, 2005). The production of the two 
inflammatory cytokines, IL-1! and IL-8, was previously shown to be induced upon 
E.coli stimuli. Therefore, to evaluate if the increased IL-1! secretion upon SFRS1 
or SFRS3 knockdown was due to increased cytokine expression, we have 
measured IL-1! and IL-8 mRNA expression upon targeting the two SF by RNAi. 
Increased mRNA expression of both inflammatory cytokines was detected upon 
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SFRS1 or SFRS3 knockdown, when compared to control cells. Moreover, the 
expression levels of both cytokines, IL-1! and IL-8, were highly increased in cells 
targeted for SFRS3, when compared to SFRS1 knockdown, correlating with the 
even higher cytokine secretion levels observed in SFRS3 knockdown cells (Figures 
S4a and S4b). The results clearly showed that both ASF/SF2 and SRp20 are 
negative regulators of IL-1! production. As mentioned above, the second step 
necessary for IL-1! secretion is the processing by the Inflammasome, in a 
Caspase-1 dependant manner. Caspase-1 activation was previously shown to be 
induced upon E.coli challenge, as measured by FACS. Taking advantage of this 
assay, we determined the impact of SFRS1 and SFRS3 knockdown in Caspase-1 
activity, as an indirect measurement of Inflammasome activation. Knocking-down 
SFRS1 did not show any impact in Caspase-1 activation. In opposition, a 
remarkable increase in Caspase-1 activation was observed upon SFRS3 
knockdown, as compared to control cells. With these results we could conclude 
that SRp20 acts as a negative regulator of both IL-1! production and processing, 
whereas ASF/SF2 is a negative regulator of IL-1! production. 
 The increased Caspase-1 activation observed upon SFRS3 downregulation, 
suggested that it could be a result of increased expression of the NALP3 
Inflammasome components, as observed for IL-1! and IL-8. Consequently, we 
evaluated the expression of the NALP3 Inflammasome components (NALP3, ASC 
and Caspase-1). Increased Caspase-1 mRNA expression was observed in cells 
targeted for SFRS3 knockdown, as compared with SFRS1 knockdown or control 
cells. The expression of the other two Inflammasome components, ASC and 
NALP3, was not altered significantly. The results obtained suggest that the 
increased Caspase-1 activity observed in SFRS3 knocked-down cells might be due 
to increased Caspase-1 expression, although further experiments are still needed to 
be performed to confirm this hypothesis.  
 The finding of SRp20 as a modulator of Caspase-1 expression and activity is 
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of great relevance. With the exception of the cytokine substrates (IL-1!, IL-18 and 
IL-33) little was known, until recently, about the spectrum of cellular proteins 
targeted by this protease. Several studies have attempted to identify the possible 
substrates of this protease, and the cellular processes regulated. One such study 
was conducted by Shao et al.  (Shao et al., 2007) where 41 proteins were identified 
to be directly cleaved by Caspase-1. Among the proteins identified, several 
involved in glycolisis were confirmed as Caspase-1 substrates, therefore 
implicating Caspase-1 in the regulation of the glycolytic pathway. In addition, 
several other substrates such as chaperones, cytoskeletal proteins, transcription 
factors and Caspase-7 were more recently identified as Caspase-1 substrates 
(Lamkanfi et al., 2008). Moreover, in vivo experiments have proven that Caspase-7 
processing was Caspase-1 dependant in conditions known to induce Caspase-1 
activation, such as after stimulation with LPS and ATP, and abolished in the 
absence of Caspase-1 (Lamkanfi et al., 2008). Together with Caspase-3 and 6, 
Caspase-7 belongs to the group of executioner Caspases, for a long time identified 
to be involved in apoptosis (Lamkanfi et al., 2002). Thus, Caspase-1 controlling 
Caspase-7 activity, can also control apoptosis in certain cellular conditions 
(reviewed in Lamkanfi et al., 2010). The involvement of Caspase-1 in certain 
diseases has also been shown, such as Neurodegenerative and Inflammatory 
diseases (reviewed in Howley et al., 2008). If in some disease states, the main 
problematic agent is the increased levels of cytokines released, such as IL-1!, and 
the treatment of the patients with anti-IL-1! or other methods to decrease circulant 
levels of this cytokine proves to be quite successful (Burger et al., 2006; Alten et 
al., 2008), others exist where it might not be thriving, as the case of septic shock. 
Recently, increased resistance to septic shock was observed in mice lacking 
Caspase-1 expression, and not in IL-1!/IL-18 double knockout mice (Li et al., 
1995; Sarkar et al., 2006). In conclusion, the described roles of Caspase-1 in 
different cellular functions and diseases, unquestionably shows the importance of 
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the regulation of this cellular protease. Therefore, the implication of the Splicing 
factor, SRp20, in the regulation of its activity and expression results in a valuable 
knowledge that can be used to unveil the mechanisms of Caspase-1 regulation and 
to the discovery of possible targets for therapeutical studies. 
 
 The major Inflammasome involved in IL-1! secretion after E.coli challenge 
was shown to be the NALP3 Inflammasome. However, we could not discard the 
hypothesis that the increased Caspase-1 activation observed upon knocking-down 
the expression of SFRS3, was due to the activation of different Inflammasomes. 
The three main Inflammasomes described so far are the NALP3, NALP1 and IPAF 
Inflammasomes (reviewed in !Martinon et al., 2009; Stutz et al., 2009; Latz, 2010), 
therefore we decided to determine the role of each one of these Inflammasomes in 
IL-1! secretion upon SFRS3 knockdown. Performing a series of double 
knockdown experiments targeting SFRS3 and at the same time NALP3, NALP1, 
IPAF or the common Inflammasome adapter ASC, we could conclude that the 
effect observed by knocking-down SFRS3 is not due to the activation of the IPAF 
Inflammasome, since no differences on IL-1! secretion were observed upon 
SFRS3/IPAF double knockdown. In what concerns the other two Inflammasomes, 
we observed that performing the double knockdown of NALP1 or NALP3 in 
addition to SFRS3, a partial reversion of the phenotype was observed; however not 
as significant as the reversion observed when knocking-down the common adaptor 
ASC. These results suggested that the increased Caspase-1 activation observed 
upon SFRS3 knockdown might be also due to different Inflammasomes activation 
(NALP1 and NALP3, but not IPAF), in addition to the increased Caspase-1 
expression described before. Further experiments are now required to evaluate this 
hypothesis. 
 A number of studies reported that the activation of the IPAF Inflammasome 
might also occur independently of the ASC adaptor (Franchi et al., 2007; 
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Mariathasan et al., 2007; Case et al., 2009); therefore we hypothesized that 
somehow by knocking-down SFRS3 we could be altering the activation or 
expression profiles of ASC. As mentioned before, no differences at mRNA 
expression levels of ASC were observed upon knocking-down SFRS3 and 
posterior E.coli challenge. Although, several Splicing variants of ASC have been 
predicted to exist (http://www.imm.fm.ul.pt/exonmine), therefore the effect could 
be due to changes in the Splicing pattern of ASC. In addition to the bioinformatics 
predictions, Matsushita et al. reported recently the existence of a splice variant of 
ASC that can regulate IL-1! (Matsushita et al., 2009a). We have performed RT-
PCR experiments in cells targeted for SFRS3 knockdown and challenged with 
E.coli for different time points, and no differences in the Splicing pattern of ASC 
were observed in comparison with control (data not shown), thus excluding this 
hypothesis. 
   
 As mentioned previously, the SR family of Splicing factors has been shown 
to play a role in different cellular processes. A recent report by Xiong et al. (Xiong 
et al., 2006) clearly shows that ASF/SF2 is downregulated in inflamed muscle. 
Moreover, it was shown that this downregulation could be induced in the presence 
of pro-inflammatory stimuli, such as TNF-! (Xiong et al., 2006; Balkwill, 2009). 
Consequently, we decided to check the expression of SFRS1 and SFRS3 upon 
E.coli challenge. In agreement to Xiong’s report, SFRS1 expression was 
downregulated upon E.coli challenge. In opposition, SFRS3 expression did not 
change significantly at the mRNA level, but was decreased at protein level upon 
E.coli challenge. In addition, we evaluated the expression of the two SF candidates 
upon M.tb infection. As reported previously, we have identified NALP3 as the 
major Inflammasome activated upon M.tb infection of THP-1 cells (Mishra et al., 
2010). As can be seen in Figure S5, after M.tb infection of THP-1 cells, decreased 
mRNA expression of both SF candidates is observed, in opposition with the 
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increased IL-1! expression and secretion, further substantiating the observations 
obtained after E.coli challenge. In future studies, similar approaches can be 
expanded to primary cells obtained from volunteer donors. In addition, differences 
in expression of these two SFs can also be evaluated in cells obtained from patients 
with several inflammatory diseases, such as Crohn’s Disease, Rheumatoid Arthritis 
or Gout, in order to evaluate if differences at the expression levels of these two SF 
can be linked with Disease. 
 We decided to go further on studying the downregulation mechanism of our 
two main candidates, ASF/SF2 and SRp20. Preliminary results obtained in 
collaboration with Margarida Carvalho and Ana Neves Costa, suggested that this 
downregulation can be hnRNPK dependent. Heterogeneous nuclear 
ribonucleoprotein K (hnRNP K) belongs to the hnRNP family of proteins, which 
directly interact with DNA and RNA through their K homology (KH) domains and 
regulate gene expression at multiple levels including transcription, RNA Splicing, 
RNA stability and translation (reviewed in  Bomsztyk et al., 2004). Preliminary 
results obtained by Bruno d’Almeida (UBCSI, IMM, unpublished data) show that 
the SFRS1 mRNA is unstable (unpublished data). Moreover, d’Almeida’s work 
also shows that SFRS1 downregulation is ERK1/2 dependent, either by using 
inhibitors or by performing ERK1/2 knockdown (unpublished data). It is already 
known that activation of ERK1/2 results in cytoplasmic accumulation of hnRNPK 
(Habelhah et al., 2001). In addition, increased cytoplasmic expression of hnRNPK 
has been reported to be able to repress translation of several proteins (Habelhah et 
al., 2001). All these data, prompted us to look to a possible regulation of SFRS1 
and SFRS3 by hnRNPK. As shown in Figure S6, IL-1! secretion is decreased upon 
hnRNPK knockdown. Moreover, SFRS1 expression after E.coli challenge seems to 
be less downregulated in cells knocked-down for hnRNPK. RNA-IP experiments 
are being performed in order to understand if hnRNPK can bind SFRS1 RNA and 
therefore control its expression. The role of hnRNPK in regulating SRp20 
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expression is also under evaluation.  
 In addition to hnRNPK, Sam68, other RNA binding protein, is also a 
promising candidate to be playing a role in the regulation of SFRS1 and SFRS3 
after E.coli challenge. This RNA-binding protein belongs to the signal transduction 
and activation of RNA metabolism family characterized by having a KH domain, 
similar to hnRNPK (Vernet et al., 1997; Lukong et al., 2003). It has been 
implicated in the regulation of cell cycle and apoptosis, and its subcellular 
localization and RNA affinity were shown to be regulated by post-translational 
modifications, such as phosphorylation and methylation (Paronetto et al., 2003; 
Taylor et al., 2004; Babic et al., 2006; Paronetto et al., 2007). Moreover, like 
hnRNPK, ERK1/2 phosphorylation was shown to be able to modulate Sam68 
activity (Paronetto et al., 2007). Unpublished data from Dr.Giuseppe Biamonti 
(IMG, Pavia, Italy) shows that Sam68 can modulate ASF/SF2 expression, and it is 
dependant on ERK1/2 phosphorylation of Sam68, as shown using Sam68 
inhibitors. In addition, Sam68 was demonstrated to counteract ASF/SF2 dependant 
Splicing of certain genes, such as Bcl-x (Paronetto et al., 2007). All these 
information thus seem to suggest that Sam68 can also play a role in IL-1! secretion 
by counteracting ASF/SF2 effects, although several experiments need to be 
performed in order to prove this hypothesis.  
 As referred earlier, the decreased expression of the Splicing factor SRp20 is 
only observed at the protein level, therefore several hypothesis can be tested in an 
attempt to identify the underlying mechanism. One of such hypothesis is the 
possible regulation of SRp20 expression by microRNAs (miRNAs). MicroRNAs 
are small noncoding RNAs, around 22 nucleotides, which regulate protein-coding 
genes via posttranscriptional repression (reviewed in Taganov et al., 2007b; 
Baltimore et al., 2008). Since the discovery of the first miRNA, lin-4 (Lee et al., 
1993; Wightman et al., 1993), more than 700 miRNAs have been shown to be 
important regulators in development, differentiation and homeostasis (reviewed in  
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Stefani et al., 2008; Williams, 2008). Increasing amount of evidence is showing 
that several Innate and Adaptative Immune responses, as well as inflammatory 
networks in various cell and tissue types are regulated by these small RNAs 
(reviewed in Taganov et al., 2007b Baltimore et al., 2008; Sheedy et al., 2008; Bi 
et al., 2009). A recent report by Taganov et al., has shown that LPS stimulation of 
THP-1 cells significantly induces the expression of miR-146, miR-132 and miR-
155, from a panel of 200 miRNA tested (Taganov, 2006). Furthermore, promoter 
analysis of the miR-146 unveiled that it is regulated by the NF-kB transcription 
factor and may function as a negative regulator of IRAK-1 and TRAF6 expression, 
therefore regulating an inflammatory response (Taganov, 2006). Another report by 
Perry et al., has shown that miR-146 expression was related to IL-1! induced 
responses (Perry et al., 2008). All these information lead us to investigate the role 
of miRNA in Inflammation, and more precisely the possible role in the regulation 
of SRp20 expression upon E.coli challenge.  The expression of several SFs has 
also been shown to be regulated by miRNA expression, as the case of the 
polypyrimidine tract-binding protein (Boutz et al., 2007). Preliminary results from 
our lab show that knocking-down the expression of DICER, a component of the 
microRNA pathway (reviewed in Taganov et al., 2007a), results in remarkably 
decreased IL-1! secretion after 24 hr E.coli challenge; as expected, due to the 
increase number of genes in this pathway that are regulated by miRNA. The 
expression of SRp20 was not yet assessed in these conditions, but it will be in the 
near future to try to disclose if SRp20 expression is being regulated by miRNAs 
induced upon an inflammatory stimulus. 
 The expression profile of the other putative Negative Regulator SF 
candidates was also determined in the outcome of an inflammatory response to 
E.coli challenge.  The expression profile of TET1 is similar to the profile observed 
for SFRS1, it is clearly downregulated at mRNA level upon E.coli challenge 
(Figure S7-e). Therefore, this gene is now also under study for its role in IL-1! 
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secretion upon E.coli challenge, by another colleague in the laboratory, Ana Neves 
Costa (UBCSI, IMM). In what concerns the other candidates, GNB2L1 expression 
is also downregulated in a similar pattern although not as significantly as TET1 or 
SFRS1 (Figure S7-a). SFPQ expression is induced at mRNA level (Figure S7-d). 
MFAP1 and PPIE show a similar kinetics of expression upon E.coli challenge: 
they are both downregulated at 4 hours and then recover their steady-state 
expression levels around 24 hr post-challenge (Figure S7-b and c). These results 
thus suggest that in the outcome of an inflammatory response, the expression of 
these Negative Regulators can be modulated in order to achieve maximum IL-1! 
secretion.  
 
 As Leeman, Lynch, Wells and others have already reported (reviewed in 
Lynch, 2004; Wells et al., 2006; Leeman et al., 2008) the extent of genes found to 
play a role in the immune responses that are regulated by AS has been increasing 
over the past years. Therefore, in an attempt to identify possible ASE that occur 
upon an E.coli challenge and SFRS1 or SFRS3 knockdown, PCR analysis was 
performed for the genes already described to play a role in IL-1! secretion. The 
ASE predictions were based on Splicing patterns described for each gene in the 
Exonmine online Database. Since the results obtained were not conclusive, we 
performed a high throughput analysis of the Splicing events using the Affymetrix® 
GeneChip® Human Exon 1.0 ST Arrays platform. This platform has been 
extensively used to detect Splicing events that occur in different biological 
processes and diseases such as Cancer (Gardina et al., 2006; French et al., 2007; 
Cheung et al., 2008); identification of tissue specific isoforms of certain genes 
(Clark et al., 2007; Das et al., 2007); identification of certain SF dependant ASE 
(Hung et al., 2008; Oberdoerffer et al., 2008). We performed a number of analysis 
addressing different questions, namely the identification of ASE that occurs upon 
E.coli challenge and moreover the ASE that are dependent on the ASF/SF2 
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expression. After data analysis and validation we have identified numerous genes 
that undergo AS after an E.coli challenge (listed on Tables S12 and S15), ASF/SF2 
knockdown (Tables S13 and S16) or upon ASF/SF2 knockdown and posterior 
E.coli challenge (Tables S14 and S17). Several genes that were previous reported 
to undergo AS that play a role in the NF-kB or TLR pathways (reviewed in 
Leeman et al., 2008) were found in our analysis, therefore validating our approach. 
Some of the genes in these pathways were found to have different Splicing patterns 
upon ASF/SF2 downregulation by RNAi and therefore constitute good candidates 
to further test their ASF/SF2 Splicing dependency and role in IL-1! secretion. In 
addition to the known candidates, several other candidates not previously described 
in the literature can be subject to further studies to identify their possible 
involvement in the regulation of IL-1! secretion in a Splicing dependent manner. 
 Focusing on the genes whose Splicing as found to be ASF/SF2 dependant, 
by crossing the data obtained in the array with the data generated by the ASF/SF2 
CLIP-Seq analysis performed by Sanford et al. (Sanford et al., 2009), we have 
found common ASE. Several bioinformatic approaches, such as ESEFinder 
(http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home), Splicing 
Rainbow (http://www.ebi.ac.uk/asd-srv/wb.cgi?method=8) or Rescue-Ese 
(http://genes.mit.edu/burgelab/rescue-ese/) have tried to predict the genes and the 
binding sites that the majority of the Splicing factors could bind and therefore 
regulate their Splicing profiles (reviewed in Long et al., 2009). Although these 
bioinformatic approaches have generated valuable information, the majority of the 
predictions and physical interactions could not be proven to exist. This problem is 
overcomed in the CLIP-Seq analysis since it relies on the identification of RNA 
sequences that are physically bound to a specific protein. Being cautious that 
different conditions exist in our experiments and the Sanford’s study, namely a 
different cell type (HEK293 vs. THP-1), the results are undoubtly encouraging, 
since they prove that ASF/SF2 binds to the RNA of several candidate genes 
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obtained by the Exon array analysis, therefore capable of regulating their Splicing 
pattern, likewise their cellular functions. Nevertheless, this is still the “tip of the 
Iceberg” and several experiments are required to determine which Splicing events 
that are dependant on ASF/SF2 do play a role in the increased IL-1! secretion 
phenotype found upon the knockdown of this SF. 
 In an attempt to identify the Splicing events related to the other SR protein, 
SRp20, a similar high throughput analysis can be done in the future. Perhaps, in 
spite of performing an Exon-array analysis, it would be of greater interest to 
perform Deep-sequencing analysis. Deep-sequencing analysis is now accepted as 
the best method to detect ASE (reviewed in Pan et al., 2008; Sultan et al., 2008; 
Wang et al., 2009)), thus, this could be performed in similar conditions to what 
was performed to ASF/SF2. Analogous set of validation would be performed and 
the most promising candidates studied in more detail for their role in the regulation 
of IL-1! secretion in an SRp20 dependant manner. 
 
 In addition to the ASE predicted by the Exon array analysis, the differences 
at gene expression level (DEG) could also be evaluated. Several genes were found 
to be differently expressed in the different analysis performed. This platform 
proved to be a very good experimental system to detect DEG, since the rates of 
validation were almost 97%. Our results are in agreement with other published 
studies that have used the Human Exon 1.0 ST Arrays platform to detect DEG in 
different conditions (Huang et al., 2007; Chahrour et al., 2008; Chiao et al., 2008; 
Duan et al., 2008; Ge et al., 2008). A preliminary Bioinformatic analysis was 
performed, using the Ingenuity® Pathway analysis software, and we could observe 
that several genes involved in the regulation of an inflammatory response are 
differentially expressed, as well as different inflammatory responses and pathways 
activated. In agreement to what was reported previously, IL-1! and IL-8 
expression is induced after E.coli challenge, whereas SFRS1 expression is 
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downregulated upon this bacterial challenge. Once more, however these results 
were expected, this is in agreement to our previous results, therefore validating our 
overall approach. In the future, the most promising candidates that are 
differentially expressed in the shSF2-S vs. Control-S analysis will be studied for 
their possible role in the regulation of IL-1! secretion. 
  
 Besides ASF/SF2 and SRp20, several other candidates have been reported to 
be linked with inflammatory processes. Among the positive regulator candidates, 
High-mobility group box-1 (HMGB1) has been reported to be an endogenous 
danger signal molecule (DAMP, reviewed in Erlandsson Harris et al., 2004). A 
recent report by Mouri et al. shows that HMGB1 can act as a transactivator of IL-
1! promoter, therefore regulating IL-1! production (Mouri et al., 2007). We 
performed a qRT-PCR assay to quantify the levels of IL-1! mRNA expression 
upon HMGB1 knockdown. The downregulation of HMGB1 by RNAi lead to 
decreased IL-1! mRNA expression and protein secretion (Figure S4-c). Moreover, 
the reduction at the secretion level is only observed at 24 hours post-challenge, 
what can be justified by the fact that HMGB1 is thought to be a late mediator of 
Inflammation (reviewed in Klune et al., 2008), therefore exerting its effect in a 
later time point after E.coli challenge, and not initially. Strong associations 
between HMGB1 and inflammatory diseases have been extensively reported, such 
as in the development of Rheumatoid Arthritis and Sepsis (Wittemann et al., 1990; 
Wang et al., 1999; Klune et al., 2008). Consequently, the identification of HMGB1 
as a positive regulator of IL-1! secretion using our methodology, is a proof of 
principle of our experimental design. 
 Interestingly, among the other candidates identified in our study, single 
nucleotide polymorphisms (SNPs) in CUGBP2, SFPQ and hnRNPM have been 
shown to be associated with Rheumatoid Arthritis Disease (Consortium, 2007), 
however the mechanisms that correlate those SNPs and the disease development 
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are not known. The strong correlation between increased IL-1! levels and the 
development of this disease suggested the treatment of these patients with anti-IL-
1! antibodies, IL-1R antagonists or by other methods to decrease IL-1! levels 
(Burger et al., 2006; Alten et al., 2008). 
 The zinc finger containing protein ZC3H13 was found in the RNAi screen to 
play a positive role in IL-1! secretion. Recently, several papers have described the 
contribution of an homolog zinc finger containing protein ZC3H12a as being 
involved in the regulation of the inflammatory response (Liang et al., 2008a; Liang 
et al., 2008b; Matsushita et al., 2009). ZC3H12a, like ZC3H13, has a CCCH-type 
zinc finger motif, and belongs to the family of proteins that bind to the AU-rich 
elements in mRNA, leading to the removal of the poly(A) tail from that mRNA 
and increasing rates of mRNA turnover (Carballo et al., 1998; Lai et al., 1999; 
Carrick et al., 2004). It was shown that ZC3H12A could regulate the stability of 
different inflammatory genes, therefore controlling its expression (Liang et al., 
2008a; Liang et al., 2008b; Matsushita et al., 2009). Among the cytokines whose 
mRNA levels were shown to be regulated by this protein, is IL-1! (Liang et al., 
2008b). Therefore we could speculate that a similar mechanism can be regulated 
by ZC3H13, although it was beyond the scope of our study. 
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“The most beautiful thing we can experience is the mysterious. It is 
the source of all true art and science” 
 
Albert Einstein 
 
  
 
 
 
“Identification of Splicing Factors with a role in IL-1! secretion”              
 
 
174 
  
 
 
  
 
 
                                                                                             Chapter 5 – Concluding Remarks          
 
175 
 The results obtained in my PhD work allowed us to identify several novel 
regulators of IL-1! secretion after E.coli challenge. We have focused in two of the 
candidates, the ASF/SF2 and SRp20, the SFs encoded by the genes SFRS1 and 
SFRS3, respectively. We have demonstrated that SRp20 plays a role in both 
Production and Processing steps required for IL-1! secretion, while ASF/SF2 is 
only involved in the regulation of the first step. The underlying mechanisms are 
not yet uncovered, nevertheless, the implication of several SF in the regulation of 
IL-1! secretion is of extreme importance and for the first time described. This 
discovery is of great relevance for the understanding of the regulation of an 
inflammatory response and possibly for clinical application, as unveiling putative 
targets to modulate this response. The increased number of diseases linked to 
Splicing disregulation definitely marks the importance of this process in cell and 
organism homeostasis (reviewed in Tazi et al., 2008). Several Splicing regulators 
are now under intensive studies as targets for the control of several diseases, such 
as shown by the work of Dr. Jamal Tazi’s group (Keriel et al., 2009), where 
specific inhibitors of ASF/SF2 can have a dramatically impact in retroviral 
pathogenesis. Possibly, such type of studies can be extended to the regulation of 
these two SFs in the context of inflammatory diseases. 
 The tight regulation of Splicing regulatory factors, either at concentration, 
localization, or activity has been revealed important in the maintenance of the 
organism homeostasis. Several reports have clearly demonstrated specific 
alterations in the expression patterns of some Splicing factors related with several 
diseases, such as cancer (reviewed in Tazi et al., 2008; Cooper et al., 2009). In 
agreement to what was previously reported (Xiong, 2006), ASF/SF2 expression is 
downregulated upon an inflammatory challenge, and we have also found that it 
occurs for the other SF studied - SRp20. The exact mechanisms by which these SF 
are being regulated are now under evaluation and will provide a deeply valuable 
knowledge in the intricate regulatory networks that are involved in the regulation 
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of an inflammatory response, namely the IL-1! secretion. 
 The discovery of the involvement of SRp20 in the regulation of Caspase-1 
expression and activity is also of great novelty and relevance. In the past years, the 
number of cellular targets, processes and diseases related to this protease has been 
increasing. Therefore, unveiling SRp20 as a Caspase-1 regulator can undoubtly 
lead to new mechanisms of regulation and possibly new therapeutical targets when 
Caspase-1 activity needs to be tightly regulated, for example during the course of a 
particular disease. 
 In conclusion, though the exact mechanisms by which these two SF may 
play a role in IL-1! secretion are not yet known, our data strongly suggest that they 
are indeed playing a role, as shown by the various methods applied getting a 
consistent result, either overexpressing experiments showing an opposite 
phenotype to what observed by knocking-down or inhibiting the Splicing 
dependent on these two SFs. Several studies are now required to determine the 
exact mechanisms by which these two SFs are playing a role in IL-1! secretion. 
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“In science the credit goes to the man who convinces the world, not 
the man to whom the idea first occurs.” 
 
Sir Francis Darwin 
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7.1 - shRNA Library subset- NLR and CARD-domain 
containing proteins. 
 
Table S1 – List of NLR/CARD-domain proteins targeted to knockdown by shRNA. 
 
Gene Name NM_Id Gene Name NM_Id 
ASC NM_013258 NALP2 NM_017852 
BIRC1 NM_004536 NALP3 NM_004895 
CARD9 NM_052813 NALP4 NM_134444 
CARDINAL NM_014959 NALP5 NM_153447 
CARMA1 NM_032415 NALP7 NM_139176 
CARMA2 NM_024110 NALP8 NM_176811 
CIITA NM_000246 NALP9 NM_176820 
CINCIN1 NM_032587 NOD1 NM_006092 
IPAF NM_021209 NOD2 NM_022162 
MDA5 NM_022168 NOD27 NM_032206 
NALP1 NM_014922 NOD9 NM_024618 
NALP11 NM_145007 RIG-I NM_014314 
NALP12 NM_144687 RIPK2 NM_003821 
NALP14 NM_176822 VISA NM_020746 
 
 
7.2 - shRNA Library subset- Splicing Factors and Splicing 
related proteins (SFs) 
 
Table S2– List of SFs targeted to knockdown by shRNA. 
 
Gene Name NM_Id Gene Name NM_Id 
A2BP1 NM_145891 NOVA1 NM_006491 
ABT1 NM_013375 NOVA2 NM_002516 
ACIN1 NM_014977 NUDT21 NM_007006 
ADAR NM_001111 NUMA1 NM_006185 
AKAP8 NM_005858 NXF1 NM_006362 
AQR NM_014691 PABPC1 NM_002568 
ARS2 NM_015908 PABPC4 NM_003819 
ASCC3L1 NM_014014 PABPN1 NM_004643 
BAT1 NM_004640 PARP1 NM_001618 
BCAS2 NM_005872 PCBP1 NM_006196 
BRUNOL4 NM_020180 PCBP2 NM_005016 
BRUNOL5 NM_021938 PCBP3 NM_020528 
BRUNOL6 NM_052840 PCBP4 NM_020418 
BUB3 NM_004725 PHF5A NM_032758 
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C10orf116 NM_006829 PIAS1 NM_016166 
C13orf10 NM_022118 PLRG1 NM_002669 
C14orf166 NM_016039 PNN NM_002687 
C1orf55 NM_152608 POLDIP3 NM_032311 
C1orf60 NM_023015 POLDIP3  NM_032311 
C1QBP NM_001212 POLR2A NM_000937 
C20orf14 NM_012469 POLR2B NM_000938 
C20orf23 NM_024704 PPIE NM_006112 
C21orf66 NM_016631 PPIH NM_006347 
C21orf70 NM_058190 PPIL1 NM_016059 
C22orf19 NM_003678 PPIL2 NM_014337 
C2orf3 NM_003203 PPIL3 NM_130906 
C9orf10 NM_014612 PPM1G NM_002707 
CCDC12 NM_144716 PPWD1 NM_015342 
CCNA1 NM_003914 PRCC NM_005973 
CCNK NM_003858 PRKRA NM_003690 
CD2BP2 NM_006110 PRPF18 NM_003675 
CDC2L2 NM_024011 PRPF19 NM_014502 
CDC40 NM_015891 PRPF3 NM_004698 
CDC5L NM_001253 PRPF31 NM_015629 
CHERP NM_006387 PRPF38A NM_032284 
CIRBP NM_001280 PRPF38B NM_018061 
CLK1 NM_004071 PRPF4 NM_004697 
CLK2 NM_003993 PRPF4B NM_003913 
CLK3 NM_003992 PRPF8 NM_006445 
CLK4 NM_020666 PSEN1 NM_000021 
CPSF1 NM_013291 PSIP1 NM_021144 
CPSF2 NM_017437 PTBP1 NM_002819 
CPSF3 NM_016207 PTBP2 NM_021190 
CPSF4 NM_006693 QKI NM_006775 
CPSF6 NM_007007 RALY NM_016732 
CRK7 NM_016507 RAVER1 NM_133452 
CRNKL1 NM_016652 RBBP7 NM_002893 
CSDA NM_003651 RBM10 NM_005676 
CSN3 NM_005212 RBM12 NM_006047 
CSTF3 NM_001326 RBM15 NM_022768 
CTNNBL1 NM_030877 RBM17 NM_032905 
CUGBP1 NM_006560 RBM22 NM_018047 
CUGBP2 NM_006561 RBM25 NM_021239 
CWF19L1 NM_018294 RBM3 NM_006743 
DDB1 NM_001923 RBM5 NM_005778 
DDX1 NM_004939 RBM7 NM_016090 
DDX17 NM_006386 RBM8A NM_005105 
DDX19B NM_007242 RBM9 NM_014309 
DDX21 NM_004728 RBMS1 NM_016836 
DDX23 NM_004818 RBMX NM_002139 
DDX26 NM_012141 RBMX2 NM_016024 
DDX39 NM_005804 RBP7 NM_052960 
DDX3X NM_001356 RDBP NM_002904 
DDX41 NM_016222 REXO1 NM_020695 
DDX46 NM_014829 REXO2 NM_015523 
DDX48 NM_014740 RKHD3 NM_032246 
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DDX49 NM_019070 RNGTT NM_003800 
DDX5 NM_004396 RNPC2 NM_004902 
DDX54 NM_024072 RNPS1 NM_006711 
DDX6 NM_004397 ROD1 NM_005156 
DEK NM_003472 RP13-297E16.1 NM_005088 
DGCR14 NM_022719 RPL22 NM_000983 
DHX15 NM_001358 RPL23A NM_000984 
DHX16 NM_003587 RPL31 NM_000993 
DHX35 NM_021931 RPL5 NM_000969 
DHX38 NM_014003 RPS10 NM_001014 
DHX8 NM_004941 RPS11 NM_001015 
DHX9 NM_001357 RPS12 NM_001016 
DIDO1 NM_022105 RPS13 NM_001017 
DKFZP434K1421 NM_032141 RPS15 NM_001018 
DNAJC17 NM_018163 RPS15A NM_001019 
DNAJC6 NM_014787 RPS16 NM_001020 
DNAJC8 NM_014280 RPS17 NM_001021 
EDG2 NM_057159 RPS18 NM_022551 
EEF1A1 NM_001402 RPS19 NM_001022 
EFTUD2 NM_004247 RPS25 NM_001028 
EIF2S2 NM_003908 RPS29 NM_001032 
EIF3S10 NM_003750 RPS3 NM_001005 
EIF3S2 NM_003757 RPS3A NM_001006 
EIF3S6 NM_001568 RPS4X NM_001007 
EIF3S6IP NM_016091 RPS4Y1 NM_001008 
EIF4A2 NM_001967 RPS5 NM_001009 
ELAVL1 NM_001419 RPS7 NM_001011 
ELAVL2 NM_004432 RPS8 NM_001012 
ELAVL3 NM_001420 RPS9 NM_001013 
ELAVL4 NM_021952 RUVBL1 NM_003707 
EP400 NM_015409 RUVBL2 NM_006666 
ERCC3 NM_000122 RY1 NM_006857 
ERVWE1 NM_014590 S100A8 NM_002964 
ET NM_024311 S100A9 NM_002965 
EWSR1 NM_005243 SAFB NM_002967 
EXOSC1 NM_016046 SAFB2 NM_014649 
EXOSC10 NM_002685 SART1 NM_005146 
EXOSC2 NM_014285 SDCCAG10 NM_005869 
EXOSC3 NM_001002269 SF1 NM_004630 
EXOSC4 NM_019037 SF3A1 NM_005877 
EXOSC5 NM_020158 SF3A2 NM_007165 
EXOSC7 NM_015004 SF3A3 NM_006802 
EXOSC8 NM_181503 SF3B1 NM_012433 
EXOSC9 NM_005033 SF3B14 NM_016047 
FAM32A NM_014077 SF3B3 NM_012426 
FAU NM_001997 SF3B4 NM_005850 
FIP1L1 NM_030917 SF3B5 NM_031287 
FKBP3 NM_002013 SF4 NM_021164 
FLJ20273 NM_019027 SFPQ NM_005066 
FLJ21827 NM_020153 SFRS1 NM_006924 
FMR1 NM_002024 SFRS10 NM_004593 
FRG1 NM_004477 SFRS11 NM_004768 
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FUBP1 NM_003902 SFRS12 NM_139168 
FUS NM_004960 SFRS16 NM_007056 
FUSIP1 NM_006625 SFRS2 NM_003016 
G10 NM_003910 SFRS3 NM_003017 
GNB2L1 NM_006098 SFRS4 NM_005626 
GPATC1 NM_018025 SFRS5 NM_006925 
GRSF1 NM_002092 SFRS6 NM_006275 
GTF2I NM_001518 SFRS7 NM_006276 
GTL3 NM_013242 SFRS9 NM_003769 
HCFC1 NM_005334 SIAHBP1 NM_014281 
HDAC2 NM_001527 SKIV2L NM_006929 
HIST1H2AC NM_003512 SKIV2L2 NM_015360 
HIST1H2BC NM_003526 SLU7 NM_006425 
HIST2H2AA NM_003516 SMARCA5 NM_003601 
HMGB1 NM_002128 SMC1L1 NM_006306 
HMGB3 NM_005342 SMC2L1 NM_006444 
HNRNPG-T NM_014469 SMNDC1 NM_005871 
HNRPA0 NM_006805 SMU1 NM_018225 
HNRPA1 NM_002136 SNIP1 NM_024700 
HNRPA2B1 NM_002137 SNRP70 NM_003089 
HNRPA3 NM_194247 SNRPA NM_004596 
HNRPAB NM_004499 SNRPA1 NM_003090 
HNRPC NM_031314 SNRPB NM_198216 
HNRPCL1 NM_001013631 SNRPB2 NM_198220 
HNRPD NM_031370 SNRPC NM_003093 
HNRPDL NM_005463 SNRPD1 NM_006938 
HNRPF NM_004966 SNRPD2 NM_004597 
HNRPH1 NM_005520 SNRPD3 NM_004175 
HNRPH2 NM_019597 SNRPE NM_003094 
HNRPH3 NM_012207 SNRPF NM_003095 
HNRPK NM_002140 SNRPG NM_003096 
HNRPL NM_001533 SNRPN NM_003097 
HNRPLL NM_138394 SNW1 NM_012245 
HNRPM NM_005968 SPEN NM_015001 
HNRPR NM_005826 SPPL3 NM_139015 
HNRPU NM_031844 SR140 XM_031553 
HNRPUL1 NM_007040 SRP19 NM_003135 
HSPA1B NM_005346 SRP46 NM_032102 
HSPA5 NM_005347 SRP68 NM_014230 
HSPA8 NM_006597 SRP9 NM_003133 
HSPC117 NM_014306 SRPK1 NM_003137 
HSPC148 NM_016403 SRRM1 NM_005839 
HTATSF1 NM_014500 SRRM2 NM_016333 
HYPC NM_012272 SSB NM_003142 
IK NM_006083 STK23 NM_014370 
ILF2 NM_004515 STRBP NM_018387 
ILF3 NM_004516 SYF2 NM_015484 
IMP-1 NM_006546 SYNCRIP NM_006372 
IMP-3 NM_006547 TAF15 NM_003487 
IQGAP1 NM_003870 TAF6 NM_005641 
KHSRP NM_003685 TCERG1 NM_006706 
KIAA0773 NM_014690 TCERG1  NM_006706 
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KIAA1008 NM_014953 TDRD3 NM_030794 
KIAA1160 NM_020701 TET1 NM_030625 
KIAA1429 NM_015496 TFIP11 NM_001008697 
KIAA1542 NM_020901 THOC1 NM_005131 
KIAA1604 NM_020943 THOC3 NM_032361 
KIAA1967 NM_021174 THOC4 NM_005782 
KIN NM_012311 TIA1 NM_022173 
KPNA2 NM_002266 TIAL1 NM_003252 
LOC138046 NM_173848 TNPO1 NM_002270 
LSM1 NM_014462 TNRC4 NM_007185 
LSM10 NM_032881 TOP1MT NM_052963 
LSM11 NM_173491 TOPORS NM_005802 
LSM2 NM_021177 TPR NM_003292 
LSM3 NM_014463 TPX2 NM_012112 
LSM4 NM_012321 TRA2A NM_013293 
LSM5 NM_012322 TRNT1 NM_016000 
LSM6 NM_007080 TTF2 NM_003594 
LSM7 NM_016199 TUBA1 NM_006000 
LSM8 NM_016200 TUBB NM_178014 
LUC7L NM_018032 TXNL4A NM_006701 
MAGOH NM_002370 U2AF1 NM_006758 
MATR3 NM_018834 U2AF1L2 NM_005089 
MBD5 NM_018328 U2AF1L3 NM_144987 
MFAP1 NM_005926 U2AF2 NM_007279 
MGC13125 NM_032725 UBL5 NM_024292 
MGC14151 NM_032356 UNK NM_152302 
MGC2803 NM_024038 USP39 NM_006590 
MGC5509 NM_024093 VIM NM_003380 
MKI67IP NM_032390 WBP11 NM_016312 
MORG1 NM_032332 WDR33 NM_001006622 
MOV10 NM_020963 WDR57 NM_004814 
MSI1 NM_002442 WDR58 NM_024339 
MSI2 NM_138962 WTAP NM_004906 
MYEF2 NM_016132 XAB2 NM_020196 
NCBP1 NM_002486 XRCC6 NM_001469 
NCBP2 NM_007362 XRN2 NM_012255 
NCL NM_005381 YBX1 NM_004559 
NDUFA1 NM_004541 ZC3H13 NM_015070 
NHN1 NM_144604 ZCCHC8 NM_017612 
NHP2L1 NM_001003796 ZFP36L1 NM_004926 
NIF3L1BP1 NM_025075 ZFR NM_016107 
NONO NM_007363 ZMAT2 NM_144723 
NOSIP NM_015953 ZNF207 NM_003457 
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7.3 - Antibodies used to perform Western-blot and their 
respective experimental conditions 
 
Table S3– List of Antibodies used to perform WB, dilutions and incubation times. 
 
Antibody Company Diluition Incubation Time       Temperature 
ASC Abnova ! 1/1000 O/N 4°C 
ASF/SF2 Abcam ! 1/200 O/N 4°C 
"-ACTIN Abcam ! 1/24000 1 hr RT 
CASP1 Abcam ! 1/1000 O/N 4°C 
HMGB1 Abcam ! 1/1000 1 hr RT 
IL-1! R&D ! 1/1000 O/N 4°C 
NALP3 Abcam ! 1/1000 O/N 4°C 
SRp20 Abnova ! 1/1000 O/N 4°C 
V5 Abcam ! 1/1000 1 hr RT 
#-Mouse Cell Signaling ! 1/5000 1 hr RT 
#-Rabbit Cell Signaling ! 1/5000 1 hr RT 
O/N-Overnight; RT-Room temperature 
 
 
7.4 - Primers used in the PCR experiments 
 
Table S4  – List of primers used in the RT-PCR experiments. 
 
Gene Name Primer Sequence 
ALAS1_E1_FW GCGTTTCGTTTGGACTTCTC  ALAS1 
ALAS1_E3-RW CATCATCTTGGGGCAGTTTT  
APAF1_FW AAGGATAATGGTGGCAGCAA APAF1 
APAF1_RW TCACCGTTTGAGACATTCCA 
PYCARD.E1F GCCGAGGAGCTCAAGAAGTT ASC 
PYCARD.E3R CTGGTACTGCTCATCCGTCA 
ATP2B4_E20FW GCAATACCTACCCGATCCCT  ATP2B4 
ATP2B4_E21RW GCTGTGGATGGACTTTTGGT  
BCLXS.FOR TTTGAACAGGATACTTTTGTGGAA BCL-X 
BCLXALL.REV GTCATGCCCGTCAGGAAC 
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BCLXL.FOR AGCCTTGGATCCAGGAGAAC BCL-X 
BCLXALL.REV GTCATGCCCGTCAGGAAC 
BCLXBOTH.FOR TTTGTGGAACTCTATGGGAACA BCL-X 
BCLXALL.REV GTCATGCCCGTCAGGAAC 
BCL_X-FW CATGGCAGCAGTAAAGCAAG BCL-X 
BCL_X-RW TGCTGCATTGTTCCCATAGA  
BCL10.E2F TCCTCTCCTTCTTCCCCATT BCL10 
BCL10.E3AR TGGACTTAACCAGCCTCCAG 
BCL10.E2F TCCTCTCCTTCTTCCCCATT BCL10 
BCL10.E4R CAGTGGATGCCCTCAGTTTT 
BCL2-FW GTTGCTTTTCCTCTGGGAAG BCL2 
BCL2-RW AGCCTGCAGCTTTGTTTCAT 
BCL2A1.E1F GAGAATGGATAAGGCAAAACG BCL2A1 
BCL2A1.E2R TGGAGTGTCCTTTCTGGTCA 
BID.E3F GTGTTTGGCTTCCTCCAAAG BID 
BID.E4R TCCGGATGATGTCTTCTTGAC 
BIN1_H-FW CCTCCAGATGGCTCCCCTGC BIN1 
BIN1_H-RW CCCGGGGGCAGGTCCAAGCG 
CARD9.E1F GCAGAACCCATCAGGAAGTG CARD9 
CARD9.E3R ACAGCTGCGGGTAGTAGAGC 
CARD9.E4F GCACCAGAGTGAGGAGAAGG CARD9 
CARD9.E6R GTACCTGGATGTAGGGGCTG 
CARD9.E6F CCAACACCATCTTCTCCCTG CARD9 
CARD9.E8R CCTCACACTGGAACACCTGC 
CARD9.E8F AGCTGCAGGTGTTCCAGTGT CARD9 
CARD9.E13AR GCAAAATGAGTGCCGCTTA 
CASP1.E2F TTATCCGTTCCATGGGTGAA CASP1 
CASP1.E5R GCGGCTTGACTTGTCCATTA 
CASP1.E6F TTTGAAGGACAAACCGAAGG CASP1 
CASP1.E9R CATCTGGCTGCTCAAATGAA 
CASP1.E2F TTATCCGTTCCATGGGTGAA CASP1 
CASP1.E9R CATCTGGCTGCTCAAATGAA 
CASP2L-FW AAACGAGGTTCCTGGTACATCG CASP2 
CASP2L-RW TCCTTGATAAGTGCGTTCACC 
CASP2S-FW TGCCCAAGCCTACAGAACAAA CASP2 
CASP2S-RW GCAGCAGTGAACAGAAGGAGG 
CASP8.E2F GCCCTTGAGTTGGTCACTTG CASP8 
CASP8.E6R GGGCACAGACTCTTTTCAGG 
CASP8.E1BF CACGTGGAGTTAGGCAGGTT CASP8 
CASP8.E6R GGGCACAGACTCTTTTCAGG 
CASP8.E1CF ATAGGCCTGTGACGAAGGTG CASP8 
CASP8.E6R GGGCACAGACTCTTTTCAGG 
CASP8.E6F TGGAGAAGAGGGTCATCCTG CASP8 
CASP8.E9R GCTCTTCAAAGGTCGTGGTC 
CASP8.E6F TGGAGAAGAGGGTCATCCTG CASP8 
CASP8.E8AR GCAAAACCCTCTATATTCGTAGC 
CASP9.E2F GCTCTTCCTTTGTTCATCTCC CASP9 
CASP9.E7R CATCTGGCTCGGGGTTACTGC 
CD44.C5F GCAGCACTTCAGGAGGTTACAT 
CD44 
CD44.V3R TCATCAATGCCTGATCCAGA 
CD44 CD44.C5F GCAGCACTTCAGGAGGTTACAT 
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 CD44.V4R GTCAAAAGCCCGTGGTGT 
CD44.C5F GCAGCACTTCAGGAGGTTACAT 
CD44 
CD44.V5R TGGTGCCATTTCTGTCTACAT 
CD44.C5F GCAGCACTTCAGGAGGTTACAT 
CD44 
CD44.V6R GTTGCCAAACCACTGTTCCT 
CD44.V7F ATGCAAGGAAGGACAACACC 
CD44 
CD44.V9F CATCACATGAAGGCTTGGAA 
CD44.V7F ATGCAAGGAAGGACAACACC 
CD44 
CD44.C7R CAAGAGGGATGCCAAGATGAT 
CD45.E2F TCTTAGGGACACGGCTGACT CD45 
CD45.E7R GGGCTCAGAGTGGTTGTTTC 
COP1.E2F AAGACCCGAGCTTTGATTGA COP1 
COP1.E3R ATAGCTGGGTTGTCCTGCAC 
COP1.E2F AAGACCCGAGCTTTGATTGA COP1 
COP1.E4RDW TTCTGAACATGGCACCTCTG 
EIF4H_E4A’_FW ACTTCGTGTGGACATTGCAG  EIF4H 
EIF4H_E5_RW CCTGCCCCCTAAGAAGTCAT  
ICEBERG.FOR GGCTCGAGTCTTGATTGACC ICEBERG 
ICEBERG.REV TGAGGCAAGTTGAGGGTCTT 
IL32_E2_FW TTGGCTCCTTGAACTTTTGG   IL-32 
IL32_E5_RW CTCTGCCAGGCTCGACAT  
IL1RN.E1F TGCTACTTTATGGGCAGCAG IL1RN 
IL1RN.E6R TCTCGCTCAGGTCAGTGATG 
IL1RNV1.E1F CTCCTCCTCTTCCTGTTCCA IL1RN 
IL1RN.E6R TCTCGCTCAGGTCAGTGATG 
INCA.FOR GGACTCTCAGCAGGTCCAAC INCA 
INCA.REV CATCTGGCTGCTCAAATGAA 
INCA.EJ2_3F CTCAGCAGGTCCAACATCTG INCA 
INCA.EJ3_4R AATCAAAGTTGATCCTAGGAAGG 
IRAK2.E11F GCCAGAAGTACCTGGAGAAGG IRAK2 
IRAK2.E13R TTGATCTCAATTTGCCACGA 
IRF7_E6FW CATTCCTGGCACACACACAT  IRF7 
IRF7_E8RW AGGGTGACAGGTACGGCTCT  
MALT1_E6FW GGTGCCTTATGTGGATTTGG  MALT1 
MALT1_E9RW  AGGCTGGTCAGTTGTTTGCT  
MAP3K5_E14FW TGGTGAACACCATTACCGAA  MAP3K5 
MAP3K5_E19RW GTCTGCTGCTTTTCCGTAGC  
MDM2_2FW CAGCTTCGGAACAAGAGACC  MDM2 
MDM2_8RW AGACAGGTCAACTAGGGGAAA  
MEFV.E1F AGAGTACGCCGTGCAGCTC MEFV 
MEFV.E3R TCAACTGGGTCTCCTTCCTG 
MEFV.E3F CATCTGCCTCATCTGCAGTC MEFV 
MEFV.E7R GGGACAGGCACTGTCTTAGC 
MEFV.E7F GTGCCTGTCCCTGAAAAGTG MEFV 
MEFV.E10R CCTCTCCCACTTGTTTCCAA 
MKNK2_11_F CCAAGTCCTGCAGCACCCCTG MKNK2 
MKNK2_13A_R GATGGGAGGGTCAGGCGTGGTC 
MKNK2_11_F CCAAGTCCTGCAGCACCCCTG MKNK2 
MKNK2_13B_R GAGGAGGAAGTGACTGTCCCAC 
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MUC2.E1F GCTCGGAGCTCCAGACAg MUC2 
MUC2.E3R TGTAGGCATCGCTCTTCTCA 
MYD88.E1F GACTGCTCGAGCTGCTTACC MyD88 
MYD88.E4R ACATTCCTTGCTCTGCAGGT 
NALP1_FW TCCTGCCTGCAAACTCATAC NALP1 
NALP1_RW GGATTCGCACAAACTGGAAT 
FW-NALP1B ATTCCAGTTTGTGCGAATCCA NALP1b 
RW-NALP1B GTTCCTTGGGGAGTATTTCCAG 
NALP3.E1F CGAGGGGTCAGACAGAGAAG NALP3 
NALP3.E3R TTCAATGCACTGGAATCTGC 
NALP3.E3F TAACATGCCCAAGGAGGAAG NALP3 
NALP3.E7R ATCCCCTTGTCTCCGAGAGT 
NALP3.E5F AGCACCTGTTGTGCAATCTG NALP3 
NALP3.E9R CCGTTTCCACTCCTACCAAG 
NFKB2.E11F TTCTGCAACTGAAACGCAAG NFKB2 
NFKB2.E16R CAGCAGAAAGCTCACCACAC 
NFKB2.E18F ACCTTTGCGGGAAACACAC NFKB2 
NFKB2.E23R CCGTACGCACTGTCTTCCTT 
NFKBIA.E1F GCCTGGACTCCATGAAAGAC NFKBIA 
NFKBIA.E3R GTCTCGGAGCTCAGGATCAC 
NFKBIA.E3F CTACACCTTGCCTGTGAGCA NFKBIA 
NFKBIA.E5R GGCAGCATCTGAAGGTTTTC 
NFKBIB_E1FW CAAAGCCCAGCTACAGGC  NFKBIB 
NFKBIB_E2RW AGGTCATTCTGCAGGTCCAT  
NFKBIB_E1AFW CATCAGCATGAACCCTTCCT  NFKBIB 
NFKBIB_E2RW AGGTCATTCTGCAGGTCCAT  
NFKBID.E9F CTGCAAATGGGTGCTAATCA NFKBID 
NFKBID.E10R AGCAGCAGCTGAACCAGAGT 
NLRX1.E9F CCTTCCCTGGAACTGCTACA NLRX1 
NLRX.E10R GGATGAGGAGAAAGCACCAA 
OS9_E12_FW AGAGGGTTGTCCCCAAAAAG  OS9 
OS9_E14_RW TCGTGTCCTCATCAGTCAGC  
P2X4-FW GCTACCAGGAAACTGACTCCG P2X4 
P2X4-RW GGTATCACATAATCCGCCACAT 
P2X7.E1F CTCGGATCCAGAGCATGAAT P2X7 
P2X7.E3R TGCTCTTGGCCTTCTGTTTT 
P2X7.E6F GCCGAAAACTTCACTGTGCT P2X7 
P2X7.E11R TGTCGATGAGGAAGTCGATG 
HPANX1_FW CCACGGAGCCCAAGTTCAA  PANX1 
HPANX1_RW CCGCCCAGCAATATGAATCC  
HPANX2_FW AAGCGCGAGATCATCGAGAAC  PANX2 
HPANX2-RW GCACAGGTAGGAGATGGGC  
HPANX3_FW TCATCAGCGAACTGGACAAATC  PANX3 
HPANX3_RW GTATCGTTCTTTCCGAGCCTTC  
POLR1D_E1_FW CGATGGAAGAGGATCAGGAG  POLR1D 
POLR1D_E2_RW ACGCCTTTCTGAAGGACAGA  
PTEN.E1F GCAGCTTCTGCCATCTCTCT PTEN 
PTEN.E4R GCAATTAAATTTGGCGGTGT 
PTEN.E2F GCAGAAAGACTTGAAGGCGTA PTEN 
PTEN.E5R GCTGTGGTGGGTTATGGTCT 
PTEN.E5F TAAAGGCACAAGAGGCCCTA PTEN 
PTEN.E7R GGGTCCTGAATTGGAGGAAT 
PTEN PTEN.E7F CCGTTACCTGTGTGTGGTGA 
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 PTEN.E9R GCTAGCCTCTGGATTTGACG 
PVRL2_E5_FW TCGTCTGCACAGTCACCAAT  PVRL2 
PVRL2_EW1_RW AGCCACAGCAGTAGCAATGA  
RASSF5_E1FW CCGTACCCGCTACTATTGGA RASSF5 
RASSF5_E3RW TCTCGCGTGTTGTAGCTGTC 
RASSF5_E2AFW GAACTCCGGGGTAGATGACC  RASSF5 
RASSF5_E3RW TCTCGCGTGTTGTAGCTGTC 
RET.E3F AGCTCTGCTTCCCAGAGACA RET 
RET.E5R TGATGCAGGTACCACGTCTG 
RGS18_E2_FW GTTTCATGAAGACACCCGCT  RGS18 
RGS18_E5_RW GCATCAAAACTGTGGAGGGT  
RGS8_E2FW AACACCTTAACCCGAAGCCT  RGS8 
RGS8_E3RW GGTTGGGTTTGTCTGGAAGA  
RIPK2_E1FW AGTCAGCTCTGGTTCGGAGA  RIPK2 
RIPK2_E1ARW CGGGGATGACGTATTTTCAC  
RIPK2_E1FW AGTCAGCTCTGGTTCGGAGA  RIPK2 
RIPK2_E3RW AGGATGCGAAATCTCAATGG 
RIPK2_E7FW GAACTTGAACCAGTTTTGAGAACA RIPK2 
RIPK2_E7ARW AAGAGAAGTGCGAGAACCCA  
RIPK2_E7FW GAACTTGAACCAGTTTTGAGAACA RIPK2 
RIPK2_E8RW GGTGAATGGCACTTGAAACA  
RPS6KB1_1_F AGACAGGGAAGCTGAGGACA RPS6KB1 
RPSKB1_R TGTCTGAGGATTTGCTGTGC 
RPS6KB1_2_F GGACGCTGGAGAAGTTCAAG RPS6KB1 
RPS6KB1_R TGTCTGAGGATTTGCTGTGC 
SERPB2.FOR CAGATGAAATTGCCGATGTG SERPINB2 
SERPB2.REV TTGCTGGTCCACTTGTTGAG 
ASF.E2_3F TCTCTGGACTGCCTCCAAGT SFRS1 
ASF.E4R GGCTTCTGCTACGACTACGG 
SHD_E4FW CAGTCCAGAGTGGGAGAGGA  SHD 
SHD_E6RW ATTTTCTAGGCCATGGGAGG  
SPPL3_E2_FW TGGTGGATTCCAGTCAAGTG  SPPL3 
SPPL3_E4_RW CAATTGGAAGGAACAGAGCC  
STAT5A_E3FW TACTTGGCCCAGTGGATTGA  STAT5A 
STAT5A_E4RW TAGTGCCCCAGCTTGATCTT  
STK40_E1FW GCTCTGGGCTACGGACTATG  STK40 
STK40_E3RW GGATGAATGGTCCAGCTCTC  
TBXSA1.E9F AACCCTGACTGCCAAGAGAA TBXAS1 
TBXSA1.E11R TTTCAGGGTTGAAGGTCTCC 
TNFAIP2.E1F GTGTTCTGCGTCTTCACCAA TNFAIP2 
TNFAIP2.E4R GGTCCATCAACTCCCTCACA 
TXNDC11_E5_FW CCAGCCTCCTGGTTATTTGA  TXNDC11 
TXNDC11_E6_RW GGATACCAGTTTCGCAAGATG  
VILL_E1FW AGGTAGCCAGGTGTCGGTCT  VILL 
VILL_E3RW GTGGCCTTCGGGCTCT  
ZNF692_E1_FW GAGAGGCACCGTTTCTTCTTA  ZNF692 
ZNF692_E2_RW CTCCTTGAGGAGGCACCACT  
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7.5 - Primers used in the qRT-PCR experiments 
 
Table S5  – List of primers used in the qRT-PCR experiments. 
 
Gene Name Primer Sequence 
AKAP8_FW CATGCACATGGCCTCTTACG  AKAP8 
AKAP8_RW GCCTCCTTCCTTGGACATCAT  
ASC_RT_FW CGAGGAGCTCAAGAAGTTCAA  ASC 
ASC_RT_RW TCTCCAGGTAGAAGCTGACCA  
CASP1_FW TCCAATAATGGACAAGTCAAGCC CASP1 
CASP1_RW GCTGTACCCCAGATTTTGTAGCA 
CCL2_FW CCCCAGTCACCTGCTGTTAT  CCL2 
CCL2_RW AGATCTCCTTGGCCACAATG  
CCL20_FW TTTATTGTGGGCTTCACACG  CCL20 
CCL20_RW GATTTGCGCACACAGACAAC  
CCL4_FW CTGTGCTGATCCCAGTGAATC  CCL4 
CCL4_RW TCAGTTCAGTTCCAGGTCATACA  
CCL4L2_FW CTTCCTCGCAACTTTGTGGT CCL4L2 
CCL4L2_RW GACTTGCTTGCCTCTTTTGG  
CLK1.FOR GAACAAGCGCTGCAAATACA CLK1 
CLK1.REV TGTCCAGGTTCACATCCTTG 
CLK4.FOR GAAGTCACAAGCGGAAGAGG CLK4 
CLK4.REV TCCCGATAATCTCGCTCATT 
CUGBP2.FOR TGAGAACGACATCAGGGTGA CUGBP2 
CUGBP2.REV GCCATTGCCCTTGTAGAAAA 
CWF19L1.FOR CCAAGTGTGTGGGGAACTTT CWF19L1 
CWF19L1.REV AGGTCTTTTCCAAAGCAGCA 
CX3CR1_FW CCCTGAATCAGTGACAGAAAACT  CX3CR1 
CX3CR1_RW ACGGAGTAGAATATGGACAGGAA  
CXCL10_FW CCAATTTTGTCCACGTGTTG CXCL10 
CXCL10_RW TTCTTGATGGCCTTCGATTC  
CXCR4_FW TACACCGAGGAAATGGGCTCA  CXCR4 
CXCR4_RW AGATGATGGAGTAGATGGTGGG  
DDX54.FOR GCTCAAGTGGGACCGTAAGA DDX54 
DDX54.REV GGTCTCGCTTGTAGGAGCTG 
DHX38.FOR CTTCCAGAAGGCTCCAGATG DHX38 
DHX38.REV AACAAACATGATGCCGTCAA 
EIF3S10.FOR AGGACTCTCGTTGGGGAGAT EIF3S10 
EIF3S10.REV CGTCTCCACTCCTTCTCTGG 
ERLIN1_FW CTGTGTACTACAGGGGAGGAG  ERLIN1 
ERLIN1_RW GACCCCACCACTTGTTCCAC  
GAPDH_F GAGTCAACGGATTTGGTCGT GAPDH 
GAPDH_R TTGATTTTGGAGGGATCTCG 
FW-GNB2L1 GACCATCATCATGTGGAAACTGA GNB2L1 
RW-GNB2L1 CCGTTGTGAGATCCCAGAGG 
GTF2I.FOR TCAGCTCTCGAGTCCATGTG GTF2I 
GTF2I.REV GCACGTCCTCTTTCAGTTCC 
HMGB1.FOR TTGCTTTTGCCCATTTTGA HMGB1 
HMGB1.REV GCAGGGTGTGTAGACAAAAGC 
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HMOX1_FW CAGTGCCACCAAGTTCAAGC  HMOX1 
HMOX1_RW GTTGAGCAGGAACGCAGTCTT  
HNRPK.F ACCTAGAGGGGGAGACCTCA HNRNPK 
HNRPK.R TTGCAGAGTCCCAAGTTTCA 
HNRPM.FOR AGCTGCGGAAGTCCTAAACA HNRPM 
HNRPM.REV CCAGTCGTAGCCATCACCTT 
FW-HYPC AGACACAAGTCGAATAGTCCTGA HYPC 
RW-HYPC CTGGGGAACGGTTAGGGAG 
ICAM1_F TCTGTGTCCCCCTCAAAAGTC ICAM1 
ICAM1_R GGGGTCTCTATGCCCAACAA 
IL1B_F CTCGCCAGTGAAATGATGGCT IL1B 
IL1B_R GTCGGAGATTCGTAGCTGGAT 
IL8-FW TTTTGCCAAGGAGTGCTAAAGA IL8 
IL8-RW AACCCTCTGCACCCAGTTTTC 
IL8RB_FW GGCCCTGCCTGTCTTACTTTT  IL8RB 
IL8RB_RW CATCCGCCAGTTTGCTGTAT  
KHSRP.FOR TGGGGATCCTTACAAAGTGC KHSRP 
KHSRP.REV CCGAGATCCGTACTCATTCC 
KIN.FOR GAAGGGAAGGAACAGGAGGT KIN 
KIN.REV AAGATGTTGCTCCGGATGAG 
LAMP3_FW ACCACCAGCCCAATTACCTAC  LAMP3 
LAMP3_RW AAGCTAGGGCCGACTGTAACT  
LSM7.FOR GACAAGACGATCCGGGTAAA LSM7 
LSM7.REV CAGGGTCTCGCATGTACTCA 
MFAP1-FW CTATGCCCCTATGGAGTCCTC  MFAP1 
MFAP1-RW GGTCACTGGATGAATCCTCCTC  
NALP3_RTIME_RW TCGGCTCATCTCTTTTTGCT NALP3 
NALP3_RTIME_FW AGCCACGCTAATGATCGACT 
NFE2_FW GCAGGAACAGGGTGATACAGC  NFE2 
NFE2_RW CTCACTTGGAGCATTCAGACC 
NUDT7_FW GACCAGCATTACGTCACACG NUDT7 
NUDT7_RW CGTCATTCCCTTGATCTGGT 
P2RX1_FW GGCACTGCAGACCCATCTAT  P2RX1 
P2RX1_RW TAGTTGGTCCCGTTCTCCAC  
P2RY2_FW TGGTCTATTACTACGCCCGC   P2RY2 
P2RY2_RW TGCTGCAGTAAAGGTTGGTG  
PABPN1.FOR TGTGGTTCAGTCAACCGTGT PABPN1 
PABPN1.REV TAAGGCCAAGGAAGTCCTCA 
PPIE_FW ACCAAGCGCGTCTTGTACG  PPIE 
PPIE_RW GCATCCTCTGCCAACTCAAAT  
PPIH_FW AAGTGCGATTGGCTGGATGG  PPIH 
PPIH_RW ACTGCGAGATCACCACAGGTA  
RIPK3_FW AACCGAACCATCACTCGTGTA  RIPK3 
RIPK3_RW CCTTCTAAGCCGGGAGTCTCA  
SCAMP5_FW AAGTGAACAACTTCCCACCATT  SCAMP5 
SCAMP5_RW TGACATGCTGGGGAGGAATATC  
SELPLG_FW CTGCTGCAAGGCGTTCTACT SELPLG 
SELPLG_RW GGACAGGTTCCCCATGTTGG  
SERPINB2_FW CAGCACCGAAGACCAGATGG  SERPINB2 
SERPINB2_RW CCTGCAAAATCGCATCAGGATAA  
SF3A3.FOR GGCACAAAACTTGGTGGAGT SF3A3 
SF3A3.REV CCAGCTTCTCAGATGCCTTC 
SFPQ SFPQ-FW TTCTGGCCTCCTGAACCATAG  
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 SFPQ-RW GTTACAGCCGAATGGGCTACA  
SFRS1_F GCGACGGCTATGATTACGAT SFRS1 
SFRS1_R CTTGGAGGCAGTCCAGAGAC 
SFRS12.FOR CGCGAAGATCTCGTAGTTCC SFRS12 
SFRS12.REV GGGGGACGGAGATCTAGAAG 
SFRS2.FOR CCCGGACTCACACCACAG SFRS2 
SFRS2.REV ACCTGGAACGACTCCGACT 
SFRS3_F AACAAGACGGAATTGGAACG SFRS3 
SFRS3_R TGGGCCACGATTTCTACTTC 
SKIV2L2.FOR TCTGCGCTGTAGCAAAGAGA SKIV2L2 
SKIV2L2.REV AAACTGGGACAACCTGCATC 
SNIP1.FOR TTGATCACCCGTCTTGTTCA SNIP1 
SNIP1.REV CCTGAGCCAAGGTCAATGAT 
SOD2_FW CTGCTGGGGATTGATGTGTGG  SOD2 
SOD2_RW TGCAAGCCATGTATCTTTCAGT  
TBC1D30_FW TTGACTGGGACAAAACCATGC TBC1D30 
TBC1D30_RW CTACAGCCTGTGCGGTGAA 
FW-CXXC6 TAATGGAAGCACTGTGGTTTGT TET1 
RW-CXXC6 GCCCCAGATTTGATCTTGGC 
TNF_FW AACCTCCTCTCTGCCATCAA  TNF 
TNF_RW GGAAGACCCCTCCCAGATAG  
TNFAIP6_FW TGGATGGCTAAGGGCAGAGTT  TNFAIP6 
TNFAIP6_RW GCGTGTGGGTTGTAGCAATA  
VLDLR_FW AGAACATGCCGCATACATGAA  VLDLR 
VLDLR_RW GTGAACTCGTCGGGACTACA  
ZC3H13.FOR TAAAGCGTGGAGAACCCAGT ZC3H13 
ZC3H13.REV TGAATGGACCTGTCGATCTG 
 
 
7.6 - DEG genes for the different analysis of the Human Exon 
1.0 ST Arrays 
 
Table S6  – List of upregulated genes of Control-S vs Control-NS analysis. 
 
Gene Name Gene Name Gene Name Gene Name 
ABCC1 F8A3 MOBKL2C SCN1B 
ABTB2 FBXO6 MMP14 SDC4 
ACSL1 FCAR MRAS SEMA7A 
ACVR2A FEZ1 MSC SERPINB9 
AHDC1 FGF2 MT1A SERPINE1 
AKT1S1 FGL2 MT1B SERPINE2 
ALAS1 FGR MT1DP SERTAD1 
AMOTL2 FLVCR2 MT1E SGK1 
AMPD3 FMNL3 MT1F SGPP2 
ANXA2 FTH1 MT1H SH2B3 
ANXA8L1 FZD7 MT1M SHROOM3 
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APOBEC3F G0S2 MT1X SIAH2 
APOL1 GADD45B MT2A SIRPA 
APOL2 GBP1 MTF1 SLAMF1 
APOL6 GBP2 MTSS1 SLAMF7 
AQP1 GBP3 MUC1 SLAMF8 
ARL17 GBP4 MX1 SLC11A2 
ARL5B GBP5 MX2 SLC15A3 
ASTL GCH1 MYD88 SLC16A3 
ATF3 GEM MYO1C SLC25A25 
ATF5 GLT8D4 NAB2 SLC25A28 
ATP10A GMPR NAV3 SLC2A6 
ATP1B1 GNG4 NCOA7 SLC31A2 
ATP2B1 GPC4 NFATC1 SLC39A8 
ATP9A GPR132 NFE2L3 SLC41A2 
AXUD1 GPR157 NFKB1 SLC43A2 
B4GALT1 GPR84 NFKB2 SLC6A6 
BAIAP2L1 GRAMD1A NFKBIA SLC7A11 
BATF H2AFB3 NFKBIB SMAD3 
BATF2 HCK NFKBID SMAD7 
BCL2A1 HERC6 NFKBIE SMOX 
BCL2L1 HESX1 NFKBIZ SNAI1 
BCL3 HIVEP1 NINJ1 SNF1LK 
BCL6 HIVEP2 NKD1 SNN 
BCL9L HIVEP3 NKX2-2 SNX11 
BID HLA-E NPTX2 SOCS1 
BIRC3 HLA-F NR4A1 SOCS3 
BTG1 HMOX1 NR4A2 SOD2 
BTG2 HRH1 NR4A3 SP110 
C10orf10 HS3ST3B1 NRP2 SPHK1 
C17orf96 ICAM1 NXF1 SPI1 
C19orf61 ICOSLG OAS1 SPIB 
C19orf66 IER3 OAS2 SPRED2 
C1orf122 IER5 OAS3 SPSB1 
C1orf38 IFI16 OASL SQSTM1 
C1orf61 IFI27 OBFC2A SRC 
C3 IFI35 OLIG1 SRXN1 
C3AR1 IFI6 OPTN ST3GAL2 
C6orf145 IFIH1 OR6N2 STARD10 
CCDC57 IFIT1 OSGIN1 STARD5 
CCDC85A IFIT2 P2RX4 STAT2 
CCL1 IFIT3 PARP12 STAT4 
CCL18 IFIT5 PAX5 STAT5A 
CCL2 IFITM1 PDE4B STEAP4 
CCL20 IFITM3 PDGFRL STX11 
CCL22 IFNGR2 PEA15 TAP1 
CCL24 IGFBP3 PHF15 TAPBP 
CCL3 IKBKE PHLDA1 TCEB3 
CCL3L1 IL10RA PHLDB1 TFAP2A 
CCL3L3 IL12B PIK3AP1 TGFBR3 
CCL4 IL15RA PIK3R5 THBS1 
CCL4L1 IL18RAP PIM1 TICAM1 
CCL4L2 IL1A PIM2 TJP2 
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CCL5 IL1B PITPNA TLR7 
CCL8 IL1RN PLA2G4C TMEM106A 
CCR7 IL23A PLAU TMEM138 
CCRL2 IL27 PLAUR TMEM140 
CD274 IL27RA PLEK TMEM171 
CD276 IL2RG PLEKHA4 TMEM2 
CD40 IL32 PLEKHO1 TMEM217 
CD44 IL33 PLEKHO2 TNF 
CD70 IL4I1 PLK3 TNFAIP2 
CD80 IL6 PML TNFAIP3 
CD83 IL7R PNKD TNFAIP6 
CDGAP IL8 PNPLA1 TNFAIP8 
CDKN1A INDO PNRC1 TNFRSF10B 
CFB IRAK2 POLR2J TNFRSF10D 
CFLAR IRF1 POLS TNFRSF9 
CHST2 IRF4 POPDC2 TNFSF10 
CKB IRF7 POU2F2 TNFSF9 
CLIP2 IRG1 PPAP2A TNIP1 
CMPK2 ISG15 PPIF TNIP3 
CNP ISG20 PPP1R15A TOM1 
CNTNAP1 JMJD3 PRDM1 TOR1B 
CPM JUN PRIC285 TP53INP2 
CRIM1 JUNB PSTPIP2 TP63 
CSF1 JUND PTAFR TRADD 
CTGF KCNJ2 PTGER2 TRAF1 
CXCL1 KCNK5 PTGER4 TRAF3 
CXCL10 KCNN4 PTGIR TRAF3IP2 
CXCL11 KIAA0247 PTGS2 TRIB1 
CXCL2 KIAA0999 PTPN1 TRIM16L 
CXCL3 KLF10 PTX3 TRIM21 
CXCL9 KLF5 QPCT TRIM22 
CYB5R2 KYNU RAB6IP1 TRIM25 
CYBASC3 LACTB RAP2C TRIM26 
CYP19A1 LAMP3 RAPGEF1 TRIM5 
CYP27B1 LAP3 RAPH1 TRIM56 
CYP7B1 LBH RARG TRIP10 
DDIT4L LFNG RASA4 TSLP 
DDX58 LHX2 RASGEF1B TTC39A 
DHX58 LIF RASGRP1 TYMP 
DIXDC1 LIMD2 RASL11A UBE2L6 
DKFZP564O0823 LITAF RASSF4 ULBP2 
DLL4 LPAR1 RASSF5 UPB1 
DNAJB5 LPL RBM24 UPP1 
DOT1L LRG1 RCAN1 USP12 
DRAM LRRC32 RCN1 USP18 
DUSP1 LTA REC8 USP41 
DUSP16 LYN REL UXS1 
DUSP2 LYRM4 RELB VCAM1 
DUSP4 MAFB RFTN1 VEGFC 
DUSP5 MAFF RGL1 VSNL1 
DUSP6 MAGI1 RGS16 WARS 
DUSP8 MAML2 RHOG WTAP 
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EBI3 MAMLD1 RILPL2 XAGE1A_1 
ECE1 MAP2K3 RIN2 XAGE1E 
EGR2 MAP3K8 RIPK2 YRDC 
EGR3 MARCKS RND3 ZC3H12A 
EHD1 METRNL RNF144B ZC3H12C 
EHD4 METTL1 RNF19B ZC3HAV1 
ELOVL7 METTL10 RRAD ZFP36 
EMP2 MFSD2 RSAD2 ZMIZ2 
EPSTI1 MGLL RTP4 ZNF8 
ETV7 MMP1 SAT1 ZNFX1 
 
 
Table S7 – List of upregulated genes of shSF2-NS vs Control-NS analysis. 
 
Gene Name Gene Name Gene Name Gene Name 
ADRBK1 DYNLRB1 MICB S100A8 
ALAD FAM120C NCSTN SLPI 
ASB12 GNAI2 OSGEP TCTA 
B3GNT7 GNMT P2RX1 TMED4 
C16orf14 HCCA2 PCBD1 TSPYL1 
C3 HSD17B10 PERLD1 U2AF1L4 
C3orf60 ITGA5 PPP1R14C YIPF3 
CHCHD10 LILRA2 RHOG  
CHMP6 MANSC1 RIPK3  
 
 
 
Table S8 – List of upregulated genes of shSF2-S vs Control-S analysis. 
 
Gene Name Gene Name Gene Name Gene Name 
C3orf60 DUSP2 LRRC32 RNF144B 
C6orf58 DYNLRB1 MAGEF1 SEC31B 
CCL22 F11R NCSTN STAT5A 
CCR7 GNAI2 NFKB2 STEAP4 
CD83 GPR157 NR4A1 THBS1 
CERCAM HCCA2 NUP210 TMEM158 
CTGF HLA-DOB OR2J2 TP53INP1 
CTSD HSD17B10 P2RX1 TP53INP2 
DDIT4L INDO PHLDA3 ZDHHC12 
DEFB114 ITGA5 QSOX1  
DUSP1 LAMP3 RAC2  
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Table S9 – List of downregulated genes of Control-S vs Control-NS analysis. 
 
Gene Name Gene Name Gene Name Gene Name 
AARS DEPDC6 MID1IP1 RNF125 
ACACB DGCR2 MIF4GD RNF166 
ADCY7 DGKG MLNR RNF26 
ADCY9 DYSFIP1 MMACHC RNF44 
ADRBK1 EBF3 MOBKL2A RPUSD3 
AKAP1 EBP MON1A RWDD2B 
ALAD ECH1 MOSC1 SASH3 
ALG3 EHMT2 MPI SCAMP5 
ALKBH2 EPHB1 MRM1 SELPLG 
AMPD2 ERLIN1 MRPS34 SERPINB2 
ANKRD13D EXDL2 MTMR4 SFXN3 
APEX1 F2R MUM1 SIGLECP3 
ARHGAP1 FAM134A MXI1 SIPA1 
ARHGAP30 FAM163A MYC SIRPB2 
ARHGEF17 FANCE MYO18A SLC12A9 
ASB13 FANCF NAT11 SLC19A1 
ATG9A FARSA NCAPD2 SLC1A5 
B3GNT1 FES NDRG1 SLC22A5 
B3GNT7 FGD3 NDUFS2 SLC25A10 
B3GNT8 FLI1 NFE2 SLC25A11 
B4GALT3 FLRT1 NLRX1 SLC29A1 
BCR FOXRED2 NMRAL1 SLC2A1 
BMP8A FUT7 NTSR1 SLC2A5 
BMP8B GFI1 NUDCD3 SLC39A3 
BRD3 GGA2 NUDT7 SLC43A1 
BRI3BP GIMAP6 OAF SLC46A1 
BSPRY GIPC1 OBFC2B SLC6A10P 
C10orf140 GIT1 OPRS1 SLC6A8 
C10orf54 GLT25D1 ORAI3 SLC9A3R1 
C10orf91 GNB5 OXCT2 SORD 
C12orf52 GPA33 P2RY2 SSH3 
C15orf58 GPR114 P2RY8 ST14 
C15orf61 GPT2 PAFAH2 STAR 
C16orf53 GRAMD4 PARP15 SYK 
C16orf74 GRK6 PCK2 TBC1D14 
C16orf88 HAL PCYOX1L TBC1D30 
C17orf62 HDAC5 PCYT2 TFAP4 
C19orf59 HEYL PDK2 TGM5 
C1orf162 HK2 PEX6 THRA 
C21orf56 HMHA1 PFKFB4 TLR9 
C21orf59 HPS4 PGPEP1 TMEM104 
C22orf9 HRH2 PHACTR3 TMEM173 
C2orf7 IL8RB PIK3C2B TMEM185A 
C9orf100 IMPA2 PIPOX TMEM37 
CA2 ING4 PLCB2 TMEM53 
CABC1 INPP5D PLCXD1 TMEM91 
CAMK2G IRX3 PLK1 TMEM97 
CARHSP1 ITGAL PNPO TNFRSF10A 
CBFA2T3 ITPK1 POLG2 TPCN1 
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CCRK KANK2 POU4F2 TSC22D3 
CD244 KCNAB2 PRAM1 TSHZ1 
CD300A KIAA1462 PRAME TST 
CD300LF KIF3C PREB TTC7A 
CD33 KLF16 PRICKLE1 TTLL1 
CD93 KLHDC3 PSRC1 TTLL12 
CDA LAIR1 PSTPIP1 UAP1L1 
CDC20 LAIR2 PTCH1 UCK2 
CDC25B LDLRAP1 PXMP4 UHRF1 
CDIPT LGALS12 PYCARD UNC84B 
CECR5 LILRA2 RAB11FIP1 VAMP8 
CIDEB LIMK2 RAB33A VLDLR 
CLCN7 LOC116236 RAB3D VPS26B 
CNPY3 LOC201164 RAC2 WDR68 
COG8 LOC440295_1 RASGRP2 WDR74 
CORO1A LPAR5 RASSF7 WDR91 
CORO2A LPCAT4 RCSD1 XTP3TPA 
CRIPAK LYL1 REEP4 XYLT2 
CSK LYPLA3 RGS14 YIPF6 
CSPG4 MAGEF1 RGS19 YPEL2 
CTDSP2 MAP3K3 RHOBTB2 YPEL3 
CX3CR1 MCAT RIMBP3B ZFYVE1 
CXCR4 METTL7B RIMBP3B ZMYM3 
CXXC1 MFNG RIMBP3C ZNF395 
DENND2D MFSD3 RIMS3 ZNF692 
 
Table S10– List of downregulated genes of shSF2-NS vs Control-NS analysis. 
 
Gene Name Gene Name Gene Name Gene Name 
ACSF2 CCL3L3 GPT2 SCD 
ACY1 CD209 LSS SFRS1 
AHNAK2 CREB3L4 NDRG1 SLC43A1 
ALDOC DHCR7 NEU1 SLC6A10P 
ATF5 EBP NKG7 SLC6A8 
BHLHB2 ESPL1 OR9Q1 TBC1D30 
C1orf148 FADS2 PFKFB4 TM7SF2 
C3AR1 FADS3 PNCK TNF 
C6orf223 FAM127C PNPLA3 WDR54 
CCL3 FTSJ3 RENBP  
CCL3L1 GPNMB RGS16  
 
Table S11– List of downregulated genes of shSF2-S vs Control-S analysis. 
 
Gene Name Gene Name Gene Name Gene Name 
AAAS CD9 MIF SLC2A3 
AACS CYP19A1 NEU1 SLC43A1 
ACSS2 EBP NKD1 SLC7A11 
ACY1 FADS2 NKG7 SLC7A7 
ADAMTS1 FADS3 OLIG2 SPIB 
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ALDOC FDPS POFUT2 STT3A 
APOC1 FTSJ3 PRAME THBD 
BCL2L14 HIST1H4E PSMB9 THTPA 
C10orf57 HIST1H4F RENBP TM7SF2 
C11orf51 HMOX1 SBF2 TNR 
C12orf10 IFI27 SCD TRIM16L 
C20orf20 LDHA SF3B3 TUBA1A 
C3AR1 MAML2 SFRS1 WDR54 
CCL1 MEIS2 SLAMF8  
CD209 METTL7B SLC2A14  
 
 
7.7 - ASE for the different analysis of the Human Exon 1.0 
ST Arrays 
 
Table S12– List of inclusion ASE observed in the Control-S vs Control-NS analysis. 
 
Gene Name Gene Name Gene Name Gene Name 
ACHE EIF4H NFATC1 SLC25A23 
AKAP1 EMR2 NR4A3 SLC2A6 
ALAS1 ERLIN2 OXA1L SSRP1 
APEH GBP6 PARVG STAT5A 
ATP13A2 GLUL PKM2 STAT5B 
ATP2B4 HAS3 PLCB2 TBCD 
ATXN7L1 HELLS PLEKHA4 TGM5 
BAIAP2 IDH3B PPARD TNFRSF9 
C1orf61 IL32 PSRC1 TNFSF10 
CAMK2A IL8 RBCK1 TNIP3 
CCND3 IL8RB RCAN1 UBAP2L 
CD44 INSIG1 RCAN2 UBAP2L 
CRIM1 IQSEC3 RET VAPA 
CTSH IVNS1ABP RGS8 VSNL1 
DAZ3 KIF1A RIN1 ZP3 
EEF1A2 KLRD1 SERPINB12  
EEF1D MED15 SETD8  
EIF4G3 MGLL SHD  
 
 
Table S13– List of inclusion ASE observed in the shSF2-NS vs Control-NS analysis. 
 
Gene Name Gene Name Gene Name Gene Name 
A2M HDLBP PPIH SCMH1 
AGRN IRF7 PTCRA STAT5A 
CYB5R2 MRPL13 PTDSS2 STAU1 
FAM122B PAK4 PTPRF SYTL2 
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GPNMB PNCK RGS8 UBAP2L 
 
 
 
Table S14– List of inclusion ASE observed in the shSF2-S vs Control-S analysis. 
 
Gene Name Gene Name Gene Name Gene Name 
ATG16L2 ESPN LRP5L SFXN1 
C15orf26 FADS3 MAPK8IP3 SNPH 
C4orf29 FAM62A MARCH6 SNUPN 
CCDC12 FAM69A MPDZ SON 
CD1E FDXR NEDD4L SRCAP 
CDH26 GLTSCR2 NFYC THOC2 
CHMP6 GLUL OR2H1 TIRAP 
CHP GORASP1 PEAR1 TNFRSF13B 
CLEC4M HDAC6 PI4KA TNR 
CNOT4 HDLBP PIBF1 TRERF1 
COL11A2 HERC2 PPIH TRPC4 
CSMD3 HSDL2 PRPF38B USP15 
DKKL1 IDI1 RP1L1 ZMYM2 
EFNA1 LOC144983 SCMH1 ZNF501 
 
 
Table S15– List of exclusion ASE observed in the Control-S vs Control-NS analysis. 
 
Gene Name Gene Name Gene Name Gene Name 
ANKZF1 INSR PAFAH1B1 SLC9A3R1 
ARSG KNTC1 PARD3 THOC2 
ATAD3C MAPKBP1 PDLIM5 THRA 
BCL2L11 MFAP5 PHLDB1 TNFAIP2 
BID MFSD2 PMS2 TNIP1 
C18orf22 MGLL PNKD TPM2 
CD1E MMP14 POU2F2 TRAF3IP2 
DHX58 NARF PRIC285 TRIP10 
DISC1 NCOR2 PSPH TTBK2 
EFCAB1 NFKBID PSRC1 TTC7A 
FAM62B NFKBIZ RCSD1 ZIC5 
FMNL3 NUP188 RGS18 ZNF217 
HLA-E NUP214 SH3BP5  
 
 
Table S16– List of exclusion ASE observed in the shSF2-NS vs Control-NS analysis. 
 
Gene Name Gene Name Gene Name Gene Name 
ABCE1 DHX58 OS9 TMEM134 
ACADM ENTPD6 PI4KB TMEM9B 
AHSA1 FAM49B PLEKHA4 TMPRSS9 
AKT1 GNAS POLR1D TRAIP 
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ALAS1 HMGA1 PVRL2 TXNDC11 
BAIAP3 HNRNPD RAB5C UBAP2L 
BCL2L13 IMPDH1 RPN2 VPS37A 
CASP2 INSIG1 SLC37A2 VTI1A 
CD1E KIAA0515 SPPL3 YWHAB 
CD9 MTMR3 SSR2 ZNF202 
CD99L2 NMT1 ST3GAL3  
 
Table S17– List of exclusion ASE observed in the shSF2-S vs Control-S analysis. 
 
Gene Name Gene Name Gene Name Gene Name 
ACAT2 HDGF PNN SMARCA4 
ACTG2 HP1BP3 PRKDC SPARCL1 
ALDH16A1 IPO13 PRMT2 SUSD3 
ARFGAP3 KLHL18 PSAT1 TFG 
BRD7 LOC23117 REM2 TMEM161A 
C21orf66 LRP10 RIMS1 TPM1 
CCND3 NAPB SERGEF TXNDC11 
CDC2L5 NOL14 SH3KBP1 USH1C 
DAPL1 NRAP SKIV2L2 WDR49 
EIF4G3 PDXK SLC44A1 ZNF138 
ERMP1 PI4KB SMAD5  
 
Table S18– List of the common genes identified in the ASF/SF2 CLIP-seq analysis 
(Sanford et al., 2009) and the ASE observed in the shSF2-S vs Control-S analysis. 
 
Common ASE of shSF2-S vs Control-S analysis and ASF/SF2 CLIP-seq 
 (Sanford et al., 2009) 
AATF GOLGA8A PI4KA SLC15A4 
ACTR2 GPI PIBF1 SLC1A5 
ACVR2B GTPBP1 PLCB3 SLC2A1 
ADAMTS1 H2AFX PLEKHF2 SLC3A2 
ADCY3 HDGF PLK1 SLC43A1 
ALKBH4 HDGF2 PNN SMARCA4 
AP2B1 HDLBP PNPLA3 SMPD4 
ARIH2 HMBS POLQ SNRPF 
ATAD3C HNRPDL POLR1D SNX15 
ATP5J HSPA4 PPFIA3 SRP68 
ATP5L IDI1 PPIE SRRM2 
BAG1 IGF2R PPIH TBC1D9B 
BIRC5 IRAK1 PRAGMIN TIRAP 
BOLA1 KIAA0515 PRKAR1A TLK1 
BRD7 LAPTM4B PRKCD TMEM103 
C12orf10 LDHA PRKDC TMEM120A 
C18orf22 LIPT1 PRMT2 TMEM160 
C4orf29 LONP1 PSAT1 TPM1 
C9orf78 LRRC37A2 PSMC1 TRERF1 
C9orf86 LYSMD1 PSRC1 TSPYL4 
CANX MCART1 QPRT TTLL5 
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CCAR1 MICALL1 RBM3 TUBA1A 
CDC2L5 MLL2 RCC1 TUBA1C 
CDRT4 MLL4 REXO1 UBP1 
CLGN MLXIP RNF157 UBQLN2 
CLNS1A MRTO4 RNPS1 WBSCR16 
CLSTN1 MSH2 ROCK1 WDR42A 
CNPY3 MYL6 RPN2 YEATS4 
COG8 MYSM1 RPS21 YIPF6 
COPS8 NBPF14 RRS1 ZBED4 
EIF3CL NDUFV3 RWDD3 ZC3H7B 
EIF4B NIP30 SAPS1 ZHX1 
ERCC8 NUDC SAPS2 ZKSCAN5 
FAM127A OS9 SAT2 ZNF138 
FAM46B PARP1 SEC24C ZNF653 
FDXR PDXK SF3B2 ZNF704 
FUZ PEA15 SFRS14  
GLUL PFKP SFRS16  
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7.8 - Overexpression of SFRS1, SFRS3, IL-1! and IL-18. 
 
 7.8.1 - pENTR11 vectors. 
Figure S1– pENTR11-SFRS3, pENTR11-
IL1b and pENTR11-IL18 vector maps.  
SFRS3, IL-1! and IL-18 genes were cloned 
into a BamHI and EcoRV sites in the multiple 
cloning site of the pENTR11® vector. Two 
restriction sites were used to evaluate insert 
orientation after the ligation step, NheI and 
KpnI. After transformation into bacterial cells, 
kanamycin selection can be performed due to a 
kanamycin resistance gene (Kan(R)) present in 
the final vector. Sequencing primers were 
designed to anneal in the outside of the multiple cloning site, therefore could be used to 
sequence all the constructs performed. 
 
 
  
  
 
 
 
“Identification of Splicing Factors with a role in IL-1! secretion”              
 
 
226 
7.8.2 - pLenti6/V5-DEST vectors. 
 
 
 
 
Figure S2– pLenti6/V5-DEST-SFRS3, 
pLenti6/V5-DEST-IL1b and 
pLenti6/V5-DEST-IL18 lentiviral vector 
maps. pENTR11 vectors were recombined 
into a pLenti6/V5-DEST Gateway® Vector 
(Invitrogen®). The expression of SFRS3, 
IL-1! and IL-18 is driven by the Human 
cytomegalovirus (CMV) immediate early 
promoter, which allows high-level and 
constitutive expression of the gene of interest (Boshart et al., 1985). A PPGK promoter 
allows high-level expression of the Blasticidin resistance gene, allowing for transduced 
cells selection (Kimura et al., 1994). Ampicillin resistance gene allows selection of the 
plasmid in E. coli, while pUC origin permits high-copy replication and maintenance in 
E.coli cells. Several restriction sites such as KpnI can be used to digest the plasmid and 
check for insert orientation and expression. Insert expression in mammalian cells can be 
visualized by the detection of the V5 epitope. 
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7.9 - Overexpression of IL-1! and/or IL-18 impact on IL-1! 
secretion after 24 hr E.coli challenge.  
 
a)     b) 
 
Figure S3- Overexpression of IL-1! and IL-18. Lentiviruses were used to overexpress 
IL-1! and IL-18 in THP-1 cells. After infection cells were challenged with E.coli and IL-1! 
concentration was measured in the supernatants by ELISA. (a) Overexpression of IL-1! 
increased IL-1! secretion after 24 hr E.coli challenge, as compared to control. In 
opposition, IL-18 overexpression did not show any impact on IL-1! secretion after E.coli 
challenge. (b) Western blot detection V5-epitope tagged IL-1! and IL-18 proteins. 
pSFRS1, pSFRS3, pIL-1! and pIL-18 are the lentivirus encoding the SFRS1, SFRS3 , IL-
1! and IL-18 V5 tagged proteins. Lanes 1 and 3 are control non-nfected cells. Lanes 2 and 
4 are cells overexpressing IL-1" and IL-18, respectively (t-student:**p<0.005, 
***p<0.0001). 
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7.10 - IL-1! secretion kinetics upon SFRS1, SFRS3 or 
HMGB1 knockdown. 
a)     b) 
 
c) 
 
Figure S4– Kinetics of IL-1! secretion 
upon SFRS1,SFRS3 or HMGB1 
knockdown.  a,b) Increased IL-1! secretion, 
detected by ELISA, in cells where SFRS1 
and SFRS3 were downregulated. Higher 
induction was found in SFRS3 knockdown 
cells, as compared with control and SFRS1 
RNAi targeted cells. c) Decreased IL-1! 
secretion observed at 24 hr post E.coli 
challenge in cells where HMGB1 was 
previously downregulated. 
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7.11 – SFRS1 and SFRS3 expression upon Mycobacterium 
tuberculosis challenge 
 
a)     b) 
 
 
 
 
 
 
 
c)     d) 
 
 
 
 
 
 
 
 
 
 
 
Figure S5 – M.tb impact on IL-1! secretion and IL-1!, SFRS1 and SFRS3 mRNA 
expression. 4% PFA fixed M.tb was used to challenge THP-1 cells at different time points. 
a,b) M.tb infection induced IL-1" mRNA expression and secretion. c,d) SFRS1 and SFRS3 
mRNA expression is downregulated upon M.tb challenge. 
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7.12 - HnRNPK role in IL-1! secretion 
 
a)     b) 
 
 
c) 
 
Figure S6 - HnRNPK role in IL-1! 
secretion. a) Knocking-down the 
expression of HnRNPK leads to decreased 
IL-1! secretion after 24 hr E.coli challenge. 
b) Validation of HnRNPK knockdown by 
qRT-PCR. c) SFRS1 expression is less 
downregulated upon E.coli challenge in 
cells previously knocked-down for the 
expression of HnRNPK. 
 
 
 
 
 
 
 
 
  
 
 
                                                                                              Chapter 7 – Supplementary data  
 
231 
7.13 – Expression of other SF Negative regulator candidates 
upon E.coli challenge  
a)     b) 
 
 
 
 
 
 
c)     d) 
 
 
 
 
 
 
 
e) 
Figure S7 - IL-1! secretion SF negative 
regulators mRNA expression after E.coli 
challenge. mRNA expression was assayed by 
qRT-PCR in cell challenged with E.coli at 
different time points. a, e) GNB2L1 and TET1 
mRNA expression is decreased after E.coli 
challenge. b, c) MFAP1 and PPIE mRNA 
expression is decreased 4 hours after E.coli 
challenge. At 24 hrs post challenge no differences 
in mRNA expression were observed, comparing 
to their expression in control (Non-challenged 
cells). d) SFPQ mRNA expression is slightly 
induced upon E.coli challenge. 
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“The experiment I have just outlined shows the first stage of 
inflammation in the animal world. Now inflammation as 
understood in man and the higher animals is a phenomenon 
that almost always results from the intervention of some 
pathogenic microbe..... Cure would come from the victory of 
the cells and immunity would be the sign of their acting 
sufficiently to prevent the microbial onslaught.”
 Metchnikoff, Nobel Lecture in 1908
“A number of genes in higher organisms and in their viruses 
appear to be split... The cell produces a full RNA transcript of 
this DNA…and then appears to splice out the nonsense 
sequences before sending the RNA to the cytoplasm 
…
a stretch of DNA in virus may produce more than one protein, 
depending on which way the primary transcript is spliced.”
         Francis Crick, 1979
licing
Inflammati
Alternative S
ernative Splicing
tive Splicing
Alternative Splicing
Inflammation
Inflammation
Inflammation
Inflammation InflammatInflammation
ammation
Alternative Splicing
Alternative Splicing
Inflam
Alternative Spli
Inflammation
Inflammation
